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Abstract 
 
Terra Irons: Defining Behavioral Phenotypes Associated with Dopaminergic 
Nervous System Toxicity in Zebrafish Larvae 
(Under the direction of Stephanie Padilla and Robert MacPhail) 
 
Parkinson’s disease and attention deficit hyperactivity disorder are motor 
conditions characterized by dysfunction of dopaminergic signaling in the brain.  The 
origins of these dopamine-related movement conditions are largely unknown.  
Epidemiological studies have suggested that environmental causes may exist, as 
evidenced by the association between the onset of these disorders and risk factors 
like exposures to pesticides and lead, both of which can target the dopaminergic 
nervous system.  In light of these suspected associations, a need exists for the 
development of a screen for dopaminergic toxicity so that potential hazardous 
chemicals can be identified.  This work describes a model of dopaminergic 
dysfunction using larval zebrafish.  Specifically, behavioral analyses following acute 
exposure to dopaminergic drugs and toxicants are detailed, in addition to the effects 
of developmental lesioning on behavior and dopaminergic pathway structure.  In 
general, larval zebrafish appear to be good predictors of dopaminergic dysfunction, 
and may serve as an efficient model system in identifying environmental agents that 
may contribute to the onset of dopamine-related movement disorders. 
 
iii 
 
 
 
 
 
 
To my mother,  
who provided me with the blueprint of hardwork and endurance, 
and never let me forget “our deepest fear is not that we are inadequate… 
[but] that we are powerful beyond measure.” 
Thank you for encouraging me to let my light shine. 
iv 
 
 
 
 
 
 
Acknowledgements 
I would like to first acknowledge my advisor and mentor, Stephanie Padilla, as well 
as my co-advisor, Robert MacPhail, for their guidance throughout my training.  I truly 
appreciate all of the time and effort you two have given over the years. 
I would also like to recognize my dissertation committee, Drs. Ilona Jaspers, Linda 
Dykstra, and Thomas Bouldin. 
I am grateful to Professors John Dowling and John Staddon, Dr. William Boyes, 
Douglas Greene, Keith Tarpley, Chuck Gaul, Beth Padnos, Samantha Frady, 
Brenda Proctor, and Dr. David Kurtz who all contributed to this work in various ways.   
I would also like to thank Drs. William Mundy, John Cowden, Edward Levin, 
Theodore Slotkin, and Ram Ramabhadran for their thoughtful reviews of abstracts 
and manuscripts that have been published on this work. 
T.D. Irons is supported by the following NIH predoctoral traineeships: the NIGMS 
Initiative for Maximizing Student Diversity, the NIDA National Research Service 
Award (T32 DA007244) and the NIEHS National Research Service Award (T32 
ES007126).  
The work presented here does not reflect the views of the US Environmental 
Protection Agency, nor does mention of trade names or commercial products 
constitute endorsement or recommendation for use. 
v 
 
 
 
 
 
 
Table of Contents 
 
List of Tables .............................................................................................................ix 
 
List of Figures ............................................................................................................ x 
 
List of Abbreviations .................................................................................................. xii 
 
Chapters 
 
I.   General Introduction ........................................................................................... 1 
 
Dopamine Signaling ........................................................................................... 2 
 
Dopamine and Locomotor Activity ..................................................................... 4 
 
Common Neurotoxicant Models of Dopamine-Related Movement Disorders .... 8 
 
Dopamine-Related Movement Disorders and Environmental Exposures .......... 9 
 
Zebrafish as a Behavioral Model ..................................................................... 10 
 
Comparative Analysis of Brain Structure ......................................................... 12 
 
Dopaminergic Nervous System Development in Zebrafish .............................. 14 
 
Approach and Scope of the Present Work ....................................................... 15 
 
Specific Aim 1: Characterize the baseline behavioral profile of 6-dpf      
zebrafish larvae. ............................................................................................ 16 
 
Specific Aim 2: Evaluate behavioral phenotypes in larval zebrafish after      
acute exposure to neuroactive drugs that target the dopaminergic nervous 
system. .......................................................................................................... 17 
 
Specific Aim 3: Assess the perturbation of dopaminergic nervous system 
structure and function following developmental toxicant exposure. ............... 18 
 
Works Cited ..................................................................................................... 25 
II.   Locomotion in Larval Zebrafish: Influence of Time of Day, Lighting and     
Ethanol ............................................................................................................. 36 
vi 
 
 
Abstract ............................................................................................................ 37 
 
Introduction ...................................................................................................... 39 
 
Materials and Methods ..................................................................................... 42 
 
Experimental animals .................................................................................... 42 
 
Embryo Rearing ............................................................................................. 42 
 
Recording fish behavior ................................................................................. 43 
 
Analysis of fish movement ............................................................................. 44 
 
Procedure ...................................................................................................... 45 
 
Inferential Statistics ....................................................................................... 48 
 
Results ............................................................................................................. 49 
 
Discussion ........................................................................................................ 52 
 
Works Cited ...................................................................................................... 66 
 
III. Acute Neuroactive Drug Exposures Alter Locomotor Activity in Larval   
Zebrafish .......................................................................................................... 69 
 
Abstract ............................................................................................................ 70 
 
Introduction ...................................................................................................... 71 
 
Methods ........................................................................................................... 74 
 
Breeding and Rearing of Experimental Animals ............................................ 74 
 
Neuroactive Drug Challenges ........................................................................ 75 
 
Recording and Analysis of Larval Locomotion ............................................... 76 
 
Statistical Analyses ........................................................................................ 76 
 
Results ............................................................................................................. 77 
 
Ethanol Challenge ......................................................................................... 77 
 
vii 
 
d-Amphetamine Challenge ............................................................................ 77 
 
Cocaine Challenge ........................................................................................ 79 
 
Discussion ....................................................................................................... 80 
 
Works Cited ..................................................................................................... 91 
 
IV. Acute Administration of Dopaminergic Drugs has Differential Effects on 
Locomotion in Larval Zebrafish ........................................................................ 95 
 
Abstract ............................................................................................................ 96 
 
Introduction ...................................................................................................... 98 
 
Materials and Methods ................................................................................... 102 
 
Husbandry ................................................................................................... 102 
 
Drugs .......................................................................................................... 102 
 
Time of Peak Effect Experiments ................................................................ 103 
 
Dose-Response Experiments ...................................................................... 104 
 
Analysis of Locomotor Activity ..................................................................... 104 
 
Results ........................................................................................................... 106 
 
Time of Peak Effect Experiments ................................................................ 106 
 
Dose-Response Experiments ...................................................................... 107 
 
Discussion ..................................................................................................... 110 
 
Works Cited ................................................................................................... 138 
 
V.  Comparison of the Effects of Developmental and Acute Exposure to MPTP   
and 6-OHDA on the Activity of Larval Zebrafish ............................................ 144 
 
Introduction .................................................................................................... 147 
 
Materials and Methods ................................................................................... 153 
 
Husbandry ................................................................................................... 153 
 
viii 
 
Neurotoxicant Handling and Safety Precautions ......................................... 153 
 
Developmental MPTP exposure .................................................................. 154 
 
Developmental 6-OHDA exposure .............................................................. 155 
 
Acute MPTP and 6-OHDA exposure ........................................................... 155 
 
Behavioral Testing and Analysis of Locomotion .......................................... 156 
 
Tyrosine Hydroxylase Immunohistochemistry ............................................. 157 
 
Statistical Analyses ...................................................................................... 158 
 
Results ........................................................................................................... 159 
 
Developmental MPTP Exposure Altered Nervous System Structure, but     
Not Behavior in Zebrafish Larvae ................................................................ 159 
 
Acute MPTP Exposure Dramatically Altered Larval Locomotion ................. 159 
 
Developmental 6-OHDA Exposure Affected the Structure and Function of       
the Dopaminergic Nervous System in Zebrafish Larvae .............................. 160 
 
Acute 6-OHDA Exposure Did Not Alter Locomotor Activity in Zebrafish      
Larvae ......................................................................................................... 161 
 
Discussion ...................................................................................................... 162 
 
Works Cited .................................................................................................... 186 
 
VI. General Conclusions/Future Directions .......................................................... 193 
 
Works Cited .................................................................................................... 209 
 
ix 
 
List of Tables 
Table 3.1 – Summary of neuroactive drug effects ................................................. 90 
 
Table 4.1 – Summary of Time of Peak Effect Determinations ............................. 130 
 
Table 4.2 – Summary of dose-response profiles ................................................. 137 
 
Table 5.1 – Published reports of MPTP toxicity in larval zebrafish ...................... 173 
 
x 
 
List of Figures 
Figure 1.1 – Dopamine biosynthesis ........................................................................ 20 
 
Figure 1.2 – Dopaminergic pathways ....................................................................... 21 
 
Figure 1.3 – Two GABA-ergic circuits in the basal ganglia ....................................... 22 
 
Figure 1.4 – Comparison of adult mouse and zebrafish brain structure ................... 23 
 
Figure 1.5 – Timeline of dopaminergic development in zebrafish ............................ 24 
 
Figure 2.1 – Effect of time of day on baseline locomotion ........................................ 58 
 
Figure 2.2 – Effects of darkness and visible light on locomotion in larval        
zebrafish .............................................................................................. 59 
 
Figure 2.3 – Effect of alternating light-dark periods on locomotion in larval    
zebrafish .............................................................................................. 60 
 
Figure 2.4 – Effects of duration of dark/light on locomotion ...................................... 61 
 
Figure 2.5 – Effects of ethanol on locomotion in larval zebrafish ............................. 63 
 
Figure 2.6 – Comparison of the effects of alternating light-dark cycles on   
locomotion in locusts and in larval zebrafish ........................................ 64 
 
Figure 3.1 – Larval zebrafish activity after acute administration of ethanol .............. 85 
 
Figure 3.2 – Larval zebrafish activity after acute administration of                             
d-amphetamine .................................................................................... 87 
 
Figure 3.3 – Larval zebrafish activity after acute administration of cocaine.............. 89 
 
Figure 4.1 – Dopaminergic drugs and targets in this study .................................... 116 
 
Figure 4.2 – Apomorphine time of peak effect ........................................................ 119 
 
Figure 4.3 – Butaclamol time of peak effect ........................................................... 121 
 
Figure 4.4 – SKF-38393 time of peak effect ........................................................... 123 
 
Figure 4.5 – SCH-23390 time of peak effect .......................................................... 125 
 
Figure 4.6 – Quinpirole time of peak effect ............................................................. 127 
 
xi 
 
Figure 4.7 – Haloperidol time of peak effect .......................................................... 129 
 
Figure 4.8 – Mean activity and time course for apomorphine ................................ 131 
 
Figure 4.9 – Mean activity and time course for butaclamol .................................... 132 
 
Figure 4.10 – Mean activity and time course for SKF-38393 ................................. 133 
 
Figure 4.11 – Mean activity and time course for SCH-23390 ................................. 134 
 
Figure 4.12 – Mean activity and time course for quinpirole .................................... 135 
 
Figure 4.13 – Mean activity and time course for haloperidol .................................. 136 
 
Figure 5.1 – Developmental MPTP exposure does not alter larval locomotion ...... 174 
 
Figure 5.2 – Developmental exposure to MPTP alters dopamine pathways .......... 177 
 
Figure 5.3 – Acute MPTP exposure alters larval locomotion ................................. 178 
 
Figure 5.4 – Developmental 6-OHDA exposure increased larval locomotion ........ 180 
 
Figure 5.5 – Developmental exposure to 6-OHDA alters dopaminergic         
pathways ............................................................................................ 183 
 
Figure 5.6 – Acute 6-OHDA exposure does not alter larval locomotion ................. 184 
xii 
 
List of Abbreviations 
6-OHDA: 5-(2-aminoethyl)benzene-1,2,4-triol 
ADHD: attention deficit hyperactivity disorder 
CC: corpus callosum 
Ce: cerebellum 
Ctx: cortex 
D1: dopamine receptor subtype 1 
D2: dopamine receptor subtype 2 
D3: dopamine receptor subtype 3 
D4: dopamine receptor subtype 4 
D5: dopamine receptor subtype 5 
DAT: dopamine transporter 
dpf: days post fertilization 
GABA: γ-aminobutyric acid 
Gαs/olf: excitatory G protein subunits 
Gαi/o: inhibitory G protein subunits 
H: hippocampus 
hpf: hours post fertilization 
hr: hours 
Hypo: hypothalamus 
L-DOPA: dihydroxyphenylalanine 
M4: muscarinic receptor subtype 4 
min: minutes 
MO: medulla oblongata 
MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
xiii 
 
NAc: nucleus accumbens 
Na+/Cl- ATPase: sodium-chloride ion exchanger 
OB: olfactory bulb 
P: pallium 
PO: preoptic region 
Pr: pretectum 
PT: posterior tuberculum 
QT: interval between the start of the Q wave and the end of the T wave  
SN: substantia nigra 
Str: striatum 
TeO: optic tectum 
TH: tyrosine hydroxylase 
Th: thalamus 
Vd/Vv: subpallium (dorsal/ventral) 
VMAT: vesicular monoamine transporter 
VTA: ventral tegmental area 
 
  
 
 
 
Chapter 1: General Introduction 
 In vertebrates, dopamine is a key neurotransmitter and neuromodulator in the 
control of motor networks (Herlenius and Lagercrantz, 2001, Thirumalai and Cline, 
2008).  Due to dopamine’s many roles in processes that control movement, 
dysfunction in the dopaminergic nervous system can lead to conditions that feature 
motor abnormalities.  Parkinson’s disease is characterized by a loss of dopaminergic 
neurons in the pars compacta of the substantial nigra, which project to the striatum 
(Hirsch, 1992; reviewed in Mehler-Wex et al., 2006).  This disease is a common 
neurodegenerative disease, and patients present with extensive motor 
abnormalities: resting tremor, rigidity and bradykinesia, among other signs 
(Rodriguez-Oroz et al., 2009).  Huntington’s disease (another late-onset condition) is 
an autosomal dominant neurodegenerative disorder that is characterized by loss of 
dopamine-regulated medium spiny neurons in the striatum (Vonsattel and DiFiglia, 
1998).  Patients suffer from progressive motor disturbances, including rigidity and 
bradykinesia (Nikolaus et al., 2007).  Neurodevelopmental motor disorders can also 
result from dopaminergic dysfunction, the most well-documented of these being 
attention deficit hyperactivity disorder (ADHD; Bowton et al., 2010; reviewed in 
Mehler-Wex et al., 2006, Palomo et al., 2003).  Children with ADHD are hyperactive 
and exhibit cognitive impairments (i.e. in memory, perception, etc.), and these signs 
may be treated with drugs that inhibit dopamine reuptake.  ADHD patients also 
appear to be at risk to develop schizophrenia or Tourette’s syndrome (reviewed in 
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Mehler-Wex et al., 2006; Peralta et al., 2011, Yordanova et al., 1997).  Both of these 
are conditions that present with motor abnormalities (Cortese et al., 2005, Honer et 
al., 2005, Rickards, 2010) accompanied by underlying alterations in dopaminergic 
signaling (Mehler-Wex et al., 2006, Reynolds and Mason, 1995). 
 
Dopamine Signaling 
Dopamine synthesis starts with the rate-limiting conversion of tyrosine to 
dihydroxyphenylalanine (L-DOPA) by tyrosine hydroxylase (see Figure 1.1; reviewed 
in Elsworth and Roth, 1997).  L-DOPA is converted to dopamine via aromatic amino 
acid decarboxylase, and dopamine is then transported from the neuronal cytoplasm 
into vesicles for storage.  In addition to dopamine’s roles in signaling, it is also a 
precursor for the synthesis of the neurotransmitter norepinephrine via dopamine β-
hydroxylase (Figure 1.1). 
 When dopamine is released into the synapse, it can bind to both pre- and 
post-synaptic receptors (reviewed in Elsworth and Roth, 1997).  In mammals, five 
dopaminergic receptors have been identified, the majority of which are conserved in 
vertebrates (reviewed in Callier et al., 2003).  These receptors all traverse the cell 
membrane 7 times and associate with G proteins that regulate the activation of 
adenylyl cyclase (reviewed in Girault and Greengard, 2004, Missale et al., 1998).  
They are classified into subfamilies according to similarities in their structure and 
signal transduction pathways (reviewed in Callier et al., 2003, Missale et al., 1998).  
D1-like receptors (D1 and D5) couple to the excitatory Gαs subunit of G proteins in 
the cerebral cortex and hippocampus (Herve et al., 2001) and the Gαolf subunit in the 
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striatum, nucleus accumbens and olfactory tubercle (Herve et al., 2001, Zhuang et 
al., 2000).  D2-like receptors (D2, D3, and D4) couple to inhibitory G protein 
subunits.  D2 and D3 couple to Gαi/o subunits, while D4 preferentially couples to Gαz 
(Obadiah et al., 1999).  These receptors are present in all known target areas for 
dopamine in the central nervous system of vertebrates, and their distribution is likely 
conserved (reviewed in Callier et al., 2003). 
The dopaminergic synapse also includes proteins that terminate the signal to 
prevent overstimulation of postsynaptic receptors.  Activation of presynaptic D2 
receptors inhibits the release of dopamine from the neuron (Talmaciu et al., 1986).  
Also, dopamine is removed from the synapse by presynaptic dopamine transporters. 
These proteins are symporters that use the ion concentration gradient generated by 
the plasma membrane Na+/Cl- ATPase to drive dopamine reuptake (reviewed in 
Torres and Amara, 2007).  D2 autoreceptors and dopamine transporters work in 
concert to regulate dopaminergic signals (Schmitz et al., 2002).  Dopamine is 
degraded by metabolizing enzymes in the neuronal cytosol (monoamine oxidase) 
and in the synapse (catechol-O-methyltransferase; reviewed in Souza and Tropepe, 
2011).    
Many drugs given to treat movement disorders act on targets in the 
dopaminergic nervous system.  Receptor agonists are given to Parkinson’s patients 
to improve motor deficits (Stocchi, 2008).  Antagonists of dopaminergic receptors 
are used as antipsychotics in schizophrenics (Citrome et al., 2010).  Lastly, drugs 
that act on dopamine transporters (i.e. reuptake blockers) are given to alleviate the 
signs of ADHD (reviewed in Solanto, 2002). 
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Dopamine and Locomotor Activity 
Neurotransmitter systems work in concert in the vertebrate nervous system to 
regulate signal transduction pathways that govern processes like behaviors (Zhou et 
al., 2003).  Although no dopaminergic cell bodies exist in the spinal cord (the major 
locomotor region in vertebrates), studies have identified dopaminergic projections in 
the spinal cord extending from the diencephalon (Holstege et al., 1996, Qu et al., 
2006).  Dopamine, along with serotonin and norepinephrine, has been implicated in 
the maturation and modulation of spinal networks (Cazalets et al., 2000, Sillar et al., 
1998, Sqalli-Houssaini and Cazalets, 2000).  For example, dopamine increases 
excitatory post-synaptic currents in motoneurons of the spinal cord during 
depolarization phases of locomotor rhythms (Han et al., 2007), while serotonin has 
been shown to increase inhibitory post-synaptic currents, slowing the onset of 
depolarization (Gabriel et al., 2009).  LaPointe and colleagues (2008) confirmed the 
interaction of the two signaling systems in spinal networks by showing that co-
administration of dopamine and serotonin receptor agonists to paraplegic animals 
(via complete spinal cord transection) synergistically activated the locomotor network 
and generated hindlimb stepping movements that were not seen when each agonist 
was given individually.   
Three sets of dopaminergic neurons project from the mammalian midbrain 
(the site of 75% of all dopaminergic neurons in the central nervous system) to 
targets in the forebrain to modulate brain functions (see Figure 1.2, top panel; 
reviewed in Hantraye, 1998, Iversen and Iversen, 2007, Riddle and Pollock, 2003, 
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Vitalis et al., 2005, Zeiss, 2005).  (1) The nigrostriatal pathway includes cell bodies in 
the substantia nigra (SN) that extend axons to the dorsal striatum (Str; caudate and 
putamen).  Lesioning this pathway led to the discovery that it plays a major role in 
both simple and complex behaviors (Oberlander et al., 1979, Ungerstedt, 1976).  (2) 
The mesolimbic pathway features cells in the ventral tegmental area (VTA) that 
ascend to the ventral striatum (NAc; nucleus accumbens) and amygdala (not noted 
in Figure 1.2).  This pathway has been shown to mediate functions like reward and 
learning, as determined by the stimulation of neurons in response to cues in trained 
animals (reviewed in Kelley, 2004; Waelti et al., 2001).  (3) Finally, the mesocortical 
pathway extends from the ventral tegmental area (VTA) to the prefrontal cortex 
(Ctx).  Studies on pharmacological stimulation of D1 receptors in this region 
confirmed its role in cognition (Goldman-Rakic et al., 1992, Sawaguchi and 
Goldman-Rakic, 1991).  
Whereas the spinal cord is the source of locomotor output, inputs from the 
brain modulate the development, selection, and execution of movement (Grillner, 
1985, Pearson, 1993).  The circuitry in the brain that controls movement is 
complicated, including many interlocked inhibitory and excitatory pathways that must 
communicate with each other (Figure 1.3).  Two parallel γ-aminobutyric acid 
(GABA)-ergic neuronal circuits located in the basal ganglia are involved in 
movement initiation (see Figure 1.3; Castellanos, 1997, Zeiss, 2005).  Both of these 
circuits are mediated by the release of dopamine in the striatum from neurons that 
originate in the substantia nigra.  The direct pathway extends from the substantia 
nigra/prefrontal cortex to the striatum through the internal segment of the globus 
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pallidus to the thalamus.  Feedback on this pathway causes the amplification of the 
original cortical output via disinhibition.  The indirect pathway extends from the 
substantia nigra/prefrontal cortex to the striatum through the external segment of the 
globus pallidus to the subthalamic nucleus, which projects to the internal globus 
pallidus and finally, the thalamus.  This pathway can lead to inhibition of the cortical 
output.  Dysregulation of dopamine levels in both pathways can have behavioral 
consequences.  In Parkinson’s disease, damage to cells in the substantia nigra 
leads to depletion of dopamine in the striatum, and thus, the direct pathway, 
inhibiting cortical stimulation and causing difficulty in movement initiation (Wichmann 
and DeLong, 1993).  In the case of disorders that include hyperactivity like ADHD 
and Tourette’s syndrome, either decreased dopamine in the inhibitory indirect 
pathway (i.e. due to increased dopamine reuptake) or increased dopamine in the 
direct pathway can result in overstimulation of the cortex (Hallett, 1993, Saint-Cyr et 
al., 1995). 
Dopamine and acetylcholine receptors are coexpressed in several regions of 
the brain, and activation of these receptors cause opposite signaling effects.  For 
example, D1 and M4 (muscarinic acetylcholine receptor 4) receptors are co-
localized in most brain regions, and while D1 activation causes an excitatory signal, 
M4 activation is inhibitory (Zhou et al., 2003).  Also, the striatum, which 
dopaminergic neurons extend to and from, is densely populated with cholinergic 
interneurons (reviewed in Mena-Segovia et al., 2008).  These neurons regulate 
neuronal firing and dopamine release (Blaha and Winn, 1993).  The activation of 
muscarinic receptors expressed on GABAergic spiny neurons inhibits the release of 
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dopamine from nerve terminals in the striatum (Zhang et al., 2002b) secondary to 
inhibition of GABA release (Marchi et al., 1990, Sugita et al., 1991).  Conversely, 
nicotinic acetylcholine receptors are expressed on the presynaptic surface of 
dopaminergic nerve terminals, and their activation enhances dopamine release 
(Zhou et al., 2002).  Dopaminergic signaling can also reciprocate by modulating the 
activity of cholinergic interneurons in the striatum.  Whereas D1-like receptor 
activation increases the release of acetylcholine, D2 receptor activation on 
cholinergic interneurons decreases acetylcholine release (DeBoer and Abercrombie, 
1996), illustrating the complex and intricate balance between the two systems.  
Serotonergic modulation of the dopaminergic nervous system has also been 
established.  Both serotonergic receptors (Alex and Pehek, 2007) and projections 
extending from cell bodies located in the dorsal raphe nucleus of the brainstem 
(Azmitia and Segal, 1978) are present in the striatum.  A modulatory role of this 
system on dopaminergic activity has been demonstrated through pharmacological 
studies with exogenous serotonin and other receptor-specific agents and reuptake 
inhibitors (David et al., 2004, Di Giovanni et al., 2010, Filip et al., 2003, Frantz et al., 
2002, Ichikawa et al., 2001).  Also, destruction of dopaminergic neurons in the 
nigrostriatal pathway has been shown to increase serotonin receptor binding sites 
(Radja et al., 1993), as well as receptor mRNA (Laprade et al., 1996) in the striatum.  
Consequently, in addition to altered dopaminergic signaling, effects on serotonergic 
pathways have been identified in Parkinson’s patients (Fox and Brotchie, 2000, 
Nicholson and Brotchie, 2002, Reynolds et al., 1995), Huntington’s patients 
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(Reynolds et al., 1995), and schizophrenics (Herrick-Davis et al., 2000, Meltzer and 
Nash, 1991).   
 
Common Neurotoxicant Models of Dopamine-Related Movement Disorders 
In an effort to understand many biological aspects of motor disorders, 
including the molecular basis for clinical presentation and cellular targets for therapy, 
many investigators have studied animal models after chemical lesioning of 
dopaminergic pathways.  This is an accepted method to model human conditions 
like Parkinson’s disease and ADHD.  Most commonly, these lesions are 
accomplished with toxicants like MPTP (1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine) and 6-OHDA [6-hydroxydopamine; 5-(2-aminoethyl)benzene-
1,2,4-triol].   
Mammalian reports of chronic and developmental MPTP exposure detail both 
decreased motor activity, as well as effects on dopaminergic pathways in the brain.  
Rats administered 10 mg/kg MPTP in utero from gestational day 13 until birth 
displayed persistent decreased locomotion through postnatal day 50 (Weissman et 
al., 1989).  Mice (which are generally more sensitive to MPTP toxicity than rats; 
Giovanni et al., 1994) that received 2.8 mg/kg MPTP from gestational days 9-17 
displayed decreased dopamine immunoreactivity in the striatum at 1 and 6 weeks of 
age (Furune et al., 1989).   
Following 6-OHDA administration, an almost complete lesion of dopaminergic 
and noradrenergic nerve terminals is produced in the target region of the brain. After 
injection into the substantia nigra, 6-OHDA decreased spontaneous voluntary 
9 
 
movement and increased bracing in rodents, both of which are similar to motor 
characteristics of Parkinson’s disease (Jurna et al., 1972, Kostrzewa and 
Jacobowitz, 1974, Whishaw and Dunnett, 1985).  When administered 
intraventricularly or intracisternally to neonatal rats, 6-OHDA caused hyperactivity 
(Luthman et al., 1997, Shaywitz et al., 1976) reminiscent of ADHD (Kostrzewa et al., 
2008, Zhang et al., 2002a). 
  
Dopamine-Related Movement Disorders and Environmental Exposures 
The etiology of sporadic dopamine-related movement disorders is largely 
unknown.  Epidemiological studies, however, suggest environmental factors may 
contribute.  Reports have established an association between Parkinson’s disease 
and risk factors common to agricultural workers and residents of rural areas (Elbaz 
and Tranchant, 2007, Priyadarshi et al., 2001, Priyadarshi et al., 2000, Strickland 
and Bertoni, 2004).  One such risk factor is exposure to chemicals like pesticides.  
Several classes of pesticide have been linked to selective dopaminergic 
degeneration, including bipyridyls, organochlorines, dithiocarbamates, and rotenoids 
(Hatcher et al., 2008, Jones and Miller, 2008), many of which have been shown to 
produce a parkinsonian syndrome, and thus, are also used in animal models of 
Parkinson’s disease (Bove et al., 2005, Drechsel and Patel, 2008).  Interestingly, 
evidence has shown that neurodegenerative diseases may result from insults during 
development (reviewed in Barlow et al., 2007).  Thiruchelvam and coworkers (2002) 
reported exposure of mice to maneb (a dithiocarbamate fungicide) during gestation 
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exacerbated the dopaminergic toxicity of paraquat (a bipyridyl herbicide) when 
exposed later in life, causing signs consistent with parkinsonism.   
Additionally, similar links have been made between ADHD and prenatal 
exposure to tobacco smoke and lead (Braun et al., 2006).  Although ADHD is 
thought to be caused by polymorphisms in genes encoding D4, D5, or dopamine 
transporter (Li et al., 2006), both of these toxicants have been shown to alter 
dopaminergic nervous system function.  Nicotine, like most addictive drugs, 
stimulates dopaminergic neurons in the mesolimbic pathway via activation of 
nicotinic receptors, causing dopamine overflow in the nucleus accumbens (reviewed 
in Balfour, 2009).  Perinatal lead exposure rendered rats less sensitive to a 
dopamine-releasing amphetamine analog later in life, suggesting impaired 
dopaminergic function (Clifford et al., 2011).  In mice, increased dopamine levels in 
the fetal brain decreased neurogenesis in the striatum, nucleus accumbens, and 
prefrontal cortex (McCarthy et al., 2007) suggesting the developing brain may be 
especially sensitive to environmental insults that disrupt dopaminergic signaling.  
 
Zebrafish as a Behavioral Model 
Zebrafish (Danio rerio) have emerged as a powerful model system for the 
study of the behavioral, genetic, and biochemical aspects of locomotion (reviewed in 
Drapeau et al., 2002, Fetcho, 2007, Guo, 2004).  Both structural and functional 
assessments of the development of locomotor activity can be studied in ways that 
are difficult or impossible in traditional animal models (reviewed in Drapeau et al., 
2002).  In zebrafish, rudimentary forms of motor activity begin to develop during 
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periods when only a few neurons have extended axons in the spinal cord.  At about 
17 hours post-fertilization (hpf), spontaneous contractions begin to occur, where the 
tail alternates from side-to-side, coiling up to the head (Saint-Amant and Drapeau, 
1998).  This activity peaks in frequency at about 19 hpf.  Next, at about 21 hpf, 
embryonic zebrafish respond to touch with contralateral rapid coils, followed by a 
slower relaxation (Saint-Amant and Drapeau, 1998).  After 27 hpf, touch elicits a 
swim episode after coiling.  This new behavior is defined as the net forward 
movement of the embryo by at least 1 body length.  At 3 days post-fertilization (dpf), 
larvae swim infrequently and in bursts (Drapeau et al., 2002).  Larvae exhibit mature, 
spontaneous beat-and-glide swimming motions by 5 dpf, prior to the development of 
feeding behaviors and functional sensory systems (Drapeau et al., 2002), which are 
present by 6 dpf (Kimmel, 1995).  
In terms of developmental exposure studies, zebrafish prove advantageous, 
because compounds can be added to the solution the embryos are reared in, and 
can freely diffuse into them.  This type of administration removes maternal influence 
as a confounder.  Specifically, unlike developmental studies in mammals, there is no 
metabolism/catabolism of the compound before it reaches the zebrafish embryo, and 
no adverse effects of the exposure occur secondary to effects on the mother.   
Although metabolic and physiologic differences may exist between fish and 
mammals, it appears that the response to chemical treatment is largely conserved 
(Langheinrich, 2003, Milan et al., 2003).  For example, Milan and colleagues (2003) 
determined that a panel of drugs that affected cardiovascular function (i.e. prolong 
QT interval) in humans produced the same effect when screened in zebrafish.  
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Larval zebrafish have not only proven useful in risk identification, but the model has 
recently been used in drug discovery (Berghmans et al., 2008, Berghmans et al., 
2007, Kokel et al., 2010, Rihel et al., 2010).  Kokel and colleagues (2010) screened 
thousands of compounds using a photomotor response endpoint.  They found that 
embryonic zebrafish (28 hpf) responded to flashes of intense light differently, 
depending on the target pathway of drug, signifying multiple pathways regulate the 
photomotor response.  They were also able to classify the targets of new drugs 
based on the responses they caused.  Applying the larval zebrafish model in this 
way, these investigators have begun “to combine in vivo relevance of traditional, 
behavior-based phenotyping with the scale and automation of modern drug 
discovery.”    
 
Comparative Analysis of Brain Structure 
In vertebrates, the organization of the hindbrain and spinal cord are highly 
homologous across species, and the morphology of the early vertebrate embryo is 
conserved (Langille and Hall, 1989).  Moreover, zebrafish brain contains all the 
major structures found in mammals (see Figure 1.4), as well as the same 
neurotransmitters in both long pathways and interneuron systems, and many of the 
genes that have been implicated in human neurodegenerative diseases (Panula et 
al., 2006).  For example, Parkin, a gene that is commonly mutated in patients with 
early onset Parkinson’s disease, has been identified in zebrafish, and the loss of its 
function caused a loss of dopaminergic neurons (Flinn et al., 2009). The similarities 
in brain structure across vertebrates, including zebrafish, have been well 
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documented, including areas that are essential in the dopaminergic signaling 
pathways (Rink and Wullimann, 2002, Wullimann and Mueller, 2004).  Wullimann 
and Mueller (2004), for example, described the structural organization of the 
zebrafish forebrain and its similarities to mammalian brain.  According to their study, 
the zebrafish telencephalon is divided into an area dorsalis telencephali, as well as a 
basal area ventralis telencephali.  The area dorsalis telencephali is regarded as the 
pallium (corresponding to part of the striatum in mammals), and the area ventralis 
telencephali, as the subpallium (corresponding to part of the striatum and septum in 
mammals).  The zebrafish diencephalon also displays a series of brain subdivisions 
characteristic of all vertebrates.  In zebrafish, the pretectum replaces epithalamic 
structures (epiphysis and habenula) present in mammalian brain.  Other structures 
present in zebrafish diencephalon include the thalamus, posterior tuberculum, and 
hypothalamus.  Similarities of zebrafish sensory, motor, and integrative central 
nervous circuits with other vertebrates also exist.  For example, as in all vertebrates, 
olfactory information enters the zebrafish telencephalon via olfactory bulb 
projections, which reach most nuclei of the subpallium and some of the pallium (or 
septum and striatum) as well (Rink and Wullimann, 2004).    
Identifying dopaminergic cell groups in any vertebrate species is confounded 
by two important facts (Rink and Wullimann, 2002, 2004, Wullimann and Mueller, 
2004).  First, in most cases, the cell groups are not confined to single, defined 
anatomical structures. Second, the distribution of cell bodies within each cell group 
varies markedly between different mammalian species, and is even more variable 
between different vertebrates (Divac et al., 1978, Smeets and Gonzalez, 2000, 
14 
 
Smeets et al., 2000).  For example, in zebrafish, no dopaminergic cells lie in the 
midbrain; therefore, the nigrostriatal pathway, which extends from the substantia 
nigra (SN) to the striatum (Str) in mammals, is homologous to the dopaminergic 
ascending pathway in zebrafish, extending from cells in the posterior tuberculum 
(PT) to the subpallium (Vd), both of which are present in the forebrain (Figure 1.2; 
(Rink and Wullimann, 2001). 
 
Dopaminergic Nervous System Development in Zebrafish 
Several studies have been conducted on the development of the 
dopaminergic nervous system in zebrafish (see Figure 1.5 for a summary time line; 
(Arenzana et al., 2006, Holzschuh et al., 2001, Li et al., 2007, Rink and Wullimann, 
2002, Sallinen et al., 2009).  As determined by tyrosine hydroxylase and dopamine 
transporter staining, dopamine-containing neurons can first be detected in the 
posterior tuberculum in the midbrain as early as 18 hpf (Holzschuh et al., 2001).  
Around this time, genes for some D2-like receptors are also expressed (Boehmler et 
al., 2007, Boehmler et al., 2004).  Other components of the dopaminergic nervous 
system such as the spinal cord and ventral diencephalon contain functioning 
neurons by 24 hpf (Arenzana et al., 2006, Holzschuh et al., 2001, Li et al., 2007, 
Rink and Wullimann, 2002, Sallinen et al., 2009).  At this time, vesicular monoamine 
transporters are also present (Wen et al., 2008).  Within the next 24 hours, D1 
receptor expression can be detected (Li et al., 2007).  Also at 48 hpf, dopaminergic 
neurons are present in the olfactory bulb, preoptic region, telencephalon, 
paraventricular organ, and hypothalamus (Arenzana et al., 2006, Holzschuh et al., 
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2001, Li et al., 2007, Rink and Wullimann, 2002, Sallinen et al., 2009).  By 72 hpf, 
dopaminergic neurons are present in the retina, pretectum, and ventral thalamus, 
with the tectum gaining dopaminergic neuronal activity by 96 hpf (Arenzana et al., 
2006, Holzschuh et al., 2001, Li et al., 2007, Rink and Wullimann, 2002, Sallinen et 
al., 2009).  By the end of 4 days (96 hpf), the full complement of dopaminergic 
neuronal groups is present in the zebrafish (McLean and Fetcho, 2004, Rink and 
Wullimann, 2002). 
 
Approach and Scope of the Present Work 
The roles of dopamine in behavior have been studied thoroughly in many 
vertebrate species.  It has been established that alterations in dopaminergic 
signaling pathways can lead to disorders and diseases of importance to public 
health, and that environmental exposures may target the dopaminergic nervous 
system.  More studies need to be conducted in order to evaluate environmental 
exposures as a causal factor in the onset of movement disorders.  Also, it is not 
clear whether developmental insults on the dopaminergic nervous system are the 
underlying cause for disorders that occur later in life.   
Zebrafish may be a useful model in addressing these uncertainties.  As a 
vertebrate, the zebrafish nervous system shares structural and functional homology 
with that in mammals, and studies have suggested this homology leads to the 
conservation of responses to chemical treatment.  In addition to its similarities to 
mammalian models, zebrafish offer other strengths over the more common 
vertebrate models.  Young zebrafish are amenable to genetic manipulation, making 
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both forward and reverse genetic screens possible (Guo et al., 1999).  Additionally, 
due to the high production of offspring and their small size at embryonic/larval 
stages, zebrafish are an ideal model for higher-throughput designs, and it is possible 
to screen many compounds at once for multiple toxicity endpoints, including 
behavior.   
Before compounds can be screened for dopaminergic toxicity, however, basic 
aspects of the larval zebrafish model must be investigated.  The goal of this work 
was to create and characterize a model of dopaminergic dysfunction in larval 
zebrafish.  Since alterations in motor function have been identified as major 
consequences of impaired dopaminergic signaling, basal activity in 6-dpf zebrafish 
larvae must be studied in detail to design an appropriate behavioral paradigm that 
includes locomotor activity as the primary endpoint.  Also, the sensitivity of larvae to 
acute and developmental exposures to dopaminergic drugs/toxicants must be 
determined.  In the event that larval locomotion is sensitive to dopaminergic insults, 
this model may be useful in predicting compounds that precipitate dopaminergic 
toxicity in mammals.   
 
Specific Aim 1: Characterize the baseline behavioral profile of 6-dpf zebrafish larvae. 
Before assessing drug/toxicant-induced effects on locomotor activity, it was 
first necessary to study the baseline activity of the larvae, as well as factors that 
affect this activity.  To guide these experiments, the following questions were asked: 
• What are the basal patterns of larval activity during a day? 
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Zebrafish are a diurnal species, and their activity levels change throughout 
the day (del Pozo et al., 2011).  They are also entrained to a specific light-dark cycle.  
Locomotor activity should be characterized over time to establish the optimal time of 
day to conduct behavioral studies.   
• How do zebrafish larvae respond to light and dark? 
The behavioral apparatus employed in all testing includes both infrared and 
visible light sources.  Because zebrafish perceive infrared light as darkness 
(Dowling, 2002), it is possible to determine whether different lighting conditions 
affect locomotor activity.  Subsequently, the optimal testing paradigm can also be 
delineated. 
 
Specific Aim 2: Evaluate behavioral phenotypes in larval zebrafish after acute 
exposure to neuroactive drugs that target the dopaminergic nervous system. 
Acute effects of drugs that act on the dopaminergic nervous system have 
been well-documented in mammals.  In this aim, the acute behavioral effects of 
several of these drugs were evaluated in 6-dpf larvae after acute exposure.  To 
compare the locomotor responses in larval zebrafish to those reported in mammals, 
the following questions were asked: 
• Are zebrafish larvae sensitive to common neuroactive drug exposures? 
These drugs included ethanol, d-amphetamine and cocaine.  All three drugs 
have indirect effects on dopaminergic signaling.  Ethanol acts on targets that 
stimulate the release of dopamine into the synapse, in addition to targeting other 
signaling pathways (Cohen et al., 1997).  Both d-amphetamine and cocaine target 
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the dopamine transporter, blocking dopamine reuptake (reviewed in Williams and 
Galli, 2006).  Additionally, d-amphetamine depletes dopamine stores, subsequently 
flooding the synapse with dopamine (reviewed in Williams and Galli, 2006).   
• What behavioral effects occur following exposure to drugs that target 
dopaminergic receptors? 
Here, the acute effects of various drugs that act directly on dopaminergic 
receptors were evaluated.  These included: a nonselective agonist (apomorphine; 
Creese et al., 1975) and antagonist (butaclamol; Andersen, 1988), a D1-selective 
agonist (SKF-38393; Gredal and Nielsen, 1987) and antagonist (SCH-23390; Hyttel, 
1983), and a D2-like selective agonist (quinpirole; Millan et al., 2002) and antagonist 
(haloperidol; Hyttel, 1983).  The nonselective drugs target all dopaminergic 
receptors, while D1-/D2-like selective drugs primarily target their respective receptor 
subtypes.   
 
Specific Aim 3: Assess the perturbation of dopaminergic nervous system structure 
and function following developmental toxicant exposure. 
Chemical lesioning of regions of mammalian brain is an accepted method to 
model human conditions like Parkinson’s disease and ADHD disorder.  Such lesions 
are accomplished with toxicants like MPTP and 6-OHDA.  In this aim, the following 
questions were asked: 
• How does MPTP exposure affect behavior and dopaminergic pathways in 
zebrafish larvae? 
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MPTP causes rapid-onset parkinsonism in humans (Langston et al., 1999).  
Like Parkinson’s disease, this compound selectively damages nigral neurons that 
extend to the striatum (Langston et al., 1984).  Its toxicity has been extensively 
studied in many species, including non-human primates, rodents, and fish (Langston 
et al., 1984, Markey et al., 1984, Sallinen et al., 2009).  Here, the effects of 
developmental and acute MPTP exposures in zebrafish larvae are compared. 
• How does 6-OHDA exposure affect behavior and dopaminergic pathways in 
zebrafish larvae? 
6-OHDA is a false neurotransmitter with a high affinity for both dopaminergic 
and noradrenergic transporters (Kostrzewa and Jacobowitz, 1974).  Because of this, 
it is the most common chemical used to lesion motor-related areas of the brain 
(reviewed in Bove et al., 2005).  Depending on its locus of administration, 6-OHDA is 
used to model both Parkinson’s disease (when injected into the nigrostriatal 
pathway) and ADHD (when injected into the ventricle) in mammalian species 
(reviewed in Bove et al., 2005).  Less is known about the effects of 6-OHDA in 
zebrafish; therefore, the developmental and acute effects of the chemical were 
characterized and compared.  
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Figure 1.1 – Dopamine Biosynthesis.  Tyrosine is converted to L-DOPA by tyrosine 
hydroxylase (rate-limiting step coupled with the oxidation of tetrahydrobiopterin).  L-
DOPA is then converted to dopamine by aromatic amino acid decarboxylase.  In 
addition to being a neurotransmitter, dopamine is a precursor for norepinephrine in a 
reaction catalyzed by dopamine β–hydroxylase coupled with the oxidation of 
ascorbate.  
(*from http://www.rpi.edu/dept/bcbp/molbiochem/BiochSci/sbello/tyr_norep.gif)
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Figure 1.2 – Dopaminergic pathways that regulate many brain functions are 
conserved across vertebrate species.  In the mouse, the nigrostriatal pathway 
extends from the substantia nigra (SN) to the striatum (Str), the mesolimbic pathway 
extends from the ventral tegmental area (VTA) to the nucleus accumbens (NAc), 
and the mesocortical pathway extends from the ventral tegmental area to the 
prefrontal cortex (Ctx).  Some homologous pathways have been identified in 
zebrafish; the most studied of these extends from the posterior tuberculum (PT) to 
the subpallium (Vd), and is functionally similar to the nigrostriatal pathway.  *The 
brain schematics are not drawn to scale. (From Souza et al., 2011)
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Figure 1.3 – Two GABA-ergic circuits in the basal ganglia are involved in movement 
initiation.  The direct pathway extends from the substanita nigra/prefrontal cortex to 
the striatum through the internal segment of the globus pallidus to the thalamus.  
Feedback on this pathway results in the amplification of the original cortical output 
via disinhibition.  The indirect pathway extends from the substantia nigra/prefrontal 
cortex to the striatum through the external segment of the globus pallidus to the 
subthalamic nucleus, which projects to the internal globus pallidus causing inhibition 
of the cortical output.
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Figure 1.4 – Comparison of adult mouse and zebrafish brain structure.  Homologous 
structures for all major structures in mouse (and other mammals) brain are present 
in zebrafish brain, as denoted by like colors.  *Schematics are not drawn to scale.
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Figure 1.5 – Timeline of Dopaminergic Development in Zebrafish. 
D1: dopamine receptor subtype 1; D2: dopamine receptor subtype 2; D3: dopamine 
receptor subtype 3; D4: dopamine receptor subtype 4; DAT: dopamine transporter; 
TH: tyrosine hydroxylase; VMAT: vesicular monoamine transporter.  
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Chapter 2: Locomotion in Larval Zebrafish: Influence of Time of Day, Lighting 
and Ethanol 
 
Preface 
Before studying the locomotor effects of drug/toxicant exposures, the baseline 
behavior of 6-dpf larvae had to be characterized for the development of a behavioral 
paradigm.  This study addressed Specific Aim 1: “Characterize the baseline 
behavioral profile of 6-dpf larvae.” The following questions were answered: 
• What are the basal patterns of larval zebrafish activity during a day? 
• How do zebrafish larvae respond to light and dark? 
 
*This work has been published: 
MacPhail, R. C., Brooks, J., Hunter, D. L., Padnos, B., Irons, T. D., and Padilla, S. 
(2009). Locomotion in larval zebrafish: Influence of time of day, lighting and ethanol. 
Neurotoxicology 30, 52-58. 
As a contributing author, I performed the ethanol challenge experiments as proof of 
concept in this method development study.  I also made many intellectual 
contributions to the work, including data analysis, as well as aiding in preparation of 
the manuscript.  
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Abstract 
 The increasing use of zebrafish (Danio rerio) in developmental research 
highlights the need for a detailed understanding of their behavior. We studied the 
locomotion of individual zebrafish larva (6 days post fertilization) in 96-well microtiter 
plates. Movement was recorded using a video-tracking system. Time-of-day results 
indicated locomotion, tested in darkness (infrared), decreased gradually from early 
morning to a stable level between 13:00 and 15:30 hr. All further studies were 
conducted in early-to-late afternoon and lasted approximately one hr. Each study 
also began with a period of darkness to minimize any unintended stimulation caused 
by transferring the plates to the recording platform. Locomotion in darkness 
increased initially to a maximum at 4 min, then decreased steadily to a low level by 
20 min.  Locomotion during light was initially low and then gradually increased to a 
stable level after 20 min. When 10-min periods of light and dark were alternated, 
activity was low in light and high in dark; curiously, activity during alternating dark 
periods was markedly higher than originally obtained during either extended dark or 
light. Further experiments explored the variables influencing this alternating pattern 
of activity.  Varying the duration of the initial dark period (10-20 min) did not affect 
subsequent activity in either light or dark. The activity increase on return to dark was, 
however, greater following 15-min than 5-min of light. Acute ethanol increased 
activity at 1% and 2% and severely decreased activity at 4%. One-percent ethanol 
retarded the transition in activity from dark to light, and the habituation of activity in 
dark, while 2% ethanol increased activity regardless of lighting condition. 
Collectively, these results show that locomotion in larval zebrafish can be reliably 
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measured in a 96-well microtiter plate format, and is sensitive to time of day, lighting 
conditions, and ethanol.  
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Introduction 
 Studies on zebrafish as a model system have steadily increased (Dowling, 
2002, Miklosi and Andrew, 2006, Orger et al., 2004, Sison et al., 2006). Zebrafish 
are now used in many fields of biomedical science, including toxicology, for studying 
processes related to human disease susceptibility and risk (Alestrom et al., 2006, 
Guo, 2004, Hill et al., 2005, Lieschke and Currie, 2007). Zebrafish have also 
become widely used in the pharmaceutical industry, where literally thousands of 
chemicals can be screened rapidly in vivo for therapeutic and toxic potential 
(Jacobs, 2006, Zon and Peterson, 2005).  
 The use of zebrafish in developmental research is of particular interest. 
Zebrafish offer a number of advantages in studies on development (Westerfield, 
2000). Their size and relatively simple husbandry requirements allow maintenance 
of large stocks of fish. Mating results in a large number of eggs. Development occurs 
rapidly, and progresses through well-defined stages (Kimmel et al., 1995). 
Transparency of the embryos and larvae allows detailed non-invasive observation of 
organ-system development.  Numerous tools are also available to probe 
physiological functions including vital dyes, fluorescent probes, and several strains 
and transgenic lines of zebrafish (Feldman 2001; Hill et al. 2005; Peterson et al. 
2008). A notable advantage for developmental toxicity studies is that exposure to 
chemicals can take place directly, thereby avoiding the maternal compartment that 
can confound similar studies in mammals.  
 Assessment of the behavior of developing zebrafish is also becoming 
popular. Behavior represents the unique interface between intrinsic and extrinsic 
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forces that determine an organism’s health and survival (MacPhail, 1989, Little et al., 
1990). Several studies have focused on the behavioral development of sensory and 
motor functions (Easter and Nicola, 1996, Saint-Amant and Drapeau, 1998, Budick 
and O'Malley, 2000, Drapeau et al., 2002, Burgess and Granato, 2007). A number of 
studies have also explored the development of reflexes, learning and memory 
(Kimmel et al.,1974, Levin et al., 2004, Orger et al., 2004, Weber, 2006, Zeddies and 
Fay, 2005). Relatively few studies, however, have evaluated behavior during 
development in the type of small testing environment (e.g., a multi-well microtiter 
plate) that would be required for large-scale chemical screening in toxicology and 
pharmacology.  
 We report the results of several studies on the behavior of 6-day-old zebrafish 
larvae. Larvae were individually raised and tested in 96-well microtiter plates. The 
small environments (250 µl) of the microtiter plate greatly limit the types of 
behavioral responses that can be studied. We therefore focused on general 
locomotion of the larvae. Most previous studies have evaluated larval behavior in 
light using optical tracking devices (e.g. Lockwood et al., 2004, Orger et al., 2004). 
Infrared image analysis, however, has permitted studies of locomotion in both light 
and darkness (Cahill, 2007, Emran et al., 2007, Prober et al., 2006, Burgess and 
Granato, 2007). The current studies therefore evaluated locomotion under both light 
and dark conditions. Initial studies determined the optimal time of testing during the 
work day. Subsequent studies measured locomotion during extended periods 
(several minutes) of dark, and light, and during shorter alternating cycles of light and 
darkness. Further studies determined the effect of manipulating light- and dark-
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period durations.  A final study determined the effects of a prototype centrally acting 
drug, ethanol, on locomotor activity. These experiments employed testing durations 
(ca. one hour) that allowed repeated manipulation of lighting conditions, thereby 
permitting detailed investigation of the role of environmental influences on 
locomotion, ethanol effects, and their interaction.  
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Materials and Methods 
Experimental animals 
 All studies were conducted in accordance with the guidelines of the 
Institutional Animal Care and Use Committee at the U.S. EPA National Health and 
Environmental Effects Research Laboratory. Wild type adult zebrafish (Danio rerio) 
were maintained in an AAALAC-approved animal facility at 28°C with a 14:10 hr 
light:dark cycle (lights on at 08:30 hr). Adult fish were housed in 9-liter flow-through 
colony tanks (Aquaneering Inc., San Diego CA) with approximately 8 females and 4 
males per tank. On the day of embryo collection, and one hour prior to light onset, all 
adults in a colony tank were placed in a 2-liter (static) breeding tank (Aquatic 
Habitats, Apopka FL). Usually, adults from 2-3 housing tanks were mated on the 
same day. One hour after light onset the adults were returned to the colony tank, 
and embryos were collected from the breeder tank. All embryos were then pooled 
from the breeding tanks and placed in a 26°C water ba th for 2 hours, followed by 
washing with 1% bleach (v/v) in 10% Hanks’ solution for 1 min. Embryos were 
distributed randomly, one per well, into 96-well mesh-bottom (40-micron nylon) 
microtiter plates (Multiscreen™ catalog #MANMN4050, Millipore Corp., Bedford 
MA), where they were reared and later tested.   
 
Embryo Rearing  
 Embryo rearing was essentially as described by Westerfield (2000). All 
embryos and larvae were maintained in microtiter-plate wells in 10% Hanks’ 
Balanced Salt Solution (13.7 mM NaCl, 0.54 mM KCl, 25 µM Na2HPO4, 44 µM 
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KH2PO4, 130 µM CaCl2, 100 µM MgSO4, 420 µM NaHCO3) hereafter referred to as 
Hanks solution. Each microtiter plate consisted of a bottom tray, buffer tray, mesh 
tray, and a lid. A photograph and schematic of the 96-well microtiter plate can be 
seen in Oxendine et al. (2006, Figure 2). A piece of Plexiglas (10.5 cm long, 7.0 cm 
wide and 0.3 cm thick) was placed between the bottom and buffer trays to stabilize 
the buffer tray and avoid the possibility of spillage between wells.  Individual wells 
within the buffer tray contained a single embryo within its own environment.  The 
mesh-bottom tray permitted rapid solution replacement by transferring it to a new 
buffer tray. Each day, 150 µl of fresh aerated 10% Hanks solution was added to 
individual wells of the buffer tray of a new plate. The mesh tray (with embryos) was 
removed from the old plate, quickly blotted dry in a matter of seconds, and inserted 
into the new buffer tray. An additional 100 µl of 10% Hanks solution was added 
immediately to each well. Each 96-well microtiter plate was sealed with a non-
adhesive material (Type A, BioRad, Hercules, CA), covered with the lid, and 
wrapped in Parafilm® to minimize evaporation. All embryos and larvae were kept in a 
26±0.7°C incubator with a 14:10 hr light:dark cycle (wi th lights on at 08:30 hr). 
Recording fish behavior  
 All testing was performed on 6-day post-fertilization (dpf) larvae in the same 
96-well plate in which they were reared. At 6 dpf, larvae still feed from their yolk sac, 
obviating the need to introduce food to the wells. They also have a sufficient level of 
locomotion for study. Larvae were housed individually for ease of tracking and 
statistical analysis.  
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 On the day of testing, larvae were placed in fresh 10% Hanks solution, the 
plate was covered, and then transferred into a light-tight drawer in the behavioral 
testing room. Temperature in the testing room was kept at 26°C.  For all 
experiments, except the time-of-day experiment, testing occurred after 13:30 hr.  
Movement of each fish was monitored with a Noldus behavior recording system 
[Noldus Information Technology, Leesburg VA (www.noldus.com)], consisting of a 
Pentax CCDIR XC E150 camera with a Pentax TV lens, a platform (light box 
containing LEDs) on which the plates were placed, with a baffle that blocked 
extraneous light.  The light box provided infrared (800-950 nm with a peak at 860 
nm) or visible (430-700 nm) light as measured with a wideband spectroradiometer 
(RPS900, International Light Technologies, Peabody, MA). The illuminance provided 
by the visible light was measured at 69.5 lux using a photometer (model DR-2550-1, 
2B silicon detector, TC284 photometric filter, Gamma Scientific, San Diego, CA). 
The camera output was fed into a standard PC system, and Canopus Mediacruise 
MVR1000 software (Canopus Corporation, San Jose CA) was used to create videos 
of fish movement.  All recordings were stored as MPEG-2 files for later analysis. 
 
Analysis of fish movement 
 Fish movement (locomotion) was tracked from videos using Ethovision 
(Noldus Information Technology) software Version 3.1.  Tracking rate was 5 
samples/sec (i.e., an image was captured every 200 msec). The subtraction method 
was used to detect objects that were darker than the background, with a minimum 
object size of 10 pixels.  Tracks were analyzed for total distance moved (cm); to 
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remove system noise, an input filter of 0.135 cm (minimum distance moved) was 
used (i.e., filtered data). Locomotion data are presented as mean ± SEM distance 
(cm) moved per unit time under each condition that was arranged during a test 
session. 
 
Procedure 
Studies were conducted to determine the influence of several variables on the 
locomotor activity of 6-dpf zebrafish larvae. Details of each study are presented 
below. 
 
Time-of-day effects:  The first study determined the optimal time for testing, that is, 
when activity did not vary from hour to hour. Embryos were reared for 6 days in 10% 
Hanks solution, which was changed daily. On the morning of the sixth day, larvae 
were transferred to fresh solution, and the plate was moved to the behavioral testing 
room.  After the plate was placed on the recording platform, the infrared light was 
turned on for the duration of the session.  Throughout, infrared illumination is 
referred to as darkness, because zebrafish do not see infrared (Dowling 2002). The 
baffle was lowered over the plate and the fish were given 20 min of acclimation to 
minimize any disturbance related to handling and transport.  Beginning at 10:00 hr, 
fish movement was recorded under infrared light for five minutes every half hour, for 
a total of 5.5 hr. 
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Activity in light and dark:  These studies were designed to assess the general 
pattern of larval activity in visible light and in darkness (infrared illumination). 
Embryos were reared in 10% Hanks solution for 6 days with solutions changed daily. 
Between 09:00 and 09:30 hr on the sixth day, larvae were transferred to fresh 
solution, and the plate was moved to a light-tight drawer in the darkened behavioral 
testing room.  Plates were tested between 13:30 and 15:30 hr. In the darkened 
room, the plate was removed from the drawer, the lid removed, the sealer removed, 
the lid replaced and the plate placed on the testing platform (light box) under the 
baffle. Following transfer to the light box, locomotion was recorded in dark for 10 min 
of acclimation. After acclimation, activity was recorded in dark or in visible light for 40 
minutes. One plate was used for testing in darkness, and the other plate was used 
for testing in light. To avoid confusion in subsequent studies, these conditions are 
described as extended dark or extended light, recognizing, of course, no reference 
to circadian rhythms of activity. 
 
Effects of alternating light and dark periods:  The larvae were reared and handled 
exactly as described above. After 10 min of acclimation in dark, the larvae were 
exposed to three cycles of alternating 10-min light and dark periods (for a total of 60 
min). 
 
Effects of varying duration of the dark period:  This experiment was designed to 
determine the role of the initial dark (acclimation) period on subsequent locomotion 
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in light and in dark. Acclimation in dark lasted for either 10 or 20 min, after which a 
20-min period of light was followed by a return to darkness for 10 min.  
 
Effects of varying duration of the light period:  A 10-min acclimation in dark was 
arranged for larvae in each of two plates. Next, larvae on one plate were exposed to 
5-min of light, while larvae on the other plate were exposed to light for 15 min. A 20-
min period of darkness followed, then either 15- or 5-min of light (respectively), and, 
finally, another 20 min of darkness. The light-period durations were arranged 
differently in the two plates to counterbalance order of presentation. 
 
Ethanol effects:  Ethanol (95% purity) was prepared in concentrations of 1, 2, and 
4% (v/v). All ethanol concentrations were non-lethal, and were selected on the basis 
of pilot studies. Group sizes were n=24/concentration, including a control (10% 
Hanks solution) group.  The larvae were placed into the ethanol solutions shortly 
before transfer to the recording platform. Ethanol doses were distributed diagonally 
because pilot work with control larvae occasionally showed an effect of well location 
in the columns or (even more infrequently) rows of the plates. A 20-min period in 
darkness was arranged for acclimation and drug uptake. Activity was next recorded 
for 10 min in the dark and was followed by a 10-min period of light, then 20 min of 
dark, and then another cycle of light (10 min) and dark (20 min). Ethanol dose-effect 
determinations were carried out in two plates in which doses were similarly 
distributed.  
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Inferential Statistics   
Details for each analysis can be found in the figure legends. All data were analyzed 
using Statview©  (SAS Institute, Inc., version 5.0.1). In general, data from each study  
were compared using a repeated-measures ANOVA. Activity throughout a test 
session was the dependent variable, whereas time of day, lighting condition (light vs 
dark) or chemical treatment (ethanol dose) was the independent variable.  
Significant interactions between time within a session and an independent variable 
were followed by step-down ANOVAs to assess lower-order effects. When 
appropriate, Fisher’s PLSD test was used to evaluate between-group contrasts.  
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Results 
 Figure 2.1 shows the results of testing locomotion across day-time hours 
(from 10:00 to 15:30 hr). Activity was evaluated in darkness (infrared) for 5 min at 
30-min intervals. Locomotor activity was highest in mid-morning when testing began, 
and then decreased to a stable level by early afternoon. No further change in activity 
was noted between 13:00 and 15:30 hr. Variability in activity between larvae was 
also lowest during this time span; standard errors were approximately 5% of the 
mean. All further testing occurred during the afternoon hours. 
 Locomotion was next tested in darkness during a 50-min session. Locomotion 
was also tested in light for 40 min, after an initial 10-min period of darkness. Results 
are shown in Figure 2. During the initial dark period, activity for both groups of larvae 
quickly increased to a maximum and then decreased.  In larvae that remained in 
darkness, activity reached a stable low level at approximately 20 min into the 
session. For larvae that were switched to light (after 10-min in darkness), activity 
decreased precipitously, but was followed by a gradual increase to a maximum 
sustained level after approximately 20 min in light (Figure 2.2). 
 In the next study, locomotor activity was assessed under alternating light-dark 
conditions. Testing began in darkness, followed by three cycles of light (10 min) and 
dark (10 min). As reported above, activity in initial dark increased to a maximum and 
then began to decrease (Figure 2.3).  Switching to light precipitously decreased 
activity. On return to darkness, however, activity rapidly increased to a level that was 
substantially higher than that obtained during the initial dark period. Additional cycles 
of alternating light and dark reliably produced alternating levels of low and high 
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activity, respectively (Figure 2.3). This pattern of activity is in stark contrast to what 
was obtained during extended periods of light or dark. The next two studies explored 
the conditions under which this “paradoxical” pattern of activity occurred. 
 Duration of the initial dark period (10 or 20 min) was varied in the next study 
(Fig 2.4A). For both durations, activity in the initial dark period quickly increased to a 
maximum and then decreased (data not shown). Switching to light for 20 min 
resulted in an initial low level of activity that was followed by a gradual increase. 
Duration of the initial dark period did not affect either the low initial level of activity in 
light or the subsequent gradual increase (Figure 2.4A). Moreover, under both 
conditions the return to darkness produced a substantial increase in activity, and to 
levels that exceeded the maximum obtained initially in dark. Thereafter, activity in 
dark progressively decreased. Figure 2.4A shows that the levels of activity when 
dark was reinstated were identical regardless of the duration of the initial dark 
period.   
 Duration of the light period was next manipulated (Fig. 2.4B). Following 10 
min of dark, visible light was presented for either 5 or 15 min, and then followed by a 
return to darkness. Order of presentation of the light-period durations was 
counterbalanced between plates. Figure 2.4B shows that the return to darkness 
reliably increased activity, and that the magnitude of the increase was greater 
following 15-min than 5-min of light. The activity in darkness (when reinstated) 
decreased progressively after the peak was reached, and the rate of decrease was 
approximately equal regardless of the duration of the preceding light period; a 50% 
decrease occurred approximately 10 min after the peak in activity. 
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 In the last study, shown in Figure 2.5, activity was recorded during acute 
exposure to 1%, 2% or 4% ethanol.  Control larvae were exposed to 10% Hanks 
solution. The lowest concentration of ethanol (1%) increased activity during the dark 
periods. At this concentration (1%), the increase in activity on return to darkness was 
greater than during the initial dark period, which was also apparent for the control 
larvae.  Figure 2.5A shows, however, that the decline in activity during reinstatement 
of the dark periods did not reach the level that was obtained in the control group at 
the end of the period. Interestingly, larvae exposed to 1% ethanol also showed a 
delayed decrease in activity during the transitions from dark to light. On the other 
hand, the rapid increase in activity during transitions from light to dark was similar to 
that obtained in vehicle-control larvae. The intermediate concentration of ethanol 
(2%) produced substantial increases in activity regardless of lighting condition, 
although transient drops in activity were noticeable immediately following the switch 
from dark to light. The highest concentration (4%) abolished activity throughout the 
test session; at this concentration the larvae were motionless but still alive. 
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Discussion 
 The increasing use of zebrafish in developmental toxicology highlights the 
need for a detailed understanding of their behavior. This challenge is difficult when 
the necessary testing environment is a multi-well microtiter plate suitable for the 
rapid screening of chemical compounds. Under these conditions the range of 
behavior for investigation appears limited. Behavior, however, has both spatial and 
temporal properties, and while the microtiter-plate wells restrict the spatial range of 
behavior, they do not necessarily constrain investigation of the time-dependent 
dimensions of behavior.  
 We began investigating the locomotion of larval zebrafish in 96-well microtiter 
plates in preparation for a series of studies on identifying toxicants that could 
potentially disrupt development of the nervous system in humans. Test-session 
durations allowed repeated manipulation of lighting conditions and a detailed 
characterization of larval locomotion. When locomotion was tested in extended dark, 
activity was high at first and then decreased to a low level (Figure 2.2). When tested 
in extended light, activity gradually increased to a stable level (Figure 2.2).  These 
time-dependent patterns of activity are similar to those reported by Burgess and 
Granato (2007) for groups of larvae in a larger test environment. When shorter light 
and dark periods alternated within a test session, however, activity was low in light 
and considerably higher in dark (Figure 2.3). Dark activity was also higher than 
activity in extended light. While this pattern of activity appeared paradoxical, we 
have found it to be a highly reliable finding under a variety of conditions. Additional 
experiments showed that the pattern of alternating activity did not depend on 
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duration of the initial dark period (Figure 2.4A).  Duration of the light period did, 
however, influence the magnitude of the increase in activity when darkness was 
reinstated (Figure 2.4B).    
 Recent reports (D'Amico et al., 2008, Emran et al., 2007, Hurd et al., 1998, 
Prober et al., 2006) have identified a similar pattern of activity in larval zebrafish with 
switches in lighting conditions. Prober et al. (2006) arranged alternating 30-min 
periods of light and dark (infrared), during night-time hours, and obtained gradually 
increasing activity during the light periods, followed by spikes in activity early in the 
dark periods that decayed rapidly. Emran et al. (2007) showed that a switch from 
light to dark (infrared) produced a sudden spike in activity and then a higher level 
than in light. A switch from dark to light also produced a sudden spike in activity, but 
then a lower level than what had occurred in dark. The time frame (several seconds) 
in which data were presented for the transitions was, however, considerably shorter 
than what we used (i.e., several minutes) to study larval behavior patterns and 
transitions. Finally, D’Amico et al. (2008) recently presented alternating larval activity 
patterns under alternating lighting conditions that are identical to what we report. 
 In the present studies, substantially higher levels of activity occurred when the 
larvae were returned to darkness than when they were tested initially in darkness. 
This result indicated that the light period played an important role in enhancing 
activity when darkness was reinstated. The greater increase in dark activity after 15-
min than 5-min of light (Figure 2.4B) further indicates the importance of the light 
period on the subsequent increase in dark activity. The results could be interpreted 
as a rebound activity increase in dark following exposure to a period of light that was 
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aversive to the larvae. This interpretation suffers from the fact that when either light 
or dark was presented for an extended period, activity was higher in light than in 
dark. Interestingly, a similar pattern of activity was reported for locusts by 
Moorhouse et al. (1978) that are presented here in Figure 2.6A.  When tested in 
dark, the activity of locusts initially increased to a maximum and then gradually 
decreased. When tested in light, activity increased more slowly and to a maximum 
that was both higher and occurred later than in dark. When light and dark periods 
alternated, activity was substantially lower in light and substantially higher in dark. 
Moorhouse and co-workers (1978) interpreted the paradoxical activity pattern as a 
case of antagonistic induction (Sherrington, 1906), where in their case light created 
an inhibitory effect on activity that was slow to dissipate, dark created a more rapid-
acting excitatory effect, and alternating light-dark conditions produced a rebound 
excitation of activity in dark (see Staddon [1983] for further discussion). Figure 2.6 
also presents results from the current studies (B).  In comparing the two panels, the 
similarity of results is clear; higher levels of activity occur in extended light than in 
extended dark, yet alternating light and dark periods produces the opposite pattern 
of activity. Together, these results suggest a common mechanism that may underlie 
the effects of light-dark alternation on activity in both species.   
In the present studies, the initial dark period was included to allow acclimation 
and minimize any disturbance accompanying transfer of the microtiter plate to the 
activity recording platform. During this period, activity increased quickly to a 
maximum and then slowly decreased.  When light followed, activity decreased 
rapidly. The return to darkness produced a rapid and substantial increase in activity. 
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The peak of activity on return to darkness exceeded the maximum level obtained 
during the initial dark period, and was greater when preceded by a long period of 
light (15 min) than a shorter (5 min) one. The results are consistent with light being 
aversive. Following the peak, activity during reinstatement of dark decreased 
steadily. Interestingly, the rate of decrease in dark was approximately equal 
regardless of the duration of the preceding light period. These results suggest the 
peak in activity and the subsequent decay may be separable phenomena. Further 
studies are warranted on the effects of a broader range of light-period durations on 
activity in both light and subsequent dark. 
The decrease in activity during dark may represent habituation, which is 
considered an ancestral form of learning. Habituation is often referred to as non-
associative learning, and occurs in a wide range of species and experimental 
conditions (e.g., Thompson and Spencer, 1966). A recent study demonstrated 
habituation of activity in larval zebrafish with repeated auditory-tone bursts (Best et 
al., 2008). The present experiments were not specifically designed to study 
habituation or the variables that influence it. It is interesting to note, however, that 
activity during light periods gradually increased, especially during the longer 
durations. These results may also reflect habituation or, alternatively, the gradual 
dissipation of some aversive properties of light onset. Further experiments are 
needed on whether the time-dependent activity changes in each lighting condition 
are due to habituation (see Thompson and Spencer [1966] for a review of 
habituation and its parameters). 
56 
 
 Exposure to ethanol produced several effects on larval locomotion that were 
concentration-dependent (Fig. 2.5). The lowest concentration (1%) increased activity 
in both light and dark periods. This concentration of ethanol also delayed the 
transition in activity when darkness switched to light.  This finding may be related to 
the results of Matsui et al. (2006), using the optokinetic response, that acute ethanol 
exposure reduced visual sensitivity in 5-dpf zebrafish larvae. Ethanol did not, 
however, affect the transition in locomotion from light to dark. These results suggest 
the effect of ethanol on activity during transitions in lighting conditions may not due 
to a common process. The lowest concentration also delayed the reduction in 
activity during the dark periods, suggesting an additional action of ethanol on 
transitions in activity, and perhaps habituation. The intermediate concentration (2%) 
greatly increased activity regardless of lighting condition. It is notable, however, that 
activity decreased briefly during the transitions from dark to light. This result 
indicates the overall increase in activity was not entirely a general effect, and that 
larval activity was still partially sensitive to a change in lighting conditions. The 
highest concentration (4%) almost completely abolished activity regardless of 
lighting condition. The present results are similar to those of Lockwood et al. (2004), 
in studies of ethanol’s effects on the activity of groups of larval zebrafish that were 
tested in a larger, rectangular environment.  In both experiments, low concentrations 
of ethanol increased activity, and high concentrations decreased activity. The 
present results show, however, how changes in lighting conditions can modulate the 
effect of ethanol on locomotor activity in larval zebrafish, and reveal the complexity 
of its actions. 
57 
 
In summary, the present results show the behavior of larval zebrafish in 
microtiter-plate wells is reliable, quantifiable and sensitive to time of day, lighting 
conditions and ethanol. By testing individual larva for extended durations, the current 
paradigm allowed multiple and repeated manipulation of lighting conditions to 
characterize the locomotor activity patterns and the effects of ethanol. As a result, 
these studies have established a complex and highly reproducible, three-phase 
pattern of activity involving (1) moderate initial activity in dark, (2) decreased activity 
in light, and (3) elevated activity on return to darkness. Screening studies using this 
paradigm, as an integral part of a test battery, can provide considerably more 
information regarding the effects of toxicants, and their behavioral selectivity, than is 
currently available. 
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Figure 2.1 – Effect of time of day on baseline locomotion in the dark (infrared).  Data 
are presented as mean distance moved (in cm) ± SEM during 5-min tests occurring 
every 30 min. Activity was highest in the morning then decreased to a stable level 
that was reached by 13:00 hr. Results are based on a total of 183 larvae from two 
plates. Repeated-measures ANOVA indicated a significant effect of time (p<.0001). 
Fisher’s PLSD test was used to compare test times; common letters (A-E) indicate 
no significant difference. 
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Figure 2.2 – Effects of darkness and visible light on locomotion in larval zebrafish. 
Data are presented as mean distance moved (in cm) ± SEM in 2-min intervals during 
50-min sessions. For both groups, activity increased and then decreased during the 
initial dark period (solid symbols in shaded area). Extended dark further decreased 
the level of activity (solid triangles). Switching to light (open circles) produced an 
initial decrease followed by a gradual increase in activity to a stable level. Results 
are based on a total of 89-91 larvae from each of two plates, one plate for evaluating 
extended light and the other for extended dark. Repeated-measures ANOVA for 
data from 10 to 50 min indicated a significant interaction (p< .0001) between lighting 
condition (light vs. dark) and time. Asterisks (*) indicate locomotion in light 
significantly (p< .05) different from locomotion in dark (Fisher’s PLSD test). 
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Figure 2.3 – Effect of alternating light-dark periods on locomotion in larval zebrafish. 
A 10-min period of darkness was followed by three alternating cycles of 10-min light 
and 10-min dark. Black and white bars at the bottom signify dark and light 
conditions, respectively. Data are presented as mean ± SEM distance moved (in cm) 
in 2-min intervals throughout a 70-min session. Results are for a total of 191 larvae. 
Based on activity summed within each 10-min period, ANOVA indicated a significant 
effect of light and dark conditions. Post-hoc comparisons indicated activity in each 
light period did not differ from one another, but was significantly different (p<.05) 
from the activity in all four dark periods. Activity in the first dark period was also 
significantly lower (p<.05) than the activity in all subsequent dark periods. 
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Figure 2.4 – (A) Effects of duration of the initial dark period on locomotion in larval 
zebrafish. Data are presented as mean ± SEM distance moved (in cm) in 2-min 
intervals. White and black bars signify activity recorded in light and dark, 
respectively. Results are based on a total of 183 larvae. The curves are displaced in 
time to allow direct comparison of activity in light and during return to darkness. 
Duration of the initial dark period did not affect activity in either light or subsequent 
dark. (B) Effects of duration of visible light on locomotion in larval zebrafish. Data are 
presented as mean ± SEM distance moved (in cm) in 2-min intervals. Following an 
initial dark period, light was presented for either 5 or 15 min. Activity data are 
presented during the return to dark for 20 min (denoted by the bottom black bar) 
after each light period. Results are based on a total of 188 larvae. Light period 
durations were counterbalanced between plates. Repeated-measures ANOVA 
indicted a significant interaction (p<.0001)  between activity during the dark period 
and length of the preceding light period. Asterisks (*) indicate significant difference in 
activity (p<.05) between larvae that had been exposed to 15 min of light and those 
that had been exposed to 5 min of light.  
62 
 
Time  (min)
0 10 20 30 40 50 60 70
Lo
co
m
o
to
r 
Ac
tiv
ity
 
(cm
/2
 
m
in
)
0
5
10
15
20
Control
1% Ethanol
2% Ethanol
4% Ethanol
Time (min)
0 10 20 30 40 50 60 70
Lo
co
m
o
to
r 
Ac
tiv
ity
 
[(m
ea
n
 
cm
/2
 
m
in
)/e
po
ch
]
0
5
10
15
20
Control 
1% Ethanol
2% Ethanol
4% Ethanol
*
*
*
*
*
*
*
*
*
*
*
*
 
63 
 
Figure 2.5 – Effects of ethanol on locomotion in larval zebrafish. Larvae were 
exposed to ethanol (1%-4% v/v) or vehicle (10% Hanks solution) for 90 min. 
Locomotion was recorded for the last 70 min. Data in (A) are presented as mean ± 
SEM distance moved (in cm) in 2-min intervals during each lighting condition. 
Repeated-measures ANOVA indicated a significant interaction (p<.0001) between 
ethanol dose and time.  (B) shows ethanol effects on activity averaged across each 
lighting period. Repeated-measures ANOVA indicated a significant interaction 
between ethanol dose and time (p< .0001). Step-down ANOVAs indicated a 
significant effect of ethanol dose (p< .0001) on activity in each lighting period. 
Asterisks (*) indicate significant (p<.05) differences from control (Fisher’s PLSD 
post-hoc test). In both panels, black and white bars signify dark and light periods, 
respectively. Results are based on a total of 46-47 larvae per dose, from two plates, 
with each plate containing all doses. 
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Figure 2.6 – Comparison of the effects of alternating light-dark cycles on locomotion 
in locusts and in larval zebrafish. Left panel shows results from Moorhouse et al. 
(1978) for locomotion in locusts under varying lighting conditions (indicated by top 
Time (min)
10 20 30 40 50
Lo
c
o
m
o
to
r 
A
ct
iv
ity
 
(cm
/2
 
m
in
)
0
2
4
6
8
10
12
14
Continuous Light
Continuous Dark
Alternating, Light Phase
Alternating, Dark Phase
65 
 
bars). Group 1 (fine dotted line) was tested in extended light; Group 2 (coarse dotted 
line) was tested in extended dark; and Group 3 (solid line) was tested in dark for one 
hour then alternating light and dark periods. Each line represents mean activity for 
10 locusts. Right panel summarizes results from the present experiments for 
locomotion of larval zebrafish in extended light, extended dark, and alternating light 
and dark (data from portions of Fig. 2 and 3 are combined). Note difference in time 
scales between panels. Results from Moorhouse et al. are reproduced with 
permission of the Company of Biologists. 
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Chapter 3: Acute Neuroactive Drug Exposures Alter Locomotor Activity in 
Larval Zebrafish 
 
Preface 
The acute effects of ethanol, d-amphetamine and cocaine are all well-documented in 
mammals.  This study evaluates the acute effects some common neuroactive drugs 
on 6 dpf larvae.  It addresses Specific Aim 2: “Evaluate behavioral phenotypes in 
larval zebrafish after acute exposure to neuroactive drugs that target the 
dopaminergic nervous system.” Specifically, the following question was answered: 
• Are zebrafish larvae sensitive to common neuroactive drug exposures? 
 
*This work has been published: 
Irons, T. D., MacPhail, R. C., Hunter, D. L., and Padilla, S. (2010). Acute 
neuroactive drug exposures alter locomotor activity in larval zebrafish. Neurotoxicol 
Teratol 32, 84-90. 
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Abstract 
As part of the development of a rapid in vivo screen for prioritization of toxic 
chemicals, we have begun to characterize the locomotor activity of zebrafish (Danio 
rerio) larvae by assessing the acute effects of prototypic drugs that act on the central 
nervous system.  Initially, we chose ethanol, d-amphetamine, and cocaine, which 
are known to increase locomotion at low doses and decrease locomotion at higher 
doses in mammals. Wild-type larvae were individually maintained in 96-well 
microtiter plates at 26ΕC, under a 14:10 light:dark cycle, with lights on at 0830 hr. At 
6 days post-fertilization, ethanol (1 – 4% v/v), d-amphetamine sulfate (0.1 – 20.0 µM) 
or cocaine hydrochloride (0.2 – 50.0 µM) were administered to the larvae by 
immersion (n ≥ 21 per dose).  Beginning 20 minutes into the exposure, locomotion 
was assessed for each animal for 70 minutes using 10-minute, alternating light 
(visible light) and dark (infrared light) periods.  Low concentrations of ethanol and d-
amphetamine increased activity, while higher concentrations of all three drugs 
decreased activity.  Because ethanol effects occurred predominately during the light 
periods, whereas the d-amphetamine and cocaine effects occurred during the dark 
periods, alternating lighting conditions proved to be advantageous.  These results 
indicate that zebrafish larvae are sensitive to neuroactive drugs, and their locomotor 
response is similar to that of mammals. 
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Introduction 
 Zebrafish are a popular model for the study of nervous system development 
and its associated behavioral phenotypes (reviewed by (Sison et al., 2006).  
Compared to rodent models, zebrafish have many advantages for high-throughput 
screening: their small size allows for easier handling and husbandry, they are 
relatively inexpensive, they produce large numbers of progeny (up to 200 eggs in 
one mating), and their development is rapid (days as opposed to weeks).  These 
characteristics, along with external fertilization and transparency of the fish at 
embryonic and larval stages, provide a useful alternative for studying the developing 
vertebrate nervous system.  
Functional assessments of zebrafish are possible early in development.  
Newly-hatched, larval zebrafish have a rich behavioral repertoire (Budick and 
O'Malley, 2000, Burgess and Granato, 2007), even in the small environment of a 
microtiter plate well (MacPhail et al., 2009).  By six days post fertilization (dpf), the 
larvae are mature swimmers with functioning sensory and motor systems allowing 
studies of locomotor, escape, goal-oriented, and optomotor responses (reviewed in 
Drapeau et al., 2002, Guo, 2004, Kimmel, 1995). 
 One accepted way to understand how the mammalian nervous system works, 
and also assess the function of the nervous system, is by administering neuroactive 
drugs.  Researchers have gathered considerable information detailing the behavioral 
response of several different species to neuroactive compounds like ethanol, d-
amphetamine, and cocaine.  It is well-established that acute ethanol administration 
produces a biphasic dose-response pattern (“inverted U”), where lower doses 
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increase activity, and higher doses decrease activity (Cohen et al., 1997, Crabbe et 
al., 1982, Frye, 1981, Masur and Martins dos Santos, 1988).  d-Amphetamine 
produced a similar response in several mammalian species (Antoniou et al., 1998, 
Badanich et al., 2008, Campbell et al., 1969, Niculescu et al., 2005, Porrino et al., 
1984.  Cocaine has produced a variety of response patterns across differing 
behaviors, either increasing activity (Antoniou et al., 1998), decreasing activity 
(Antoniou et al., 1998), or causing an “inverted U” dose-response pattern (Katz et 
al., 1999).  Human studies have found that naïve individuals exhibit motor changes 
similar to their laboratory animal counterparts in response to acute administration of 
methamphetamine, an amphetamine-related compound (reviewed by Caliguri and 
Buitenhuys, 2005).  Also, behavioral inhibition studies conducted in parallel with rats 
and humans exposed to either ethanol or d-amphetamine yielded comparable 
results: augmented inhibition after amphetamine administration, and attenuated 
inhibition after ethanol administration (de Wit et al., 2000, Feola et al., 2000).  
Studies with ethanol, d-amphetamine or cocaine challenges have also proven useful 
in uncovering latent effects of developmental exposures to behavioral teratogens 
(Adriani et al., 1998, Canales and Graybiel, 2000, Crozatier et al., 2003, Gerlai et al., 
2006, Glatt et al., 2000, Kunko et al., 1993). 
There are only a few reports of the behavioral effects of neuroactive drugs in 
zebrafish, and almost all were conducted in adults.  Adult zebrafish behavior 
changed in response to either acute cocaine (Darland and Dowling, 2001, Lopez-
Patino et al., 2008) or ethanol (Dlugos and Rabin, 2003, Gerlai et al., 2000, Gerlai et 
al., 2006) administration. We are unaware of any studies of acute d-amphetamine 
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effects in zebrafish. Because the mammalian literature suggests that the response to 
neuroactive drugs may differ as the brain develops (Adriani et al., 1998, Badanich et 
al., 2008, Campbell et al., 1969, Frantz et al., 2007, Lanier and Isaacson, 1977, 
Laviola et al., 1994, Niculescu et al., 2005, Simansky and Kachelries, 1996, 
Stanwood and Levitt, 2003), it cannot be assumed that larval zebrafish show the 
identical response to these drugs as do adult zebrafish. There is only one study on 
locomotor effects of acute ethanol exposure in zebrafish larvae (Lockwood et al. , 
2004), and none assessing the effects of d-amphetamine or cocaine in larvae.  In 
the ethanol study, 7-dpf zebrafish larvae responded similarly to rodents, showing a 
biphasic, “inverted U” dose-response pattern. 
 In the present studies, a drug challenge paradigm for 6-dpf zebrafish larvae 
was developed to assess the behavior of the larval zebrafish in a rapid and 
informative manner. To evaluate our paradigm, we tested the acute effects of three 
neuroactive drugs known to produce an “inverted U”-shaped dose-response in 
mammals to determine if larval zebrafish would behave in a similar manner.  This 
paradigm may be of use in future studies to unveil abnormal nervous system 
development/maturation due to developmental neurotoxicants.
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Methods 
Breeding and Rearing of Experimental Animals  
All studies were conducted in accordance with the guidelines of the 
Institutional Animal Care and Use Committee at the National Health and 
Environmental Effects Research Laboratory.  Wild-type adult zebrafish (Danio 
rerio) were maintained as breeders in an Association for Assessment and 
Accreditation of Laboratory Animal Care (AAALAC)-approved animal facility at 
28°C with a 14:10 hr light:dark cycle with lights on at  0830 hr. On the day of 
embryo collection, one hour prior to light onset, all adults in a colony tank were 
placed in a breeding tank (Aquatic Habitats, Apopka, FL). One hour after light 
onset, the adults were returned to the colony, and embryos were collected from 
the breeder tank. The embryos were then pooled, placed in a 26°C waterbath for 
2 hours, washed with a 1% bleach solution in 10% Hanks’ balanced salt solution 
(13.7 mM NaCl, 0.54 mM KCl, 25 µM Na2HPO4, 44 µM KH2PO4, 130 µM CaCl2, 
100 µM MgSO4, 420 µM NaHCO3) for 1 min, and then rinsed several times with 
10% Hanks’ solution.  After bleaching, fertilized eggs were individually placed 
into 10% Hanks’ solution in 96-well mesh microtiter plates (Multiscreen™ catalog 
#MANMN4050, Millipore Corp., Bedford, MA) and reared for six days. Each day, 
the 250 µL of aerated 10% Hanks’ solution in each well was renewed. The 
embryos/larvae (hatch on or before 4 dpf) were then returned to an incubator, 
where they were maintained on a 14:10 light:dark cycle (lights on at 0830 hr) at 
26±0.7°C.  
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Neuroactive Drug Challenges 
For challenges with ethanol, d-amphetamine or cocaine, the larvae (6 dpf) 
were placed into fresh 10% Hanks’ solution the morning of the test day, and the 
plate was immediately put into a light-tight drawer in the darkened test room kept 
at 26°C.  In the afternoon, the larvae were exposed t o a range of concentrations 
of one of the neuroactive drugs, which were distributed evenly throughout the 
plate.  Drug concentrations were: 1, 2, or 4% for ethanol (95% v/v; Aldrich, 
Milwaukee, WI); 0.1, 0.2, 0.7, 2.2, 6.6, or 20.0 µM for d-amphetamine; and 0.2, 
0.6, 1.9, 5.6, 16.7, or 50.0 µM for cocaine (d-amphetamine sulfate and cocaine 
hydrochloride were obtained from Sigma, St. Louis, MO).  Each plate also had 
control solutions that contained only the vehicle (10% Hanks’ solution).  Each 
plate was immediately placed under the baffle on the recording platform:  a light 
box equipped with both infrared and visible light capabilities.  After 20 minutes, 
recording was started in infrared light (which will hereafter be referred to as 
“dark”), and the infrared light remained on throughout the 70 minute recording 
session. Every 10 minutes the visible light (or “light”) was switched on for 10 
minutes, and then switched off for 10 minutes (dark session). This pattern was 
continued for a total recording session of 70 minutes.  Each drug challenge was 
conducted on two separate plates with n = 12-24 larvae/dose/plate (for controls, 
n = 24 larvae/plate).   
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Recording and Analysis of Larval Locomotion 
Movement of each larva was monitored with a Noldus behavior recording 
system (Noldus Information Technology, Leesburg VA).  Fish movement 
(locomotion) was quantified from videos using Ethovision software Version 3.1 
(Noldus Information Technology, Leesburg VA), with a tracking rate of 5 image 
samples/sec.  A minimum-distance input filter of 0.135 cm was used to remove 
background noise.  Dead larvae or larvae that displayed physical abnormalities 
were not included in any data analyses or figures.   
 
Statistical Analyses 
The data for each drug were first assessed using a repeated measures 
analysis of variance (ANOVA) with time and dose as the independent variables 
and locomotor activity (distance moved/time) as the dependent variable.  With 
each compound, a significant interaction (p ≤ 0.001) of time and dose was found.  
Subsequent ANOVAs were performed for each ten-minute light and dark period 
to determine which doses differed from control (p ≤ 0.05).  All data are presented 
as mean ± standard error of the mean (SEM). 
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Results 
Ethanol Challenge 
The time course for the ethanol challenge is shown in Figure 3.1A.  
Control larvae displayed a consistent pattern of locomotor activity: when the 
visible light was applied, the animals ceased movement; however, when the light 
is removed (dark), the larvae rapidly and markedly increased activity.  The 
orderly activity pattern of the untreated larvae produced in response to the 
alternating lighting conditions is perturbed by ethanol treatment in a 
concentration-dependent manner.  Figure 3.1B shows the effect of ethanol on the 
total activity of the larvae during each 10-minute period.  Larvae exposed to 
either 1 or 2% ethanol were hyperactive.  Specifically, larvae treated with 1% 
ethanol were hyperactive during the initial dark period as well as two of the three 
subsequent light periods.  Animals treated with a higher dose of ethanol (2%) 
showed a higher degree of hyperactivity in every light period and in the initial 
dark periods.  Larvae exposed to 4% ethanol were immobile.  Because lower 
doses of ethanol increased activity and the highest dose decreased activity, the 
challenge of zebrafish larvae with ethanol produced an “inverted U” dose-
response pattern. 
 
d-Amphetamine Challenge 
Exposure of larvae to d-amphetamine also produced an “inverted U” dose-
response pattern (Figure 3.2).  The time courses (Figures 3.2A-F) show the 
responses of the larvae by dosage group compared to controls. The behavioral 
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patterns of the larvae in response to the alternating light and dark were highly 
consistent, regardless of the dose of d-amphetamine.  Summation of locomotor 
activity for each ten-minute light or dark period revealed activity changes across 
the entire range of d-amphetamine doses during varying cycles, and were more 
prevalent in darkness (Figure 3.2G).  Generally, the lower doses of d-
amphetamine (0.1, 0.2, or 0.7 µM) increased locomotor activity.  The lowest dose 
(0.1 µM) increased activity only in the first light period (Figures 3.2A and G).  At 
twice that dose (0.2 µM), there was obvious and sustained hyperactivity in three 
of the four dark periods, but not during the light periods (Figures 3.2B and G).  
Larvae treated with 0.7 µM d-amphetamine displayed marked hyperactivity 
during the first three dark periods, as well as the initial light period (Figures 3.2C 
and G).  Interestingly, animals administered 2.2 µM d-amphetamine were 
hyperactive only during the initial dark period and one of the light periods 
(Figures 3.2D and G).  Larvae treated with this dose showed the most variability 
in effect, which may be evidence of a transition between the lower doses that 
cause hyperactivity and the higher doses that cause hypoactivity.  At doses 
higher than 2.2 µM d-amphetamine, there was a general, dose-dependent 
decrease in activity.  Larvae treated with 6.6 µM d-amphetamine were hypoactive 
in two of the three dark periods that followed periods of light (Figures 3.2E and 
G).  The highest dose of d-amphetamine, 20 µM, caused more substantial and 
sustained hypoactivity in all three dark periods that followed light (Figures 3.2F 
and G).  Overall, larvae treated with d-amphetamine showed an “inverted U”-
shaped dose-response curve that was primarily evident in the dark. 
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Cocaine Challenge 
Acute cocaine exposure did not elicit an “inverted U” dose-response 
curve, but higher doses did produce pronounced hypoactivity (Figure 3.3).   The 
time courses show the same general behavior patterns in response to the light 
and dark (Figures 3.3A-F).  Lower doses of cocaine did not produce any 
substantial hyperactivity in the zebrafish larvae (Figures 3.3A-C).  The highest 
three doses (5.5, 16.7, and 50 µM cocaine), however, elicited hypoactivity, only 
during dark periods (Figures 3.3D-G). 
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Discussion 
These three neuroactive drugs had differential effects on the locomotor 
activity of 6-dpf larvae (Table 3.1). Cocaine and d-amphetamine had similar 
potencies, both far exceeding that of ethanol (−105-fold difference).  Ethanol and 
d-amphetamine elicited an “inverted U” dose-response, where lower doses 
caused hyperactivity and higher doses caused hypoactivity.   
The biphasic, “inverted U” dose-response pattern in locomotion has been 
reported numerous times in mammals using these same neuroactive drugs.  
Acutely administered d-amphetamine produced an “inverted U” dose-response 
pattern in young (Campbell et al., 1969, Niculescu et al., 2005) and adult rodents 
(Antoniou et al., 1998, Campbell et al., 1969, Porrino et al., 1984).  The data 
regarding acutely administered cocaine are less consistent, with one report (Katz 
et al., 1999) showing an “inverted U”-shaped dose response pattern in young 
rodents, and others reporting only increased activity (Badanich et al., 2008, 
Niculescu et al., 2005) in rodents. In adult rats, a related study of acute cocaine 
exposure detected only increased activity (Antoniou et al., 1998).  Studies on 
ethanol in adult and young rodents (Cohen et al., 1997, Crabbe et al., 1982, 
Frye, 1981, Masur and Martins dos Santos, 1988), as well as adult zebrafish 
(Gerlai et al., 2000) have reported an “inverted U” dose-response pattern in 
locomotor activity.   
In a study similar to the present investigation on acute ethanol effects in 
zebrafish larvae (Lockwood et al., 2004), the larvae responded much like adult 
zebrafish (Gerlai et al., 2000), showing hyperactivity at the lower doses and 
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hypoactivity at the higher doses.  The experimental conditions of the Lockwood 
et al. study were, however, quite different than the experimental conditions of the 
present group of studies:  7-dpf larvae were tested in groups of ten in a novel 
tank (8x6x2 cm), with activity recorded over a 20-minute period in the light.   In 
contrast, our paradigm is a higher-throughput assay that is designed for 
screening applications.  We tested 6-dpf zebrafish larvae individually in a much 
smaller environment (1 fish per well of a 96-well plate), using alternating light and 
dark, and over a longer period of time (70 minutes).  Even given all these 
differences, the results obtained in the two studies were consistent: hyperactivity 
occurred at 1 and 2% ethanol, and hypoactivity, at 4% ethanol.  It appears, 
therefore, that the small well of the microtiter plate does not dampen the effect of 
ethanol, and perhaps, other neuroactive drugs. 
In addition to using in a 96-well plate to increase our testing throughput 
capability, we also manipulated lighting conditions due to their significant effects 
on larval zebrafish locomotor activity (Burgess and Granato, 2007, MacPhail et 
al., 2009, Prober et al., 2006).  Alternating light and dark periods produces a 
consistent pattern of locomotor activity (MacPhail et al., 2009); refer also to 
control pattern of activity in Figs. 3.1A, 3.2A, and 3.3A of the present study): in 
visible light, the larvae first cease movement, and then slowly increase activity 
over the ten-minute period; when darkness is imposed, the larvae rapidly and 
markedly increase activity, which then slowly abates with time.  Also larvae are 
typically more active in the dark periods that follow light periods versus initial dark 
periods. 
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Administration of the neuroactive drugs had differential effects on this 
activity pattern in light and dark conditions.  Treatment with d-amphetamine or 
cocaine did not alter the general pattern of response of the larvae to the light or 
dark; however, when treated with ethanol, the animals showed a lag (response 
latency) in their response to the light. That is, when the light was turned on, the 
larvae treated with 1 or 2% ethanol did not slow their activity as quickly as the 
controls (Figure 3.1A).  Additionally, larvae treated with ethanol experienced less 
attenuation of activity compared to that of the controls.  This lack of response to 
the light may be related to findings that 5-dpf larvae exposed acutely to 1.5 or 
1.75% ethanol had a higher visual threshold to light than controls (Matsui et al., 
2006).  Other investigations have noted that acute d-amphetamine and acute 
ethanol administration cause different patterns of response on other endpoints. 
Human and rat studies have shown that impulsivity is lost in a stimulus-
dependent stop task as a result of acute ethanol administration, but not acute 
amphetamine administration (de Wit et al., 2000, Feola et al., 2000). 
Complementary studies on the neurochemical effects of these drugs in 
zebrafish larvae would be beneficial.  Pharmacological agents could be used to 
specifically target major signaling pathways in the nervous system to determine if 
the effects of the drugs used in the present study are altered.  Both d-
amphetamine and cocaine act on the dopamine transporter; however, d-
amphetamine is taken up into neurons by the transporter, where it then displaces 
stored dopamine, while cocaine only blocks the reuptake of dopamine that has 
already been released into the synapse (Gold et al., 1989, Williams and Galli, 
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2006).  Perhaps the small difference in these mechanisms or some subtle 
difference in the maturation of the dopaminergic nervous system accounts for the 
differences in larval response to d-amphetamine and cocaine (summarized in 
Table 3.1). Studies in rodents have shown that behavioral effects of cocaine and 
d-amphetamine can be blocked by agents that target dopamine signaling (Leite 
et al., 2008, Miller et al., 2001, Sobrian et al., 2003, Swerdlow et al., 1986).  
Counteracting the effects of ethanol by pharmacological intervention may be 
more intractable since its mechanism(s) of action do not appear to be well-
defined.  Ethanol has many neural substrates including GABA, NMDA, and 
nicotinic acetylcholine receptors (reviewed by (Harris et al., 2008, Kamens and 
Phillips, 2008).  It is interesting to note, however, that reversal of ethanol-induced 
hyperactivity with dopamine antagonists has been reported in mice (Cohen et al., 
1997).  
In summary, we have presented a pharmacological challenge paradigm 
using 6-dpf zebrafish larvae in a 96-well microtiter plate format.  Behavioral 
studies using this paradigm have numerous advantages.  It is rapid throughput, 
with the activity of 96 larvae being assessed simultaneously.  The larvae are 
raised and tested in the same environment, which reduces stress (and possible 
injury) caused by transfer to a new environment.  Increases or decreases in 
baseline locomotor activity can also be controlled by varying lighting conditions.   
Finally, we have shown that prototype neuroactive drugs produce dose-response 
patterns that are similar to those obtained in rodent studies, and that effects can 
be modulated by lighting conditions.  All these features give the investigator a 
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rapid, flexible and controllable behavioral screen for probing development of the 
nervous system.   
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Figures 
 
Figure 3.1 – Larval zebrafish activity after acute administration of ethanol.  The 
larvae were placed into the ethanol solutions and recording began 20 minutes 
later in alternating periods of darkness and light for a total of 70 minutes.  (A) 
Time course by dose in two-minute intervals.  (B) Total activity (distance moved, 
cm) in each ten-minute light and dark period.  In both panels, white and black 
bars at the bottom denote light and dark periods, respectively.  The legend 
corresponds to both panels.  Values are reported as mean (n=21-24 
larvae/concentration/plate, for 2 plates) ±SEM (*p<0.05 compared to control).
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Figure 3.2 – Larval zebrafish activity after acute administration of d-
amphetamine.  The larvae were placed into the d-amphetamine solutions and 
recording began 20 minutes later in alternating infrared and visible light for a total 
of 70 minutes.  (A-F) Time course by dose in two-minute intervals. In each panel 
the open circles represent the mean distance moved for control larvae every two 
minutes; black triangles represent larvae that received d-amphetamine. The 
control activity data are reproduced in each panel. They are repeated in each 
panel for ease of comparison.  (G) Total activity (distance moved, cm) in each 
ten-minute light and dark period.  In all panels, white and black bars at the 
bottom denote light and dark periods, respectively.  Values are reported as mean 
(n=11-24 larvae/concentration/plate, for 2 plates) ±SEM (*p<0.05 compared to 
control). 
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Figure 3.3 – Larval zebrafish activity after acute administration of cocaine.  The 
larvae were placed into the cocaine solutions and recording began 20 minutes 
later in alternating infrared and visible light for a total of 70 minutes.  (A-F) Time 
course by dose in two-minute intervals.  In each panel, the open circles represent 
the mean distance moved for control larvae every two minutes; black triangles 
represent larvae that received cocaine. The control activity are reproduced in 
each panel. They are repeated in each panel for ease of comparison.  (G) Total 
activity (distance moved, cm) in each ten-minute light and dark period.  In all 
panels, white and black bars at the bottom denote light and dark periods, 
respectively.  Values are reported as mean (n=11-24 larvae/concentration/plate, 
for 2 plates) ±SEM (*p<0.05 compared to control). 
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Compound 
“Inverted U” 
dose-
response? 
“Inverted U”  
in light 
“Inverted U”  
in dark 
Lowest 
hyperactive 
dose 
Lowest 
hypoactive 
dose 
Ethanol Yes Yes No 1% 4% 
d-Amphetamine Yes No Yes 0.2 µM 6.6 µM 
Cocaine Hypoactivity 
only No 
Hypoactivity 
only N/A 5.5 µM 
 
Table 3.1 – Summary of neuroactive drug effects.
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Chapter 4: Acute Administration of Dopaminergic Drugs has Differential 
Effects on Locomotion in Larval Zebrafish 
 
Preface 
Acute effects of drugs that act on the dopaminergic nervous system have been 
studied extensively in mammals, but not as well in zebrafish.  This study addresses 
Specific Aim 2: “Evaluate behavioral phenotypes in zebrafish larve after acute 
exposure to neuroactive drugs that target the dopaminergic nervous system.”  
Specifically, it answers the question: 
• What behavioral effects occur following exposure to drugs that target 
dopaminergic receptors?” 
 
*This work is being prepared for submission: 
Irons, T.D., Kelly, P., Hunter, D.L., MacPhail, R.C., and Padilla, S.  “Acute 
Administration of Dopaminergic Drugs has Differential Effects on Locomotion in 
Larval Zebrafish.”  In preparation, Neuropsychopharmacology. 
.
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Abstract 
Altered dopaminergic signaling causes behavior changes in mammals.  In 
general, agonists of dopamine receptors increase locomotor activity, while 
antagonists decrease locomotor activity.  In this study, the acute effects of drugs 
known to target dopaminergic receptors in mammals were assessed in zebrafish 
larvae.  The goal was to assess the behavioral manifestations of altered 
dopaminergic signaling in this model, and further, to determine if stimulating and 
blocking receptors would have differential effects on locomotor activity.  Larvae (6 
dpf) were maintained in 96-well microtiter plates (1 larva/well) at 26°C and under a 
14:10 hr light:dark cycle, with lights on at 0830 hr.  Non-lethal concentrations of 
dopaminergic agonists (apomorphine, SKF-38393, and quinpirole) and antagonists 
(butaclamol, SCH-23390, and haloperidol) were administered by immersion.  Each 
drug was screened on individual plates, with a broad range of concentrations (0.2-50 
µM) and vehicle controls included.  An initial experiment identified the time of peak 
effect of each drug (20-260 minutes post-dosing, depending on the drug).  
Locomotor activity was then assessed for a period of 70 minutes in alternating light 
and dark conditions at the time of peak effect to analyze the dose-dependent effects 
of the drug.  All drugs altered the locomotor activity of 6-dpf zebrafish in a dose-
dependent manner.  Both the D1- and D2-like selective agonists (SKF-38393 and 
quinpirole, respectively) increased locomotion, while the selective antagonists (SCH-
23390 and haloperidol, respectively) decreased activity.  In addition to the effects on 
activity, the selective antagonists also blunted the response of the larvae to changes 
in lighting conditions at higher doses.  The dose-response profiles of the 
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nonselective drugs were more complex than the selective compounds, displaying 
biphasic effects on locomotor activity.  Apomorphine, the agonist, increased activity 
at the low dose, and at the higher dose.  Butaclamol, however, increased activity at 
low doses, and decreased locomotion at high doses.  This study shows that (1) 
zebrafish larvae are sensitive to dopamine receptor-mediated changes in locomotor 
activity, (2) receptor agonists and antagonists generally have opposite effects, and 
(3) the locomotor responses of zebrafish to drugs that target dopaminergic receptors 
are similar to mammals.   
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Introduction 
Dopamine is an essential neurotransmitter involved in the control of many 
physiological functions of the brain (reviewed in Iversen and Iversen, 2007).  With 
the majority of dopaminergic neurons innervating the midbrain in mammals (Vitalis et 
al., 2005), dopaminergic signaling modulates a wide array of behaviors (e.g. motor 
activity, stereotypy; Ungerstedt, 1976, Oberlander et al., 1979).  Impaired 
dopaminergic signaling can lead to the development of various behavioral disorders 
such as Parkinson’s disease, schizophrenia, and attention deficit hyperactivity 
disorder (Bowton et al., 2010, Cortese et al., 2005, Hirsch, 1992, Zeiss, 2005). 
Both pre- and post-synaptic receptors for dopamine are present in the 
nervous system of vertebrates (reviewed in Missale et al., 1998).  These are G-
protein coupled receptors that have seven transmembrane domains (Girault and 
Greengard, 2004).  In mammals, these receptors exist in two subfamilies: D1-like 
(D1 and D5) and D2-like (D2, D3, and D4) receptors.  D1-like receptors share 
extensive homology across their transmembrane domains and are positively coupled 
to adenylyl cyclase stimulation (Herve et al., 2001, Zhuang et al., 2000).  The 
transmembrane domains of D2-like receptors (which are distinct from D1-like 
receptors) are also conserved, but stimulation of these receptors inhibits adenylyl 
cyclase (Obadiah et al., 1999).  Through signaling events mediated by these 
receptors, dopamine can govern the initiation and execution of movement (Han et 
al., 2007).  
Zebrafish are becoming a popular model in studies of behavior (reviewed in 
Drapeau et al., 2002, Fetcho, 2007).  This model provides many benefits over the 
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use of mammals, such as rapid and external development (Kimmel, 1995), small 
size, and low cost.  Zebrafish maintain a great level of biological integrity when 
compared to mammals, as many aspects of the nervous system are highly 
conserved across vertebrate species (Grillner, 1985).  Specifically, the major 
pathways of the dopaminergic nervous system are all present in the zebrafish brain 
(Panula et al., 2006).  The system begins to develop in zebrafish at about 15 hpf, 
when expression of D2 receptor genes are detected (Boehmler et al., 2004).  
Homologous receptors for all the mammalian subtypes have been identified in the 
zebrafish, with the exception of D5, and are detected by 30 hpf in the zebrafish brain 
(Boehmler et al., 2007, Boehmler et al., 2004, Li et al., 2007).  Dopaminergic 
neurons (which are visualized by tyrosine hydroxylase expression) are first detected 
in the developing zebrafish at about 18 hpf (Holzschuh et al., 2001), and by 4 dpf, all 
neuronal cell groups are present (Rink and Wullimann, 2002).   
In the current study, the acute effects of several dopaminergic drugs (Figure 
4.1) on larval locomotion were investigated.  In mammals, agonists of dopaminergic 
receptors accentuate dopaminergic signaling in the brain.  Apomorphine, a drug 
given to patients with Parkinson’s disease (Stocchi, 2008), is a nonselective agonist, 
acting on all receptor subtypes, but with differing affinities (Millan et al., 2002).  The 
experimental drugs SKF-38393 and quinpirole are D1-like and D2-like selective 
agonists, respectively (Millan et al., 2002).  In mammals, these drugs stimulate 
locomotor activity (Archer et al., 2003, Ardayfio et al., 2010, Beninger et al., 1991, 
Hooks et al., 1994, Sobrian et al., 2003) via receptors in multiple brain regions, such 
as the nucleus accumbens, frontal cortex, habenula nucleus, and substantia nigra 
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pars reticulata (Beninger, 1991).  Antagonists of dopaminergic receptors block the 
dopaminergic signaling pathway, inhibiting the activation of downstream effectors.  
Nonselective dopaminergic antagonists like butaclamol, as well as D1- and D2-like 
selective blockers (SCH-23390 and haloperidol, respectively) reportedly decrease 
locomotor activity in mammals (Beninger et al., 1991, Choi et al., 2009, Shireen and 
Haleem, 2011, Sobrian et al., 2003).  These drugs are considered antipsychotics 
(haloperidol is given clinically; Citrome et al., 2010), and their effects can be 
attributed to inhibition of receptors in the nucleus accumbens, striatum, frontal 
cortex, and globus pallidus (Beninger et al., 1991).    
Little is known about the behavioral effects of these compounds in larval 
zebrafish.  Specifically, altered locomotor activity as a result of acute exposure to 
drugs that target dopaminergic receptors has been reported in only two studies  
Boehmler and colleagues (2007) found that quinpirole increased activity in 7-dpf 
larvae 1 hr after administration.  Additionally, Giacomini and colleagues (2006) 
reported decreased locomotor activity in 7-dpf larvae 2 hr after haloperidol exposure.  
Both of these studies used only one dose of the drugs.  Previously, studies in our 
laboratory have shown acute administration of neuroactive drugs that indirectly alter 
dopaminergic signaling (i.e. ethanol, d-amphetamine, and cocaine) caused similar 
effects on locomotor activity in zebrafish larvae as in mammals (Irons et al., 2010, 
MacPhail et al., 2009).  Other studies have assessed the behavioral manifestations 
(i.e. wake/sleep activity, photomotor response) of acute drug exposure in embryonic 
and larval zebrafish in screening assays, featuring some dopaminergic receptor 
drugs amongst many other neuroactive compounds (Kokel et al., 2010, Rihel et al., 
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2010).  Although most of the findings in these studies were consistent with what has 
been reported in mammals, there was some evidence in the study by Rihel and 
colleagues (2010) that suggested differences may exist between zebrafish and 
mammals in the roles of dopaminergic receptors in the control of behavior or target 
selectivity of dopamine receptor drugs. 
Armed with this information, we hypothesized that zebrafish larvae would 
respond to drugs that target dopaminergic receptors with dose-dependent changes 
in locomotor activity.  It was also expected that these locomotor responses would 
differ following the administration of receptor agonists vs. antagonists.  To test this, 
the time of peak effect was first identified for each drug, and then detailed-dose-
response studies were conducted using a light-stimulated behavioral testing 
paradigm.  It was found that larval zebrafish are sensitive to drugs that target 
dopaminergic receptors, and that the locomotor responses to each drug are target- 
(i.e. selective vs. nonselective) and dose-dependent.   
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Materials and Methods 
Husbandry 
 All studies were conducted in accordance with the guidelines of the 
Institutional Animal Care and Use Committee at the National Health and 
Environmental Effects Research Laboratory (Guide for the Care and Use of 
Laboratory Animals, National Academy Press, 1996).  Wild-type adult zebrafish 
(Danio rerio) were maintained as breeders in an Association for Assessment and 
Accreditation of Laboratory Animal Care (AAALAC)-approved animal facility at 28°C 
on a 14:10 hr light: dark cycle with lights on at 0830 hr.  The adult zebrafish were 
placed in breeding tanks (Aquatic Habitats, Apopka, FL) 1 hr prior to light onset.  
After 2 hr, embryos were then collected and incubated in a water bath at 26°C until 
the afternoon.  The embryos were cleaned using a 0.06% bleach solution for 5 
minutes, and then rinsed 3 times using 10% Hanks’ balanced salt solution.  This 
process was repeated once more, then embryos were placed individually into 250 µl 
of 10% Hanks’ (changed daily) in the wells of 96-well mesh microtiter plates 
(Multiscreen™ catalog #MANMN4050, Millipore Corp., Bedford, MA). The 
embryos/larvae were housed in an incubator at 26 ± 0.7°C on a 14:10 hr light:dark 
cycle until testing at 6 dpf.  
 
Drugs 
All dopaminergic drugs were purchased from Sigma-Aldrich (St. Louis, MO).  
Dopamine receptor agonists included apomorphine hydrochloride hemi-hydrate 
(non-selective), (±)SKF-38393 hydrochloride (D1-like receptors), and (-)quinpirole 
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hydrochloride (D2-like receptors).  Dopamine receptor antagonists included 
(+)butaclamol hydrochloride (non-selective), R-(+)-SCH-23390 hydrochloride (D1-
like receptors), and haloperidol (D2-like receptors).  All drug stock solutions were 
made by dissolving the compounds in deionized water (with the exception of 
haloperidol).  Solutions were diluted further with 10% Hanks’ balanced salt solution 
(13.7 mM NaCl, 0.54 mM KCl, 25 µM Na2HPO4, 44 µM KH2PO4, 130 µM CaCl2, 100 
µM MgSO4, 420 µM NaHCO3) to reach final concentrations of 0.2-50 µM.  
Haloperidol was dissolved in dimethyl sulfoxide (DMSO), and initially, this stock 
solution was also diluted with DMSO to make concentrated solutions for dosing 
(further diluted in buffer trays with 10% Hanks’ to reach final concentrations of 0.2-50 
µM haloperidol, each in 0.4% DMSO).  The range of drug concentrations was the 
same for all experiments.   
 
Time of Peak Effect Experiments 
To determine the optimal time to perform the dose-response studies, a time of 
peak effect study was conducted for each drug.  Larvae were changed into fresh 
10% Hanks’ on the morning of day 6, and placed in a light-tight drawer in a darkened 
testing room (kept at 26°C).  That afternoon, larvae were placed into 250 µl of the 
broad range of concentrations of one of the drugs, which were evenly distributed on 
the 96-well plate.  The plate was then placed onto the recording platform in the dark.  
After allowing 20 minutes of rest, activity was recorded for 26 minutes in alternating 
dark and light (6 min dark, 10 min light, 10 min dark) using a Noldus behavior 
system (Leesburg, VA).  The microtiter plate remained on the recording platform, 
 104 
 
and recording was repeated every hr for the next 4 hrs.  One plate was used for 
each drug (n=12 larvae/dose, 12-24 larvae for vehicle controls).  Using visual 
inspection, the time of peak effect was defined as the time after administration at 
which effects were seen at the most doses. 
 
Dose-Response Experiments 
To determine dose-response profiles, a more detailed assessment of 
locomotor activity was conducted at the time of peak effect for each drug.  On the 
morning of the test, 6-dpf larvae were changed into fresh 10% Hanks’ solution, and 
placed in the light-tight drawer in the darkened testing room. The larvae were later 
placed into 250 µl of the broad range of drug concentrations (evenly distributed on 
the 96-well plate), and returned to the light-tight drawer until the time of peak effect 
was reached.  Larvae were then placed onto the recording apparatus in the dark 10 
min prior to recording.  Activity was recorded for a total of 70 minutes using the 
following lighting conditions: 10 minutes of dark, 10 minutes of light, 20 minutes of 
dark, 10 minutes of light and 20 minutes of dark.  Dose-response experiments were 
conducted on two separate plates for each drug (n=24 larvae/dose, 24-48 larvae for 
vehicle controls). 
 
Analysis of Locomotor Activity 
Videos of larval behavior were tracked using Ethovision software Version 3.1 
[Noldus Information Technology, Leesburg, VA (www.noldus.com)].  Locomotor 
activity was calculated as distance moved (cm) per 2 min.  An input filter of 0.135 cm 
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was used to exclude any slight movement that was not considered swimming.  Dead 
or malformed larvae were not used in the analysis.  Activity levels for the two 
observation periods under each lighting condition were averaged before statistics 
were calculated (i.e. “dark” = average activity of second and third dark periods per 2 
min).  All data were collapsed by lighting condition and the mean activity/2 min in 
each condition was analyzed using Statview© (SAS Institute, Inc., Cary, NC; version 
5.0.1).  The data for each drug were first assessed using an analysis of variance 
(ANOVA) with dose and lighting condition as the independent variables and 
locomotor activity (distance moved) as the dependent variable.  Significance was set 
at p ≤ 0.05 (only effects that reached significance were described in the Results 
section).  When an effect of dose was obtained, Fisher’s PLSD comparisons were 
conducted to compare between groups.  All data are presented as mean ± standard 
error of the mean (SEM).    
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Results 
Time of Peak Effect Experiments 
 The time when the maximal effects were reached at the largest number of 
doses was first determined for all 6 drugs.  Peak effects were reached at 20 min for 
both apomorphine (nonselective agonist; Figure 4.2) and butaclamol (nonselective 
antagonist; Figure 4.3), 140 min for SKF-38393 (D1-like agonist; Figure 4.4), 260 
min for SCH-23390 (D1-like antagonist; Figure 4.5), 80 min for quinpirole (D2-like 
agonist; Figure 4.6), and 200 min for haloperidol (D2-like antagonist; Figure 4.7).   
To illustrate the analysis for time of peak effect, the observations of the time 
of peak effect data for haloperidol are detailed from Figure 4.7.  At 20 min post-
administration, no maximal effects of haloperidol administration were reached at any 
dose.  After 80 min, this drug markedly affected locomotion at the highest dose (50 
µM), where larvae were hypoactive in both light and dark.  At 140 min, in addition to 
hypoactivity at 50 µM, larvae that were given 16.7 µM were also hypoactive in light 
and dark.  After 200 min, larvae exposed to 1.8 µM haloperidol appeared to be 
hyperactive in the dark, while 5.5 µM caused larvae to maintain a constant level of 
activity throughout the entire test regardless of lighting condition.  Larvae that 
received 16.7 and 50 µM haloperidol were still hypoactive at this time point.  The 
effects at 5.5 µM and above persisted even at the final time point of 260 min post-
dosing.  Larvae that were given 0.2-0.6 µM haloperidol did not display altered 
locomotion at any time point.  Based on these observations, 200 min was chosen as 
the time of peak effect for haloperidol, since this was when the maximum number of 
doses produced the biggest effects.   
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Applying the same approach for the other drugs, the peak effect observations 
are summarized in Table 4.1. 
Dose-Response Experiments 
Apomorphine (nonselective agonist): When larval behavior was recorded 20 
min following apomorphine administration, biphasic changes in locomotor activity 
were observed (Figure 4.8).  In the dark, hyperactivity was produced in larvae that 
were given the lowest and highest concentrations (0.2 and 50 µM; 67% and 89% 
increases, respectively), while intermediate concentrations did not significantly alter 
locomotion (Figure 4.8A and 4.8C).  In the light, a similar pattern emerged, with 0.2, 
5.5, and 50 µM all increasing activity (by 123%, 76%, and 107%, respectively) 
compared to controls (Figure 4.8B and 4.8C).   
 Butaclamol (nonselective antagonist): When butaclamol was given 20 min 
before testing, larvae also displayed biphasic changes in locomotor activity, although 
its dose-response profile differed from that of apomorphine (Figure 4.9).  Here, the 
intermediate concentrations (0.6 and 1.8 µM) caused hyperactivity.  In the dark, 0.6 
µM increased activity by 168%, and 1.8 µM, by 58% (Figures 4.9A and 4.9C).  In the 
light, 0.6 µM increased activity by 220%, and 1.8 µM increased activity by 96% 
(Figures 4.9B and 4.9C).  On the other hand, the highest concentrations caused 
severe hypoactivity: 16.7 µM butaclamol decreased activity by 99% in dark and 98% 
in light, and 50 µM completely abolished activity in both dark and light (Figures 4.9A, 
4.9B, and 4.9C).  
 SKF-38393 (D1-like selective agonist): SKF-38393 increased locomotor 
activity in a dose-dependent manner at the time of peak effect, 140 min (Figure 
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4.10).  In the dark (Figures 4.10A and 4.10C), increased activity was noted at 0.6 
(39%), 5.5 (48%), 16.7 (42%), and 50 µM (95%) SKF-38393.  In the light (Figures 
4.5B and 4.5C), the activity of larvae was increased at 5.5 (162%) and 50 µM SKF-
38393 (136%). 
 SCH-23390 (D1-like selective antagonist): SCH-23390 altered activity in a 
dose-dependent manner after 260 min (Figure 4.11).  In the dark (Figures 4.11A and 
4.11C), decreased activity was seen at 0.6 (19%), 1.8 (26%), 5.5 (41%), 16.7 (25%), 
and 50 µM (37%).  In the light (Figures 4.11B and 4.11C), however, a seemingly 
biphasic pattern emerged as activity decreased at lower concentrations of 0.6 (71%) 
and 5.5 µM (59%), but markedly increased at the highest concentration, 50 µM 
(262%).  Closer inspection of the time course revealed that larvae given 50 µM SCH-
23390 were just as active in the light as they were in the dark, and did not appear to 
respond to changes in lighting condition (i.e. the transition from dark to light did not 
depress locomotor activity, nor did the transition from light to dark decrease activity). 
Quinpirole (D2-like selective agonist): Quinpirole increased larval locomotion 
after 80 min.  As seen in Figure 4.7, in the dark (Figures 4.12A and 4.12C), this drug 
increased larval locomotion at 1.8 and 16.7 µM (by 34 and 80%, respectively).  
Increases in activity were also seen in the light (Figures 4.12B and 4.12C) at 5.5 
(198%) and 16.7 µM (288%). 
 Haloperidol (D2-like selective antagonist): Haloperidol, which reached its 
peak effect on larval locomotion after 200 min, showed differing patterns of effects in 
the two lighting conditions (Figure 4.13).  In the dark, haloperidol markedly 
decreased activity at 16.7 µM (81%), and completely abolished it at 50 µM (Figures 
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4.13A and 4.13C).  In the light, however, biphasic effects occurred, as intermediate 
concentrations of haloperidol (0.6 and 5.5 µM) increased activity (by 54 and 205%, 
respectively), while the highest concentration (50 µM) abolished activity (Figures 
4.13B and 4.13C).  The mean activity data suggest that larvae given 5.5 or 16.7 µM 
haloperidol moved at similar levels in dark and light, and visual inspection of the time 
course reveals that they had blunted responses to changes in lighting conditions, 
similar to the effect seen with 50 µM SCH-23390 (D1-like antagonist).  At 5.5 µM, 
larval locomotion throughout the test was comparable to the control levels obtained 
in dark periods, while 16.7 µM depressed activity levels to a low level throughout the 
test.  
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Discussion 
The goal of this study was to test whether dopamine receptor agents would 
alter locomotor activity in larval zebrafish.  This proved to be the case, as dose-
dependent changes in locomotor activity were observed following acute exposure to 
various drugs that target dopaminergic receptors (summarized in Table 4.2).  The 
larval zebrafish assay was also able to distinguish the actions of agonists from those 
of antagonists, regardless of whether the agents were non-selective or preferentially 
acted on a specific receptor subtype.  The nonselective agonist apomorphine and 
antagonist butaclamol both caused biphasic dose-response patterns regardless of 
lighting condition; apomorphine yielding hyperactivity at the lowest and highest 
doses, while butaclamol caused hyperactivity at lower doses and hypoactivity at high 
doses.  Furthermore, the selective agonists could be distinguished from the selective 
antagonists regardless of lighting condition.  The D1- and D2-like agonists both 
increased activity in the dark and light, while the selective antagonists decreased 
activity in the dark, and had biphasic effects in the light.   
It should also be noted that the time of peak effect for each agent clustered by 
target receptors.  The nonselective compounds (apomorphine and butaclamol), 
which act on both D1- and D2-like receptors, were both fast-acting, having reached 
their maximal effects within 20 min of administration.  Also, selective agonists were 
faster acting than selective antagonists, and the D2-like drugs were faster acting 
than the drugs that acted preferentially on D1 receptors.  Quinpirole (a D2-like 
selective agonist) and SKF-38393 (a D1-like selective agonist) reached maximal 
effect at 80 and 140 min, respectively.  Likewise, haloperidol (a D2-like selective 
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antagonist) reached its time of peak effect at 200 min post administration, while 
SCH-23390 (a D1-like selective antagonist) administration took 260 min to reach 
maximum effect.  Little has been reported previously about the pharmacodynamics  
or pharmacokinetics of these drugs in zebrafish, but the current finding that 
haloperidol administration took about 200 min to reach maximal effect is consistent 
with reports in humans, where side effects of haloperidol administration occurred 3-4 
hr after a single administration (Lynch et al., 1996). 
The effects of the selective compounds in this study are consistent with 
findings in mammals (see Table 4.2).  In our study, dopaminergic receptor-selective 
agonists increased larval locomotion in a dose-dependent manner.  Likewise, both 
SKF-38393 (a D1-like agonist) and quinpirole (a D2-like agonist) have been reported 
to increase locomotor activity in rodents (Beninger et al., 1991, Sobrian et al., 2003), 
even though D2 agonists appear to be more potent and efficacious than D1 agonists 
(Beninger et al., 1991).  SCH-23390 and haloperidol decreased activity in rodents 
(Beninger et al., 1991, Choi et al., 2009, Morato et al., 1989), and haloperidol has 
been reported to cause a sedative effect in humans (King et al., 1995).  Further, the 
nonselective and D2-like receptor antagonists tested in the present study abolished 
larval locomotion at high doses, which is consistent with reports of increased 
catatonia observed in rotarod tests in rats (Melo et al., 2010, Morato et al., 1989). 
In addition to effects on the level of locomotor activity, the selective 
antagonists affected the response of larvae to changes in lighting conditions in the 
current study.  It is possible that these effects are mediated via the retina.  Like other 
aspects of the central nervous system, the structure and function of the retina is 
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highly conserved in all vertebrate species, including zebrafish (Joselevitch and 
Kamermans, 2009).  Dopamine is the major catecholamine in the vertebrate retina, 
and dopaminergic receptors are found throughout the structure (reviewed in 
Nguyen-Legros et al., 1999).  While D1-like receptors are located in bipolar and 
horizontal cells of the retina (Nguyen-Legros et al., 1997, Veruki and Wassle, 1996), 
D2-like receptors modulate the actions of dopamine in photoreceptors (Cohen et al., 
1992, Dearry et al., 1991, Vuvan et al., 1993).  Both types of dopaminergic receptors 
are present in amacrine cells (Hadjiconstantinou et al., 1990, Hampson et al., 1992) 
and ganglion cells (Nguyen-Legros et al., 1997, Veruki and Wassle, 1996, Wagner 
et al., 1993).  Among its many functions in the retina, dopamine acts as a 
neurohormone in photoreceptors, regulating the light-evoked circadian rhythm of rod 
and cone metabolism and function, along with melatonin (Nowak et al., 1992, 
Witkovsky et al., 1988).  In ganglion cells, dopamine functions mainly as a modulator 
of light adaptation, decreasing the firing of ON retinal ganglion cells, while increasing 
OFF retinal ganglion cell firing (Ames and Pollen, 1969).  Blockade of either D1- or 
D2-like receptors in ganglion cells could perturb ON and/or OFF cell functions, and 
possibly disrupt the locomotor response to the light/dark transitions in the present 
test.  In line with the current findings, acute haloperidol administration has been 
reported to disrupt visual processing in both rabbits (Jensen and Daw, 1983) and 
humans (Lynch et al., 1997).   
Although the larval zebrafish drug responses reported here were highly 
comparable to previous mammalian studies, the present study has also uncovered 
some novel concepts.  Not only were larval locomotor responses in this test 
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sufficient to distinguish between agonists and antagonists, they also differed for 
nonselective (biphasic effects) vs. selective agents (monophasic effects).  The 
nonselective compounds appear to have more complex dose-response profiles in 
the present study than previously reported (Archer et al., 2003, Ardayfio et al., 2010, 
Beninger et al., 1991, Hooks et al., 1994, Sobrian et al., 2003).  This is likely due to 
the larger number of concentrations assessed here.  When examining the lower 
doses given in the present study, an additional phase of effects is seen.  For both 
the agonist (apomorphine) and the antagonist (butaclamol), the lower doses caused 
an initial phase of hyperactivity, with return to control levels of activity at intermediate 
doses.  These patterns were followed by an additional phase of hyperactivity in the 
case of apomorphine, and marked hypoactivity with butaclamol.  A few studies in 
rodents have suggested biphasic effects on locomotor activity due to apomorphine 
exposure, but those studies describe an initial hypoactive phase, which correlates 
with the activation of presynaptic D2 autoreceptors at low doses (Cabib and Puglisi-
Allegra, 1985, Protais et al., 1983).  Interestingly, some reports have noted similar 
biphasic effects for acute quinpirole administration, also identifying high affinity of the 
drug at presynaptic D2 (as well as postsynaptic D3) receptors as the cause for the 
decreased activity seen at lower doses (Sobrian et al., 2003).  Although the 
locomotor dose-response pattern reported in the present study for apomorphine is 
novel, a previous study by Hooks and colleagues (Hooks et al., 1994) suggested 
that indirect and nonselective dopamine receptor agonists (including apomorphine) 
may cause distinct profiles across a wide range of behaviors when compared to 
receptor-selective agonists (i.e. SKF-38393 and quinpirole).   
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The complexities of the biphasic patterns of the dose-response profiles of 
apomorphine and butaclamol (and the characteristics that distinguish these agents 
from selective drugs) may be attributed to the drugs acting on multiple dopaminergic 
receptors.  Aside from the normal opposing effects of D1-like and D2-like receptors, 
one factor to consider is that stimulation/inhibition of D3 receptors appears to have 
opposite effects compared to D2 and D4 receptors.  The stimulation of D3 receptors 
has been shown to decrease locomotor activity, while D3 receptor blockade 
increases activity (Kolasiewicz et al., 2008, Missale et al., 1998).  Additionally, the 
presence of pre- and post-synaptic D2 receptors may contribute to the biphasic 
profiles, as stimulation of pre-synaptic D2 receptors blocks the release of dopamine, 
thereby inhibiting behavioral activation (Van der Weide et al., 1988), while the 
stimulation of post-synaptic D2 receptors increases locomotion (Beninger et al., 
1991, Missale et al., 1998).  Interestingly, studies in mammals have established 
interdependency between D1-like and D2-like receptor stimulation such that D1 
stimulation is needed to achieve D2-induced behavioral responses; D1 stimulation, 
however, occurs independent of D2 stimulation (Braun and Chase, 1986, Murray 
and Waddington, 1989).  This cooperation may also contribute to the dose-
dependent biphasic effects of apomorphine and butaclamol observed in this study. 
While the current findings resemble mammalian reports of altered locomotor 
activity that have been attributed to drug-induced dopaminergic dysfunction, 
additional studies are needed to rule out the acute effects of these agents on other 
signaling pathways.  Even though these drugs are known to have higher affinities for 
their dopaminergic targets than receptors of other pathways, none of these drugs 
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can be considered exclusive dopaminergic receptor ligands.  Indeed, studies have 
shown that these drugs may also bind to adrenergic, cholinergic, histaminergic, and 
serotonergic receptors, albeit with lower affinities (Bymaster et al., 1996, Hyttel, 
1983, Millan et al., 2002).  The nominal concentrations reported in the present study 
(µM range) are higher (in most cases) than the associated inhibitory constants (Ki, 
reported in nM range) for these off-target receptors in mammals.  Therefore, the 
relative affinities for these receptors should be determined in zebrafish.  Also, 
without measurements of internal concentrations in the larvae, it is uncertain how 
much of each drug has crossed the biological membranes and barriers (i.e. skin, 
blood-brain barrier, etc.) to gain access to the brain and its receptors. 
The findings in this study provide strong evidence that the dopaminergic 
nervous system in larval zebrafish may function similarly to that of mammals.  The 
administration of both clinical and experimental drugs that target dopaminergic 
receptors in humans and other mammals elicits similar effects on locomotor activity 
in this model when compared to those obtained in higher vertebrates.  Therefore, 
this study supports and extends recent efforts in the field to establish zebrafish as a 
useful model in predicting behavioral effects in mammals of acute exposures to 
drugs/chemicals suspected to target the nervous system.   
 116 
 
Figures 
 
Figure 4.1 – Dopaminergic drugs and targets in this study.  This scheme illustrates 
the dopaminergic synapse.  Dopamine (DA) is synthesized from tyrosine (TYR) in a 
reaction in which tyrosine hydroxylase (TH) is the rate-limiting enzyme.  The 
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neurotransmitter is then stored in vesicles via vesicular monoamine transporters 
(VMAT) until it is released from the neuron.  Once in the synaptic cleft, dopamine 
can be removed via dopamine transporters (DAT).  The drugs used in this study act 
on the four dopaminergic pre-/post-synaptic receptor subtypes (D1-D4) in zebrafish.  
Apomorphine (APO) is a nonselective agonist.  Butaclamol (BUT) is a nonselective 
antagonist.  SKF-38393 (SKF) is a D1-like agonist, while SCH-23390 (SCH) is a D1-
like antagonist.  The D2-like selective drugs are quinpirole (QUI; agonist) and 
haloperidol (HAL; antagonist).  Green arrows indicate stimulation of receptors 
(agonists); red lines indicate receptor blocking (antagonists).   
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Figure 4.2 – Apomorphine time of peak effect.  The time of peak effect for 
apomorphine was determined by identifying the timepoint at which the most doses 
produced maximal effects.  Data are presented as mean ± SEM.  The controls are 
the same in each panel, and all dose groups were present on the same experimental 
plate (n = 12/dose).  The black and white bar indicates periods of dark and light, 
respectively and applies to each recording timepoint (shown at 20 min for example) 
in each panel.  Timepoints circled in purple denote maximal effects considered in the 
determination.  Because the greatest number of maximum effects was reached at 20 
min and above, 20 min was determined to be the time of peak effect for 
apomorphine. 
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Figure 4.3 – Butaclamol time of peak effect.  The time of peak effect for butaclamol 
was determined by identifying the timepoint at which the most doses produced 
maximal effects.  Data are presented as mean ± SEM.  The controls are the same in 
each panel, and all dose groups were present on the same experimental plate (n = 
12/dose).  The black and white bar indicates periods of dark and light, respectively 
and applies to each recording timepoint (shown at 20 min for example) in each 
panel.  Timepoints circled in purple denote maximal effects considered in the 
determination.  Because the greatest number of maximum effects was reached at 20 
min and above, 20 min was determined to be the time of peak effect for butaclamol.
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Figure 4.4 – SKF-38393 time of peak effect.  The time of peak effect for SKF-38393 
was determined by identifying the timepoint at which the most doses produced 
maximal effects.  Data are presented as mean ± SEM.  The controls are the same in 
each panel, and all dose groups were present on the same experimental plate (n = 
12/dose).  The black and white bar indicates periods of dark and light, respectively 
and applies to each recording timepoint (shown at 20 min for example) in each 
panel.  Timepoints circled in purple denote maximal effects considered in the 
determination.  Because the greatest number of maximum effects was reached at 
140 min and above, 140 min was determined to be the time of peak effect for SKF-
38393.
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Figure 4.5 – SCH-23390 time of peak effect.  The time of peak effect for SCH-23390 
was determined by identifying the timepoint at which the most doses produced 
maximal effects.  Data are presented as mean ± SEM.  The controls are the same in 
each panel, and all dose groups were present on the same experimental plate (n = 
12/dose).  The black and white bar indicates periods of dark and light, respectively 
and applies to each recording timepoint (shown at 20 min for example) in each 
panel.  Timepoints circled in purple denote maximal effects considered in the 
determination.  Because the greatest number of maximum effects was reached at 
260 min and above, 260 min was determined to be the time of peak effect for SCH-
23390. 
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Figure 4.6 – Quinpirole time of peak effect.  The time of peak effect for quinpirole 
was determined by identifying the timepoint at which the most doses produced 
maximal effects.  Data are presented as mean ± SEM.  The controls are the same in 
each panel, and all dose groups were present on the same experimental plate (n = 
12/dose).  The black and white bar indicates periods of dark and light, respectively 
and applies to each recording timepoint (shown at 20 min for example) in each 
panel.  Timepoints circled in purple denote maximal effects considered in the 
determination.  Because the greatest number of maximum effects was reached at 80 
min and above, 80 min was determined to be the time of peak effect for quinpirole. 
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Figure 4.7 – Haloperidol time of peak effect.  The time of peak effect for haloperidol 
was determined by identifying the time point at which the most doses produced 
maximal effects.  Data are presented as mean ± SEM.  The controls are the same in 
each panel, and all dose groups were present on the same experimental plate (n = 
12/dose).  The black and white bar indicates periods of dark and light, respectively 
and applies to each recording time point (shown at 20 min for example) in each 
panel.  Time points circled in purple denote maximal effects considered in the 
determination.  Because the greatest number of maximum effects was reached at 
200 min, 200 min was determined to be the time of peak effect for haloperidol.
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Drug 20 min 80 min 140 min 200 min 260 min Peak Effect 
Apomorphine 4 3 0 1 2 20 min 
Butaclamol 5 3 5 4 2 20 min 
SKF-38393 3 4 5 5 5 140 min 
SCH-23390 2 4 4 4 6 260 min 
Quinpirole 2 4 4 3 3 80 min 
Haloperidol 0 1 2 4 3 200 min 
 
Table 4.1 – Summary of Time of Peak Effect Determinations.  Numbers indicate the 
number of maximal effects that were observed at each timepoint out of the possible 
6 doses.   
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Figure 4.8 – Mean activity and time course for apomorphine.  Apomorphine 
administration had biphasic effects on locomotion.  (A) In the dark, apomorphine 
increased activity at the lowest and highest doses (0.2 and 50 µM).  (B) In the light, 
activity was increased by 0.2, 5.5, and 50 µM apomorphine.  Data in (A) and (B) are 
presented as mean activity in 2 min ± SEM (*p ≤ 0.5).  (C) The complete timecourse 
of the 70-min test illustrates these changes in activity.  Data in (A) and (B) are 
expressed as mean ± SEM (n = 24/dose).  The black and white bar denotes periods 
of dark and light, respectively.  
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Figure 4.9 – Mean activity and time course for butaclamol.  Butaclamol 
administration had biphasic effects on locomotion.  (A) In the dark, butaclamol 
increased activity at intermediate doses (0.6 and 1.8 µM), while abolishing activity at 
the high doses (16.7 and 50 µM).  (B) In the light, similar effects were seen at the 
same doses.  Data in (A) and (B) are presented as mean activity in 2 min ± SEM (*p 
≤ 0.5).  (C) The complete timecourse of the 70-min test illustrates these changes in 
activity.  Data are expressed as mean ± SEM (n= 24/dose).  The black and white bar 
denotes periods of dark and light, respectively.   
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Figure 4.10 – Mean activity and time course for SKF-38393.  SKF-38393 
administration increased larval locomotion.  (A) In the dark, SKF-38393 increased 
activity at 0.6, 5.5, 16.7 and 50 µM.  (B) In the light, increases were seen at 5.5 and 
50 µM.  Data in (A) and (B) are presented as mean activity in 2 min ± SEM (*p ≤ 
0.5).  (C) The complete timecourse of the 70-min test illustrates these changes in 
activity.  Data are expressed as mean ± SEM (n = 24/dose).  The black and white 
bar denotes periods of dark and light, respectively.  
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Figure 4.11 – Mean activity and time course for SCH-23390.  SCH-23390 
administration decreased larval locomotion.  (A) In the dark, SCH-23390 decreased 
activity at 0.6, 1.8, 5.5, 16.7 and 50 µM.  (B) In the light, decreases were seen at 0.6 
and 5.5 µM, while larvae given 50 µM appeared hyperactive.  Data in (A) and (B) are 
presented as mean activity in 2 min ± SEM (*p ≤ 0.5).  (C) The complete timecourse 
of the 70-min test illustrates these changes in activity.  At 50 µM, it appears that 
larvae no longer respond to changes in lighting conditions.  Data are expressed as 
mean ± SEM (n = 24/dose).  The black and white bar denotes periods of dark and 
light, respectively.  
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Figure 4.12 – Mean activity and time course for quinpirole.  Quinpirole administration 
increased larval locomotion.  (A) In the dark, quinpirole increased activity at 1.8 and 
16.7 µM.  (B) In the light, increases were seen at 5.5 and 16.7 µM.  Data in (A) and 
(B) are presented as mean activity in 2 min ± SEM (*p ≤ 0.5).  (C) The complete 
timecourse of the 70-min test illustrates these changes in activity.  Data are 
expressed as mean ± SEM (n = 24/dose).  The black and white bar denotes periods 
of dark and light, respectively.  
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Figure 4.13 – Mean activity and time course for haloperidol.  Haloperidol 
administration affected larval locomotion differently depending on lighting condition.  
(A) In the dark, haloperidol decreased activity at 16.7 and 50 µM.  (B) In the light, 
however, decreased activity was only seen at 5.5 µM, while larvae given 1.8 and 5.5 
µM appeared hyperactive.  Data (A) and (B) are presented as mean activity in 2 min 
± SEM (*p ≤ 0.5).  (C) The complete timecourse of the 70-min test illustrates these 
changes in activity.  As dose increases, the response of larvae to changes in lighting 
conditions is progressively blunted, accounting for the appearance of hyperactivity in 
light.  Data are expressed as mean ± SEM (n = 24/dose).  The black and white bar 
denotes periods of dark and light, respectively.  
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Drug Type of Drug Mammal Activity 
Zebrafish - 
Activity in 
Dark 
Zebrafish - 
Activity in 
Light 
Apomorphine Non-selective Agonist 
 
  
Butaclamol Non-selective Antagonist 
 
  
SKF-38393 D1-like Agonist 
 
  
SCH-23390 D1-like Antagonist 
 
  
Quinpirole D2-like Agonist 
 
  
Haloperidol D2-like Antagonist 
 
  
 
Table 4.2 – Summary of dose-response profiles.  Arrows with positive slopes denote 
dose-response profiles of increasing activity, while arrows with negative slopes 
denote dose-response profiles of decreasing activity.  U-shaped arrows (    ) 
represent biphasic dose-responses, where activity either increases at low doses, 
then again at high doses, or activity decreases at low doses, then increases at high 
doses (i.e. with apomorphine/quinpirole in mammals).  Inverted U-shaped arrows  
(    ) represent patterns in which activity increases at low/intermediate doses, then 
decreases at high doses.  
or 
or 
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Chapter 5: Comparison of the Effects of Developmental and Acute Exposure to 
MPTP and 6-OHDA on the Activity of Larval Zebrafish 
 
Preface 
Chemical lesioning of regions of mammalian brain is an established method to 
model human conditions like Parkinson’s disease and attention deficit hyperactivity 
disorder.  Such lesions are accomplished with toxicants like MPTP (1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine) and 6-OHDA [6-hydroxydopamine; 5-(2-
aminoethyl)benzene-1,2,4-triol].  This group of studies evaluated the effects of 
developmental exposures to these toxicants in larval zebrafish.  Specific Aim 3 was 
assessed: “Assess the perturbation of dopaminergic nervous system structure and 
function following developmental toxicant exposure.”  Specifically, the following 
questions were addressed:  
• How does MPTP exposure affect behavior and dopaminergic pathways in 
zebrafish larvae? 
• How does 6-OHDA exposure affect behavior and dopaminergic pathways in 
zebrafish larvae? 
 
*This work is being prepared for submission: 
Irons, T.D., Hunter, D.L., Olin, J., Tennant, A., Jensen, K., MacPhail, R.C., and 
Padilla, S.  “Comparison of the Effects of Developmental and Acute Exposure to 
MPTP and 6-OHDA on the Activity of Larval Zebrafish.”  In preparation, Toxicol Appl 
Pharmacol.
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Abstract 
MPTP and 6-OHDA are neurotoxicants that destroy dopaminergic neurons in 
mammals, producing abnormalities in locomotor activity that resemble human motor 
disorders such as Parkinson’s disease and ADHD.  While previous developmental 
studies of the chemicals in larval zebrafish (Danio rerio) have also reported 
alterations in motor activity (MPTP only) and dopaminergic pathways (both MPTP 
and 6-OHDA), it is not clear whether these effects were due to exposure during 
critical periods of development or to persisting acute effects at the time of testing.  
No previous studies have directly assessed the acute effects of MPTP or 6-OHDA in 
larvae.  To determine if developmental and acute exposures produce distinct effects 
on locomotor activity, two studies were designed: (1) groups of larvae were treated 
with a broad range of concentrations of either MPTP or 6-OHDA by immersion from 
5 hours to 5 days post-fertilization in 96-well microtiter plates, followed by one 
washout day; and (2) groups were treated acutely on day 6 with the same doses of 
MPTP or 6-OHDA.  On the sixth day, locomotor activity was assessed during 
alternating periods of light and dark.  Developmental exposure to MPTP did not alter 
larval locomotion, while acute exposure to MPTP yielded extensive behavioral 
changes.  Developmental 6-OHDA increased activity at only one dose, while acute 
exposure did not alter locomotor activity.  Both developmental treatments reduced 
tyrosine hydroxylase immunolabeling in the larval zebrafish brain.  Because acute 
MPTP exposure yielded many effects compared to the lack of effects following 
developmental exposure, acute effects cannot be ruled out in previous 
developmental studies with MPTP in larval zebrafish.  In contrast, the distinct profiles 
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of the two types of 6-OHDA exposures, coupled with its rapid half-life in brain, 
suggest that the effects seen with developmental 6-OHDA exposure are due to 
perturbation of the development of dopaminergic pathways. 
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Introduction 
The neurotransmitter dopamine has been associated with movement 
disorders such as Parkinson’s disease, Attention Deficit Hyperactivity Disorder, 
schizophrenia and Huntington’s disease (reviewed in Mehler-Wex et al., 2006, 
Palomo et al., 2003).  The etiology of dopamine-related movement disorders is 
largely unknown.  Epidemiological studies, however, suggest that environmental 
causes may exist, as evidenced by the association between Parkinson’s disease 
and risk factors common to agricultural workers and residents of rural areas, 
including exposure to pesticides (Elbaz and Tranchant, 2007, Priyadarshi et al., 
2001, Priyadarshi et al., 2000, Strickland and Bertoni, 2004).  Several classes of 
pesticides have been linked to selective dopaminergic degeneration including 
bipyridyls, organochlorines, dithiocarbamates, and rotenoids (reviewed in Hatcher et 
al., 2008, Jones and Miller, 2008).  Some, such as paraquat (a bipyridyl) and 
rotenone (a rotenoid), have been shown to produce a parkinsonian syndrome, and 
thus, are used in animal models of Parkinson’s disease (reviewed in Drechsel and 
Patel, 2008).   
Parkinson’s disease is characterized by damage to the nigrostriatal 
dopaminergic pathway; there is a loss of neurons that originate in the pars compacta 
of the substantial nigra, and project to the striatum (Hirsch, 1992).  Damage to this 
area of the brain can be induced in animal models with MPTP (Langston et al., 1984; 
reviewed in Przedborski et al., 2001), a neurotoxicant that was discovered as a by-
product in the illicit synthesis of a meperidine analog with potent opioid-like effects.  
Due to its hydrophobicity (log P = 2.7; Dictionary of Pharmacological Agents, 1997), 
 148 
 
MPTP readily crosses the blood-brain barrier, and once in the brain,  it is oxidized by 
monoamine oxidase to its active metabolite, MPP+, in glial cells (Miller et al., 1999, 
Przedborski et al., 2001, Trevor et al., 1987).  MPP+ is then selectively taken up into 
dopaminergic neurons in the striatum by dopamine transporters (Kitayama et al., 
1992, Miller et al., 1999), where the metabolite either inhibits mitochondrial complex 
I (resulting in cell death; Nicklas et al., 1987), or is sequestered in vesicles via 
vesicular monoamine transporters (thereby protecting the neuron; Reinhard et al., 
1988).  The syndrome produced in humans by MPTP is almost identical to 
Parkinson’s disease; however, active neurodegeneration due to MPTP occurs in 
days as opposed to years (Langston et al., 1999).     
The toxicity of MPTP has been studied in a variety of animal models, 
including non-human primates (Clarke et al., 1987, Langston et al., 1984), rodents 
(Bradbury et al., 1986, Sedelis et al., 2001), cats (Schneider et al., 1986), pigs 
(Mikkelsen et al., 1999), and zebrafish (Anichtchik et al., 2004, Bretaud et al., 2004, 
Lam et al., 2005, McKinley et al., 2005, Sallinen et al., 2009, Wen et al., 2008).  
Sensitivity to the compound can vary across species (Giovanni et al., 1994a, 
Giovanni et al., 1994b, Johannessen et al., 1985, Staal et al., 2000), but decreases 
in both brain dopamine content and locomotion are a common outcome.  Among the 
sensitive regions in the zebrafish brain is the diencephalon (see Table 1), which 
projects to the subpallium, considered to be the equivalent of the human striatum 
(Rink and Wullimann, 2001).   
Another way to lesion dopaminergic pathways in experimental animals is with 
6-OHDA.  Because it does not readily cross the blood-brain barrier, 6-OHDA is 
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usually injected directly into the brain (Blandini et al., 2008, Kostrzewa et al., 2008a).  
In mammals, injection of 6-OHDA into the substantia nigra pars compacta, medial 
forebrain bundle, or striatum is one of the most efficient ways to lesion the 
nigrostriatal pathway of the dopaminergic nervous system (Blandini et al., 2008, 
Bove et al., 2005).  These lesions cause maximal neuronal damage 3-4 days after 
the injection (Bove et al., 2005).  Due to its structural similarity to dopamine, the 
compound has a high affinity for the dopamine transporter.  It is taken up into 
dopaminergic neurons via dopamine transporters, and accumulates in the cytosol, 
where it is oxidized to form free radicals (Blandini et al., 2008).  Mitochondrial 
oxidative phosphorylation (due to the blocking of complex I) is then disrupted, 
causing energy depletion, and ultimately, death of the neurons.   
Animals administered 6-OHDA directly into the substantia nigra display 
decreased spontaneous voluntary movement, and increased bracing reminiscent of 
the dyskinesia and rigidity seen in Parkinson’s patients, among other signs (Jurna et 
al., 1972, Kostrzewa and Jacobowitz, 1974, Whishaw and Dunnett, 1985).  Injection 
of 6-OHDA into other areas of the brain results in varied effects on behavior, causing 
hyperactivity in some cases (e.g. when administered intraventricularly or 
intracisternally; Luthman et al., 1997, Shaywitz et al., 1976).  Because of these 
effects, 6-OHDA has also been used to model other conditions like ADHD 
(Kostrzewa et al., 2008b, Zhang et al., 2002). 
Zebrafish (Danio rerio) have emerged as a powerful model system for the 
study of the behavioral, genetic, and biochemical aspects of locomotion (reviewed in 
Dougherty and Kiehn, 2010, Drapeau et al., 2002, Fetcho, 2007, Fetcho et al., 
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2008).  In vertebrates, the organization of the hindbrain and spinal cord are highly 
homologous across species, and the morphology of the early vertebrate embryo is 
conserved (Dougherty and Kiehn, 2010, Fetcho, 2007, Langille and Hall, 1989, 
Tropepe and Sive, 2003).  Additionally, both structural and functional assessments 
of the development of locomotor activity can be studied in ways that are difficult or 
impossible in traditional animal models (reviewed in Drapeau et al., 2002).  Zebrafish 
produce a large number of progeny that develop externally and rapidly, and are 
transparent during embryonic and larval stages, all optimal conditions for 
developmental studies (Kimmel, 1995).  Also, the small size of the fish at these 
stages of development allows automated testing of many individuals at once 
(Bretaud et al., 2004, Cahill, 2007, Irons et al., 2010, MacPhail et al., 2009, Sallinen 
et al., 2009).  In zebrafish, simple motor activities (i.e. spontaneous coiling) begin to 
develop during periods when only a few neurons have extended axons in the spinal 
cord (about 17 hpf; reviewed in Saint-Amant and Drapeau, 1998).  Larvae exhibit 
mature, spontaneous beat-and-glide swimming motion by 4 dpf, prior to the 
development of feeding behaviors and functional sensory systems, which are 
present by 6 dpf (Kimmel, 1995).  
Previous studies in zebrafish have shown that behavior can be altered by 
MPTP exposure.  In adults, a single intramuscular injection of MPTP markedly 
decreased the total distance moved for the next several days (Anichtchik et al., 
2004).  Additional studies have exposed zebrafish to MPTP by immersion during 
development at both the embryonic and larval stages.  Embryos showed a loss of 
response to touch at 800 µM MPTP (Lam et al., 2005).  Larvae displayed increased 
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episodes of fictive swimming (extracellular recordings from the isolated tails of 
embedded larvae) at 10 µM (Thirumalai and Cline, 2008), and decreased locomotor 
activity at concentrations as low as 43 µM (Bretaud et al., 2004, Sallinen et al., 
2009).   
Studies have also described the effects of 6-OHDA in zebrafish.  In adults, 
intramuscular injection resulted in depression of locomotor activity that persisted for 
several days (total distance moved; Anichtchik et al., 2004).  Although no behavioral 
assessments have been done in larvae following developmental exposure, 
histological analyses following developmental exposures displayed a marked 
decrease of tyrosine hydroxylase-positive cell groups in the diencephalon (Parng et 
al., 2007). 
While previous studies in which MPTP or 6-OHDA was given developmentally 
have shown a number of effects in larval zebrafish, it is not clear whether these 
effects were due to exposure during critical periods of development or to residual 
levels of the compound still acting on dopaminergic (or other) targets in the brain at 
the time of testing.  MPTP has a relatively long half-life in brain, which is about 10 
days in mammals (Markey et al., 1984).  6-OHDA, however, appears to have a rapid 
half-life in biological tissues, which is reported to be about 25 min in rat brain 
(McCreery et al., 1974).  No studies have investigated the half-life of MPTP or 6-
OHDA in zebrafish brain or the acute effects of the compounds in zebrafish larvae. 
In the present investigation, MPTP and 6-OHDA exposures were studied in 
larval zebrafish to confirm that the behavioral effects of the compounds are due to 
alteration of the development (and thus, the function) of the dopaminergic nervous 
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system, and not the transient effects of the compounds acting pharmacologically on 
the system.  This was done using a behavioral testing paradigm that employs 
changes in lighting conditions to manipulate larval locomotor activity (Irons et al., 
2010, MacPhail et al., 2009).  Larvae were individually exposed to MPTP or 6-OHDA 
for several days during development.  A broad range of doses was used for a more 
complete understanding of the spectrum of effects of MPTP and 6-OHDA on motor 
function.  Histological analyses were also conducted following developmental 
exposures to assess effects on the structure of the dopaminergic nervous system.  
The acute effects of the compounds were also studied to determine (a) if acute 
behavioral effects exist in zebrafish, and (b) whether those effects were distinct from 
the developmental effects.  
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Materials and Methods 
Husbandry 
Wild-type adult zebrafish (Danio rerio) were maintained as breeders in an 
Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)-
approved animal facility at 28°C with a 14:10 h light:dark cycle with lights on at 0830 
h.  On the day of embryo collection, one hour prior to light onset, all adults in a 
colony tank were placed in a breeding tank (Aquatic Habitats, Apopka, FL).  One 
hour after light onset, the adults were returned to the colony, and embryos were 
collected from the breeder tank.  The embryos were then pooled, placed in a 26°C 
waterbath for 2 h, washed twice with a 0.06% bleach solution in 10% Hanks’ 
balanced salt solution (13.7 mM NaCl, 0.54 mM KCl, 25 µM Na2HPO4, 44 µM 
KH2PO4, 130 µM CaCl2, 100 µM MgSO4, 420 µM NaHCO3) for 5 min each, followed 
by three rinses with 10% Hanks’ solution.  Next, fertilized eggs were individually 
placed into 10% Hanks’ solution in 96-well mesh microtiter plates (Multiscreen™ 
catalog #MANMN4050, Millipore Corp., Bedford, MA).  
All studies were approved by, and are in accordance with the guidelines of 
the Institutional Animal Care and Use Committee at the National Health and 
Environmental Effects Research Laboratory of the US Environmental Protection 
Agency (Guide for the Care and Use of Laboratory Animals, 1996). 
 
Neurotoxicant Handling and Safety Precautions 
MPTP hydrochloride and 6-OHDA hydrobromide (stabilized with 0.1% 
ascorbic acid) were purchased from Sigma (St. Louis, MO).  Because of their highly 
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neurotoxic natures, all solutions containing the compounds were handled with care 
(Przedborski et al., 2001).  Dosing was carried out in a fume hood, and appropriate 
safety equipment (labcoat, gloves, mask, and goggles) was worn throughout all 
experiments.  All surfaces and solutions were bleached following use, and materials 
were disposed of in hazardous waste containers. 
 
Developmental MPTP exposure  
Non-lethal, sub-teratogenic concentrations of MPTP were selected from a 
pilot, range-finding experiment prior to this study.  Stock solutions of MPTP (0.04-2.5 
mM) were made using dilutions in 10% Hanks’ solution.  Each concentration was 
pipetted into the wells of the treatment plates (5 µl/well, evenly distributed throughout 
the plate), and the plates were then sealed, and stored at -80°C until use.  For 
exposures, the solutions in each well were diluted with 245 µl 10% Hanks’ to reach a 
total of 250 µl of the final concentration (0.8-50 µM).  Embryos were placed into the 
solutions starting at about 5 hpf.  Control embryos/larvae were immersed in 10% 
Hanks’ solution.  Each day, the solution in each well was renewed.  The 
embryos/larvae (hatch on or before 4 dpf) were then returned to an incubator, where 
they were maintained on a 14:10 hr light:dark cycle (lights on at 0830 hr) at 
26±0.7°C.  On day 5, the entire plate was placed into fresh 10% Hanks’ solution, and 
the larvae were allowed one day of depuration.  On the morning of the sixth day, the 
10% Hanks’ solution was renewed, and the plate was moved to a darkened testing 
room (kept at 26°C), and placed in a light-tight drawer until testing commenced that 
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afternoon.  Developmental MPTP exposure was conducted on two separate plates 
(n = 12 larvae/dose/plate) with all doses and controls represented on each plate. 
 
Developmental 6-OHDA exposure  
The developmental 6-OHDA exposures were performed using the same 
method as the developmental MPTP exposure, with the exception of the storage of 
stock solution and preparation of treatment plates.  Since the compound is light-
sensitive, all solution preparations and dosing were performed in a darkened fume 
hood.  Stock solutions of 6-OHDA (0.005-3.3 mM) were made using dilutions in 10% 
Hanks’ solution, and each concentration was pipetted into the wells of a black 
microtiter plate, which was then sealed, and stored at 4°C until use.  For exposures, 
the solutions were pipetted into each well (5 µl/well) of the treatment plates, and 
diluted with 245 µl 10% Hanks’ to reach a total of 250 µl of the final concentration 
(0.1-66.7 µM; also determined to be non-lethal and sub-teratogenic doses in a pilot 
study).  This process was repeated daily to renew the solutions.  
 
Acute MPTP and 6-OHDA exposure  
Embryos/larvae were reared for 6 days in 96-well microtiter plates.  Each day, 
the 250 µl of 10% Hanks’ solution in each well was renewed.  The embryos/larvae 
were then returned to an incubator, where they were maintained on a 14:10 hr 
light:dark cycle (lights on at 0830 hr) at 26±0.7°C.  On the morning of the sixth day, 
the larvae were placed into solutions of MPTP (0.8-50 µM) or 6-OHDA (0.1-66.7 
µM).  The plate was then placed in a light-tight drawer in the darkened testing room 
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until testing commenced 4 h later.  The acute exposure was conducted on two 
separate plates (n = 12 larvae/dose/plate) with all doses and controls represented on 
each plate. 
 
Behavioral Testing and Analysis of Locomotion  
The recording platform was equipped with a lightbox that contained both 
infrared (which is perceived by larvae as “dark”; Dowling, 2002) and visible (“light”) 
light sources.  Activity was recorded for 10 minutes in the dark to allow acclimation, 
and was followed by two cycles of 10 minutes of light, then 20 minutes of dark. The 
testing period was 70 minutes in duration.  Movement of each larva was monitored 
with a Noldus behavior recording system (Noldus Information Technology, Leesburg 
VA).  Fish movement (locomotion) was quantified from videos using Ethovision 
software Version 3.1 (Noldus Information Technology, Leesburg VA), with a tracking 
rate of 5 image samples/sec.  A minimum-distance input filter of 0.135 cm was used 
to remove background noise.  A low incidence of death/malformations was observed 
in these experiments (these larvae were excluded from the analyses); however, non-
lethal, sub-teratogenic doses of the neurotoxicants were used to ensure that these 
infrequent occurrences were not dose-related.  Fish were either euthanized or 
anesthetized (for staining, developmentally-exposed larvae only) with tricaine 
solution (250 mg/l tricaine plus 1g/l sodium bicarbonate) immediately following 
behavioral tests. 
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Tyrosine Hydroxylase Immunohistochemistry 
Larvae were deeply anesthetized in tricaine solution, and then fixed by 
immersing in 4% paraformaldehyde in phosphate buffer (pH 7.4) overnight at 4˚C.  
The following day, the larvae were rinsed in 0.1M phosphate buffer (PB), then 
embedded in 1% agarose, and placed in fixative overnight.  The agarose blocks 
were cryo-protected by transferring to 20% sucrose in PB for 6 hours at 4˚C.  Blocks 
were sectioned at 100 µm on a sliding microtome with a freezing stage (Reichert-
Jung, Austria).  Free-floating sections were collected and rinsed thoroughly in 
phosphate buffer containing 0.3% Triton X-100 (PBTx).  The sections were blocked 
in 10% normal goat serum/PBTx for 30 minutes and then incubated with a mouse 
monoclonal anti-tyrosine hydroxylase primary antibody (1:1000; ImmunoStar, 
Hudson, WI) overnight at room temperature.  After washing in PBTx, the sections 
were incubated with a Rhodamine Red-X conjugated goat anti-mouse secondary 
antibody (1:1000; Molecular Probes, Carlsbad, CA) for 4 hours at room temperature.  
Sections were rinsed in PB before immersing in 4',6-diamidino-2-phenylindole 
(DAPI) overnight.  The following day, sections were rinsed thoroughly in PB before 
transferring to a glass-bottom 96-well plate containing glycerol/0.1M PB (1:1).  
Sections were examined using laser scanning confocal microscopy.  DAPI was 
excited with a 402 nm laser, and rhodamine was excited with a 561 nm laser.  Using 
a 20x objective, image stacks of labeled sections were collected in 5 µm z-steps.  
Maximum intensity projections of those stacks were generated using NIS Elements 
(version 3.0, Nikon Instruments, Inc., Melville, NY).  Using these projections, the 
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extent of tyrosine hydroxylase immunolabeling in larval zebrafish brain was 
observed. 
 
Statistical Analyses 
All data were collapsed by lighting condition and the mean activity/2 min in 
each condition was analyzed using Statview© (SAS Institute, Inc., Cary, NC; version 
5.0.1).  The data were first assessed using an analysis of variance (ANOVA) with 
dose and lighting condition as the independent variables and locomotor activity 
(distance moved) as the dependent variable.  Significance was set at p ≤ 0.05 (only 
effects that reached significance were described in the Results section).  When an 
effect of dose was obtained, Fisher’s PLSD comparisons were conducted to 
compare between groups.  All data are presented as mean ± standard error of the 
mean (SEM).  
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Results 
Developmental MPTP Exposure Altered Nervous System Structure, but Not 
Behavior in Zebrafish Larvae 
When larvae were exposed to MPTP during development, no overall effect of 
treatment on behavior was observed.  Changes in activity were not seen in dark 
(Figure 5.1A) or light (Figure 5.1B).  Developmental exposure to MPTP also did not 
alter responses of the larvae in most dose groups to changes in the lighting 
conditions: in general, larval activity decreased when transitioning from dark to light, 
and increased when transitioning from light to dark (Figure 5.1C).   
To determine if changes in the dopaminergic circuitry could be detected in 
larvae treated with 50 µM MPTP during development, tyrosine hydroxylase 
immunolabeling was examined in control (Figure 5.2A) and treated (Figure 5.2B) 
larvae following behavioral assessments.  Even though tyrosine hydroxylase is 
expressed in all catecholaminergic neurons, those that originate in the forebrain are 
mainly dopaminergic (Holzschuh et al., 2001).  Tyrosine hydroxylase 
immunolabeling was decreased in the diencephalon of the forebrain in MPTP-
treated larvae compared to controls.  This reduction was apparent in both cell bodies 
and neuronal processes, consistent with substantial alteration in dopaminergic 
circuitry in the brains of larvae treated developmentally with MPTP.  
 
Acute MPTP Exposure Dramatically Altered Larval Locomotion 
In order to distinguish between developmental and acute effects of MPTP, it 
was necessary to profile larval behavior following acute exposure (Figure 5.3).  
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When MPTP exposure occurred approximately 4 hours before testing on day 6, 
larval zebrafish showed extensive dose-dependent changes in locomotor activity 
under both lighting conditions.  In the dark (Figure 5.3A), activity was markedly 
increased at lower doses (0.8 and 1.6 µM).  These increases in activity generally 
emerged later in the dark periods as levels of control activity decreased (Figure 
5.3C).  At doses of 25 µM MPTP and above, activity was decreased compared to 
controls in the dark.  In the light, a similar, biphasic pattern emerged (Figure 5.3B).  
Again, the lowest doses (0.8 and 1.6 µM) increased activity, while 25 and 50 µM 
MPTP decreased activity compared to controls.  Larvae exposed to 3.1-12 µM 
displayed locomotor activity levels similar to controls under both lighting conditions.  
Although marked alterations in locomotor activity were observed, the larvae 
maintained responsiveness to changes in lighting conditions following acute MPTP 
exposure (Figure 5.3C).   
 
Developmental 6-OHDA Exposure Affected the Structure and Function of the 
Dopaminergic Nervous System in Zebrafish Larvae 
 Developmental exposure to 6-OHDA produced limited effects on locomotor 
activity in larval zebrafish.  In the dark, only one dose produced changes in larval 
locomotion.  Larvae that received 0.8 µM 6-OHDA exhibited hyperactivity in this 
lighting condition (Figure 5.4A).  No effects on locomotor activity were seen in 
periods of light (Figure 5.4B).  The response to changes in lighting conditions was 
not altered by developmental treatment with this compound (Figure 5.4C). 
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 To determine the effects of this exposure on the structure of the dopaminergic 
nervous system, tyrosine hydroxylase immunostaining was also performed (Figure 
5.5).  Larvae that were given 66.7 µM 6-OHDA (Figure 5.5B) exhibited reduced 
immunolabeling compared to controls (Figure 5.5A), most notably in the density of 
the axons that project from diencephalic cell groups. 
 
Acute 6-OHDA Exposure Did Not Alter Locomotor Activity in Zebrafish Larvae 
Acute 6-OHDA exposure was also investigated to determine if a different 
behavioral profile existed from that of the developmental exposure.  When 
administered 4 hr before testing, 6-OHDA did not alter larval locomotion in dark 
(Figure 5.6A) or light (Figure 5.6B).  This exposure also did not affect the responses 
of the larvae to the changes in lighting conditions (Figure 5.6C).  
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Discussion 
In these studies, developmental exposure to MPTP and 6-OHDA had little to 
no effect on locomotion in larval zebrafish, although deficits in dopaminergic 
pathways were observed.  When given acutely, however, MPTP and 6-OHDA had 
differing effects: MPTP had pronounced biphasic effects on locomotor activity, while 
6-OHDA had no effect.  
Previous behavior studies of developmental MPTP in zebrafish using doses 
similar to those given here have produced inconsistent results (summarized in Table 
5.1).  Perhaps this should be expected, as none of these were experimental 
replicates of each other (with variations in duration of exposure, duration of 
depuration before testing, size of observation chamber, etc.).  As is highlighted in the 
commonly used MPTP mouse model, any number of factors (e.g. strain, 
administration schedule, interval between administration and testing, test duration, 
etc.) may affect the results of behavioral assessments (reviewed by Sedelis et al., 
2001).  Developmental exposure to MPTP in the present study did not cause deficits 
in locomotor activity.  Bretaud and colleagues (2004) reported a marked decrease in 
locomotor activity at 43 µM MPTP in 7-dpf larvae following a 5-day exposure.  
Thirumalai and Cline (2008), however, reported an increase in episodes of fictive 
swimming (extracellular recordings from the isolated tails of embedded larvae) in 3-
dpf larvae after a 2-day exposure to 10 µM MPTP.  Many possible considerations 
could explain why the findings in the current study did not agree with previous 
studies.  One possible reason is that developmental exposure in the current study 
started at about 5 hpf, but exposure did not begin until 24 hpf in all previous studies.  
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This may mean the consequences of the exposures are different, as the rapid 
development of zebrafish highlights several events (including the structural and 
functional development of the dopaminergic nervous system) between these two 
times.  While dosing scenarios in the previous studies may have damaged existing 
dopaminergic neurons, here, perturbation of the development of the system may be 
occurring.  Also, in the present study, when given on the day of testing, larvae 
treated with MPTP showed extensive changes in locomotion, both hyperactivity and 
hypoactivity, depending on concentration.  No previous studies have been identified 
that have assessed the acute effects of MPTP in zebrafish larvae.  Our findings, 
however, established the extensive acute effects of MPTP.  Because MPTP has a 
relatively long half-life in the brain, it is possible that the effects noted in the previous 
studies are actually acute effects. 
In zebrafish, reports of dose-dependent effects on the structure of the 
dopaminergic nervous system due to MPTP exposure also vary.  In the present 
study, effects were seen on total immunolabeling of tyrosine hydroxylase-positive 
cell bodies and neuronal processes in the diencephalon at 50 µM MPTP.  Consistent 
with this finding, McKinley and colleagues (2005) reported tyrosine hydroxylase 
expression was drastically decreased in this region, as well as in the pretectum, in 4- 
and 7-dpf larvae treated for 3 days with concentrations of MPTP as low as 25 µM.  
Dopamine transporter expression was also reduced in these larvae, as well as in a 
study by Boehmler and colleagues (2009), where larvae were treated with 40 µM 
MPTP for 4 days.  Effects on dopamine transporter expression are a more specific 
measure of MPTP toxicity in dopaminergic pathways, because tyrosine hydroxylase 
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is present in both dopaminergic and noradrenergic neurons (Axelrod and 
Weinshilboum, 1972).  Tyrosine hydroxylase immunolabeling in the forebrain was 
also decreased in the study by Thirumalai and Cline (2008) in which larvae were 
fixed at 3 dpf after exposure to 10 µM MPTP.  Although the present study supports 
these findings, other studies suggest higher concentrations of MPTP are needed to 
observe decreased tyrosine hydroxylase-positive neurons in the diencephalon.  In 
one such study (Wen et al., 2008), 50 µM MPTP decreased tyrosine hydroxylase 
expression in the pretectum, but not in the ventral diencephalon of 5-dpf larvae that 
had been treated for 4 days.  At 100 µM, however, the diencephalon was affected.  
Further, Bretaud and colleagues (2004) reported no effect on tyrosine hydroxylase 
expression at 43 µM (which did affect activity, as stated previously), but decreased 
expression in the diencephalon at 215 µM MPTP.  The many differences in 
experimental design (see Table 1) were probably the reason for the variability in the 
dose-related results across studies. 
Mammalian reports of developmental MPTP exposure detail both decreased 
motor activity, as well as effects on dopamine-containing pathways in the brain.  
Rats administered 10 mg/kg MPTP in utero daily from gestational day 13 until birth 
displayed persistent decreased locomotion through postnatal day 50 (Weissman et 
al., 1989).  Mice (which are generally more sensitive to MPTP toxicity than rats; 
Giovanni et al., 1994b) that received 2.8 mg/kg MPTP daily from gestational days 9-
17 displayed decreased dopamine immunoreactivity in the striatum at 1 and 6 weeks 
of age (Furune et al., 1989).  
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The biphasic profile of locomotor activity in response to acute MPTP 
exposure across a broad range of concentrations reported here is consistent with 
more limited findings in mammalian models.  In the acute MPTP mouse model, 
hyperreactivity to external stimuli has been noted (Linder et al., 1987).  Several 
factors may contribute to the increased activity observed at low doses in the present 
study.  First, there may be increased dopamine release in the synapse caused by 
stress (Abercrombie et al., 1989) that may be experienced by the larvae in response 
to the changing lighting conditions (external stimuli).  There may also be decreased 
uptake of dopamine by dopamine transporters due to MPTP (Araki et al., 2001).  
These increases in activity may also be due to dopamine-mediated changes in other 
pathways of the nervous system that also regulate locomotion.  Indirect activation of 
serotonergic neurons causing release of the neurotransmitter, for example, can lead 
to increases in activity (Geyer, 1996).  Indeed, Kapitza and colleagues (2008) 
reported increased serotonin levels in the striatum 90 min after MPTP injection in 
mice.  MPTP caused a marked efflux of serotonin in the neostriatum of mice that 
exhibited Straub tail (another sign of acute MPTP exposure), and the administration 
of a serotonin blocker prevented its occurrence (Mitra et al., 1992).   
Most often, acute exposure to MPTP is reported to cause a rapid 
parkinsonian syndrome in mammals, which is characterized by decreased 
locomotion, among other dyskinesias (Kapitza et al., 2008).  In that study, mice 
given a single intraperitoneal injection of 30 mg/kg MPTP showed decreases in 
activity as soon as 90 min post-injection.  Dopamine turnover in the striatum also 
decreased in these animals.  In zebrafish larvae, acute MPTP exposure decreased 
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locomotor activity at the higher concentrations given.  At these doses, the expected 
mechanism of action (i.e. uptake by the dopamine transporter, followed by inhibition 
of mitochondrial complex I) may be responsible for the effects on behavior.   
Acute behavioral effects of MPTP administration in non-human primates have 
been shown to change over time.  One study noted hyperactivity occurs immediately 
following the injection, then hypoactive conditions are present by 1 hr post-injection 
(Lermontova et al., 1990).  This finding suggests that there is a biphasic profile 
associated with the relationship between locomotor activity and the amount of the 
compound that is taken up in the brain.  The mammalian studies, however, did not 
incorporate a detailed dose-response design, whereas in the present study, using a 
broad range of concentrations allowed illustration of this biphasic relationship. 
Given the findings in the previous reports on MPTP exposure, it is not clear if 
the compound causes long-lasting developmental effects in zebrafish.  Transient 
effects of MPTP have been reported by several investigators.  Sallinen and 
colleagues (2009) reported that larvae exposed to 1mM MPTP for 4 days displayed 
decreased activity, as well as decreased tyrosine hydroxylase immunoreactivity 2 
days after exposure; however, both endpoints recovered to control levels by the third 
day.  Additionally, a study in adult zebrafish (Anichtchik et al., 2004) revealed that 
decreased activity caused by a single injection of MPTP (20 mg/kg) recovered by 
day 9 post-injection.   
The mouse model has also provided evidence of functional recovery of the 
dopaminergic nervous system following MPTP administration.  Recent studies have 
shown that MPTP-associated damage of dopaminergic neurons drives de novo 
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dopaminergic neurogenesis within days (Shan et al., 2006, Zhao et al., 2003).  
Additionally, Sedelis and colleagues (2001) highlighted other changes that occur in a 
short period of time, including increased dopamine turnover in the remaining, 
undamaged cells, increased postsynaptic dopamine receptor density, and the 
migration of dopamine to the striatum from other sites in the brain.  These findings 
may give some insight into why there are more pronounced acute behavioral effects 
than developmental behavioral effects in the present study, as well as why 
developmental exposure yielded no behavioral effects even though marked 
structural effects occurred. 
The developmental effects of 6-OHDA found in this study are consistent with 
effects in developing mammals.  When administering the compound intracisternally 
or intraventricularly in rat pups, damage to dopamine-containing pathways manifests 
as increased locomotor activity, but this sign is only present until postnatal day 35 
(Luthman et al., 1997, Zhang et al., 2002).  This lesioning method is used to produce 
rodent models of ADHD.  On the contrary, the administration of 6-OHDA directly into 
the nigrostriatal pathway produces animals with suppressed locomotor activity 
(Jurna et al., 1972, Kostrzewa and Jacobowitz, 1974, Whishaw and Dunnett, 1985).  
This lesion is the most efficient in modeling Parkinson’s disease.  Because of its 
selectivity for all dopaminergic and noradrenergic transporters, multiple sites in the 
brain may have been affected by 6-OHDA exposure in the present study.  It is 
reasonable to conclude, then, that actions on different targets may be concentration- 
and (thus) uptake-dependent.  If this is the case, hyperactivity at the intermediate 
concentration (7.4 µM) may result from exposure resembling 
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intraventricular/intracisternal injections in mammals, while no observed effects at 
higher doses may reflect the compound beginning to act on the nigrostriatal pathway 
as well.  Although locomotor activity was not altered at the highest concentration 
(66.7 µM), histological analysis of tyrosine hydroxylase staining revealed decreased 
immunoreactivity in dopaminergic neuronal regions, which is consistent with 
previous findings in zebrafish larvae (Parng et al., 2007).   
The absence of behavioral effects due to developmental exposure to either 
MPTP or 6-OHDA at concentrations that decreased tyrosine hydroxylase staining in 
this study is not surprising.  Studies in mammals suggest that more that 80% of 
dopamine in the striatum must be depleted in order to cause persistent effects on 
basal behavior (Fornaguera and Schwarting, 1999).  In line with this, mutant 
zebrafish larvae deficient in Parkin expression (a gene implicated in the occurrence 
of familial Parkinson’s disease) exhibit a loss of about 20% of their diencephalic 
neurons with no behavioral consequences (Flinn et al., 2009).  The histology data in 
the present study show robust effects on processes that extend from dopaminergic 
cell bodies, as well as moderate effects on the cell bodies themselves.  It is possible 
that the damage observed is not extensive enough in the relevant brain regions (i.e. 
subpallium, posterior tuberculum) to cause the characteristic behavioral effects.   
Contrary to the finding that developmental MPTP effects may be due to 
residual acute effects, the effects seen here following developmental 6-OHDA 
exposure appear to be due to developmental insults rather than acute effects.  This 
is probable since 6-OHDA has such a rapid half-life in brain (about 25 min post-
injection in rat striatum; McCreery et al., 1974).  Analysis of the acute experiment 
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showed no changes in locomotor activity, unlike the observed hyperactivity in the 
developmental experiment.   
The results of acute 6-OHDA exposure in the present study were expected.  
This compound does not readily cross the blood-brain barrier, and in mammals, it 
must be injected into the brain to produce lesions.  In zebrafish, the blood-brain 
barrier becomes functional at about 3 dpf (Jeong et al., 2008).  Since 6-OHDA was 
administered by immersion on day 6, it was hypothesized that no changes in activity 
would be observed.  Indeed, acute exposure did not alter locomotion in this study. 
Both MPTP (administered intraperitoneally in mice; Tatton et al., 1990) and 6-
OHDA (injected into the retina of adult zebrafish; Li and Dowling, 2000) have been 
shown to deplete dopamine in the retina.  Interestingly, in addition to motor 
abnormalities, visual deficits are also associated with dopaminergic dysfunction in 
Parkinson’s patients (reviewed in Bodis-Wollner, 1990; see also Onofrj et al., 1986).  
The behavioral paradigm in the present study features alternating lighting conditions 
as a visual stimulus.  Administration of the dopaminergic toxicants did not perturb 
larval responses to this stimulus in most cases. Transitions from light to dark caused 
larval locomotion to increase in all dose groups in all experiments, while transitions 
from dark to light severely depressed activity in all groups.  The exceptions to this 
finding were larvae given the high concentrations of MPTP (25 and 50 µM) in the 
acute study, who remained severely hypoactive throughout the test.  Therefore, the 
observed effects on locomotion are not likely due to effects on the retina.   
In terms of histology, developmental exposure to MPTP or 6-OHDA was 
detrimental to the dopaminergic nervous system in larval zebrafish.  Both toxicants 
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reduced tyrosine hydroxylase immunolabeling in the brain.  MPTP, however, 
produced marked effects on dopaminergic neurons compared to 6-OHDA, which 
mainly showed effects on axonal projections.  Taking into account the chemical 
properties of these two compounds may provide an explanation for the extents of the 
lesions.  MPTP, which is highly hydrophobic and readily crosses the blood-brain 
barrier, can accumulate in the brain, where it has a relatively long half-life (Markey et 
al., 1984).  6-OHDA, on the other hand, does not diffuse across the blood-brain 
barrier, and has a short-half life in the brain (McCreery et al., 1974).  Because the 
administration route in the present study is by immersion, the MPTP exposure 
persisted the entire exposure period (5 hpf to 5 dpf), while theoretically, the 6-OHDA 
exposure ended when the blood-brain barrier was functional at 3 dpf.  Thus, since 
the larval zebrafish brain encountered a longer exposure to MPTP than 6-OHDA, it 
is reasonable that the MPTP lesion is more extensive. 
Although both of these compounds are used to lesion dopaminergic pathways 
in the brain, MPTP and 6-OHDA exposures have different behavioral consequences 
in larval zebrafish.  These differences are may be due to their corresponding half-
lives and/or mechanisms of action in the brain.  In their toxic forms (MPTP must be 
metabolized into its active form, MPP+; Trevor et al., 1987), both are taken up by 
dopamine transporters; however, 6-OHDA exerts it toxicity by inducing oxidative 
stress, while MPP+ inhibits mitochondrial complex I, leading to cellular damage.  
Their differences in selectivity of the two compounds may also contribute to the 
different behavioral profiles, as 6-OHDA can be taken up by both dopamine and 
norepinephrine transporters with high affinity (Kostrzewa and Jacobowitz, 1974).  
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Regardless of the reason for these differences, the similarities of these findings to 
those in mammals, along with the novel aspects of the profiles that we observed, are 
strong indicators that zebrafish may be an efficient model for the detection of 
developmental exposures to dopaminergic toxicants. 
  
 172 
 
Figures 
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Table 5.1 – Published reports of MPTP toxicity in larval zebrafish.  Histology - TH: 
tyrosine hydroxylase enzyme; th: gene encoding for tyrosine hydroxylase; dat: gene 
encoding for dopamine transporter; VMAT: vesicular monoamine transporter.  
Behavior – no studies mentioned lighting condition during testing. 
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Figure 5.1 – Developmental MPTP exposure does not alter larval locomotion.  
Larvae were administered MPTP from 5 hpf to 5 dpf, then tested on day 6 
(n=24/dose).  Locomotor activity of larvae treated with MPTP was not significantly 
different form controls in dark (A) or light (B).  Data represent the mean activity 
(distance moved) in 2 min of the second and third dark periods and the two light 
periods, and are expressed as mean±SEM (p ≤ 0.05).  (C) The timecourse of the 
entire 70-min test is shown.  Data are represented as activity (distance moved) in 
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each 2-min interval (mean±SEM).  Black and white bar denotes periods of dark and 
light, respectively.    
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Figure 5.2 – Developmental exposure to MPTP alters dopamine pathways in the 
brain.  Larvae were administered 50 µM MPTP from 5 hpf to 5 dpf, then fixed on day 
6.  Red staining is tyrosine hydroxylase-positive catecholaminergic cells (DAPI-
positive staining not shown).  A rich tyrosine hydroxylase-positive area is detected in 
the forebrain in the control (A).  MPTP exposure (B) decreased tyrosine hydroxylase 
immunolabeling in the diencephalon (white oval) and telencephalon (white star), 
which is noticeable in the cell bodies and neuronal processes (white bracket).  
These are dorsal views of 100 micron brain sections.  For orientation, in both 
images, the olfactory bulbs are the brightly stained structures to the right. 
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Figure 5.3 – Acute MPTP exposure alters larval locomotion in a biphasic manner.  
Larvae were administered MPTP on the morning of day 6, and then tested 4 hr later 
(n=24/dose).  Locomotor activity of larvae that received MPTP was significantly 
increased at 0.8 and 1.6 µM, and decreased at 25 and 50 µM in dark (A) or in light 
(B).  Data represent the mean activity (distance moved) in 2 min of the second and 
third dark periods and the two light periods, and are expressed as mean±SEM (p ≤ 
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0.05).  (C) The timecourse of the entire 70-min test is shown.  Data are represented 
as activity (distance moved) in each 2-min interval (mean±SEM).  Black and white 
bar denotes periods of dark and light, respectively.    
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Figure 5.4 – Developmental 6-OHDA exposure increased larval locomotion at 7.4 
µM.  Larvae were administered 6-OHDA from 5 hpf to 5 dpf, then tested on day 6 
(n=24/dose).  Only larvae that were given 7.4 µM 6-OHDA during development 
exhibited locomotor activity that was significantly increased compared to controls in 
dark (A).  No significant differences were observed in light (B).  Data represent the 
mean activity (distance moved) in 2 min of the second and third dark periods, and 
are expressed as mean±SEM (p ≤ 0.05).  (C) The timecourse of the entire 70-min 
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test is shown.  Data are represented as activity (distance moved) in each 2-min 
interval (mean±SEM).  Black and white bar denotes periods of dark and light, 
respectively.    
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Figure 5.5 – Developmental exposure to 6-OHDA alters dopaminergic pathways in 
the brain.  Larvae were administered 66.7 µM 6-OHDA from 5 hpf to 5 dpf, then fixed 
on day 6.  Red staining is tyrosine hydroxylase-positive catecholaminergic cells 
(DAPI-positive staining not shown).  A rich tyrosine hydroxylase-positive area is 
detected in the diencephalon of the forebrain in the control (A).  6-OHDA exposure 
decreased tyrosine hydroxylase immunolabeling in the zebrafish brain (B), which is 
noticeable in the neuronal processes extending from the diencephalon (denoted by 
white arrows).  This exposure did not appear to affect tyrosine hydroxylase labeled 
cell bodies in the diencephalon (white ovals) and locus coeruleus (white boxes).  
These are dorsal views of 100 micron brain sections.  For orientation, the olfactory 
bulbs are the brightly stained structures to the right. 
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Figure 5.6 – Acute 6-OHDA exposure does not alter larval locomotion.  Larvae were 
administered 6-OHDA on the morning of day 6, and then tested 4 hr later 
(n=24/dose).  Locomotor activity of larvae that received 6-OHDA was not 
significantly different form controls in dark (A) or in light (B).  Data represent the 
mean activity (distance moved) in 2 min of the second and third dark periods, and 
are expressed as mean±SEM (p≤0.05).  (C) The timecourse of the entire 70-min test 
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is shown.  Data are represented as activity (distance moved) in each 2-min interval 
(mean±SEM).  Black and white bar denotes periods of dark and light, respectively.    
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Chapter 6: General Conclusions/Future Directions 
The precise origin of movement disorders like Parkinson’s disease and ADHD 
is unknown.  Many of these disorders, however, share a common feature in 
dysfunction of dopaminergic signaling in the brain.  Environmental factors have been 
linked to the onset of these disorders, creating the need to develop efficient 
screening methods to identify possible hazards.  Here, a model of dopaminergic 
dysfunction was created using 6-dpf larval zebrafish.  This dysfunction was mainly 
characterized using behavioral assessments of locomotor activity.  The similarities 
found between zebrafish larvae and mammalian models of altered dopaminergic 
signaling suggest the larval zebrafish model may prove to be very useful in future 
studies to elucidate potential causes for these disorders.  In this chapter, the major 
findings of the current work are summarized, the implications of these findings are 
discussed, and future avenues of research are identified.  
 
Specific Aim 1: Characterize the baseline behavioral profile of 6-dpf larvae. 
The experiments conducted in this aim were necessary to determine the 
baseline activity of the larvae, as well as variables that affect activity in the 
behavioral paradigm.   
• What are the basal patterns of larval zebrafish activity during a day?  
In the time of day study, zebrafish larvae exhibited a high level of activity (with 
considerable variability) in morning hours, and reached a low stable baseline in the 
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afternoon.  Generally, this agrees with the natural diurnal cycle of the species.  
Zebrafish exhibit higher activity during daylight hours than in night time hours (del 
Pozo et al., 2011), one of many circadian rhythms governed by oscillators in the 
retina, hypothalamus and pineal gland of all vertebrates, including mammals 
(reviewed in Turek, 1985).  This is an important factor that must be taken into 
account when assessing the effects of chemical exposures on locomotor activity in 
zebrafish larvae.  For example, two studies by Gerlai and colleagues (2000, 2006) 
examined the effects of ethanol in zebrafish using the same concentrations, but with 
different outcomes.  When reviewing their methods, it was noted that behavioral 
testing was performed between 1000 h and 1700 hr.  Perhaps, the differences in 
testing times affected the reproducibility in these studies.   
• How do zebrafish larvae respond to light and dark? 
Previously, it was reported that light suppresses activity in nocturnal 
mammals, while promoting activity in diurnal mammals (reviewed in Redlin, 2001).  
In recent years, studies have begun to focus on the response of larval zebrafish to 
changes in light (reviewed in Portugues and Engert, 2009).  One of the first 
observations was that, in a lighted environment, young zebrafish (as early as 3 dpf) 
exhibited a visual startle (defined as a C-start turn followed by high levels of 
swimming within 2 sec of the stimulus) in response to a focal dark spot (Easter and 
Nicola, 1996, 1997), possibly to avoid what they perceived as a looming predator.  In 
line with this, Burgess and colleagues (Burgess et al., 2010) reported that in a dark 
field, 5-7 dpf larvae oriented (regulated by OFF retinal ganglion cells, which control 
light-to-dark transitions) and swam (regulated by ON retinal ganglion cells, which 
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control dar-to-light transitions) towards a focal light.  It has also been established 
that in a lighted environment, larvae exhibited a characteristically different response 
to a dark flash, which is slower than the visual startle response and includes a 
complete circular turn (or O-bend) towards the flash (Burgess and Granato, 2007).  
That flashes of light elicited behavioral responses in even younger zebrafish 
(embryonic stages), and that these responses can be manipulated by neuroactive 
drug exposure has also been demonstrated (Kokel et al., 2010).   
Here, by characterizing larval locomotion in both light and dark conditions for 
more extended test periods, it was found that very different patterns of response 
emerged depending on whether the zebrafish larvae were in continuous light, 
continuous dark, or alternating light and dark.  In continuous light, activity in 6-dpf 
zebrafish larvae gradually increased until it reached a plateau.  Conversely, in 
continuous dark, activity decreased to a low, stable level.  In alternating conditions, 
however, larval locomotion immediately dropped in light and slightly increased with 
time, but then rose to a high level upon return to dark, decreasing as the dark period 
progressed.  These general patterns that result when zebrafish larvae are 
transitioned from light to dark and dark to light have been noted in an earlier study 
(Burgess and Granato, 2007) that established that, in light phases that followed 
dark, there was an initial lag in turns and slow swimming that increased with time.  In 
dark phases that followed light, however, locomotor activity (turns and slow 
swimming) increased in the first few min, but by 10 min, started to decline, reaching 
baseline levels by 30 min.  The present results in alternating lighting conditions 
seem paradoxical at first glance, since larvae naturally move more in daylight hours 
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than at night.  A recent study by Steenbergen and colleagues (2011) determined that 
zebrafish larvae avoided entering, and moved less while in a black compartment 
compared to a white compartment in a preference test.  The changing of lighting 
conditions is possibly a stressor to the fish, as evidenced by their activity during 
lighting transitions in the current studies.  Transition into light causes a freeze 
response within the first 30 sec.  Depression of activity persists throughout the light 
period, with only gradual increases occurring.  When lighting conditions are changed 
to dark, however, larvae display an instantaneous escape response similar to the O-
bend mentioned previously (Burgess and Granato, 2007) accompanied by higher 
levels of activity.  In this case, activity peaks in the first 2-4 min of the period, and 
then gradually decreases for the rest of the period.  Interestingly, zebrafish larvae 
did not appear to habituate to the transitions in the current studies, as the responses 
to the lighting changes were not blunted following multiple cycles of light and dark 
(see Figure 2.4).  The activity pattern that results from alternating lighting conditions 
was also reported later by Emran and colleagues (2010).   
The present studies also established that the amount of time in dark does not 
affect the level of activity in the following light period; however, the time in light does 
affect the level of activity upon return to dark.  This finding suggests that being in the 
light is somehow suppressing larval locomotion, and if this is true, return to dark then 
disinhibits activity.  Further inspection of these data revealed larvae will respond to 
the return to dark with the same type of action (an O-bend, followed by increased 
activity), but the amount of activity that followed this response was directly 
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determined by how long the fish were in light (i.e. the longer light period, the higher 
the activity in the following dark period). 
In summary, in this aim, many novel concepts were defined involving 
locomotion in zebrafish larvae.  The first of these was that due to the diurnal nature 
of the species, assessments of zebrafish activity should be conducted in the 
afternoon when a stable baseline is reached.  Next, it was determined that 
alternating lighting conditions provides unique information that cannot be obtained 
when testing in continuous light or dark, and that lighting can be used to manipulate 
locomotor activity.  This was evidenced in the subsequent aims, as the acute 
exposures to drugs yielded different patterns: some drugs had effects in either the 
dark or light, some had effects throughout the entire test regardless of lighting 
condition, and others had different effects depending on lighting condition.  
Additionally, the only change in locomotor activity due to a developmental exposure 
(6-OHDA) was in dark periods that followed light.  These findings will be useful in 
designing future assessments of larval zebrafish locomotion. 
 
Specific Aim 2: Evaluate behavioral phenotypes in larval zebrafish after acute 
exposure to neuroactive drugs that target the dopaminergic nervous system. 
Acute locomotor effects of drugs that act on the dopaminergic nervous 
system have been studied extensively in mammals, especially rodents.  In this aim, 
the acute behavioral effects of some of these drugs were evaluated in 6-dpf 
zebrafish larvae.   
• Are zebrafish larvae sensitive to common neuroactive drug exposures? 
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Zebrafish larvae responded to acute ethanol exposure in a biphasic manner.  
Low doses caused hyperactivity, while the highest dose caused hypoactivity.  These 
findings resembled previous results in mammals; in rodents, stimulated activity at 
low doses of ethanol have been noted, while higher doses have had a sedative 
effect (Cohen et al., 1997, Crabbe et al., 1982, Frye, 1981, Masur and Martins dos 
Santos, 1988).  The two phases of acute ethanol effects have been shown to be 
modulated by separate processes, since the zebrafish fan (a gene encoding for type 
5 adenylyl cyclase in the brain) mutant is less sensitive to locomotor activation 
induced by ethanol at low doses, but high doses still reduce activity (Peng et al., 
2009). 
Interestingly, two drugs that target the dopamine transporter, d-amphetamine 
and cocaine, caused different dose-related locomotor response profiles in zebrafish 
larvae.  The response to d-amphetamine was biphasic, similar to that seen after 
ethanol administration.  This is consistent with mammalian studies, which suggest 
that the biphasic response reflects the stimulation of the locomotion at low doses, 
followed by a transition to more complex behaviors at higher doses (i.e. stereotypy; 
Porrino et al., 1984).  In rodents, cocaine has been reported to cause either 
increases in activity (Antoniou et al., 1998, Niculescu et al., 2005) or biphasic effects 
(Katz et al., 1999).  It is probable that in studies that noted only increases in activity, 
the dose range may have only allowed observation of the rising phase of the 
biphasic profile.  In the present study, only decreased locomotor activity was 
observed in zebrafish larvae.  Since only the hypoactive phase was observed in our 
study (which included a broad dose range), it may be possible that the hyperactive 
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phase in the cocaine dose-response profile is mediated by a different process.  
Although both phases of the dose response are seen with d-amphetamine, and the 
two drugs act on the same target, there is evidence in mammals that suggests that 
the behavioral manifestations of the two drug exposures may be attributed to 
different mechanisms.  For example, one study (Frantz et al., 2002) determined the 
behavioral effects d-amphetamine and cocaine are mediated by different secondary 
signaling pathways, as serotonin receptor blockade enhanced the effects of d-
amphetamine, but not cocaine.   
• What behavioral effects occur following exposure to drugs that target 
dopaminergic receptors? 
Because drugs that act on dopaminergic receptors are commonly used to 
assess the functional integrity of the dopaminergic nervous system in mammals, it 
was important to characterize the behavioral manifestations of these drugs in the 
larval zebrafish model.  In general, zebrafish larvae displayed different behavioral 
responses to nonselective drugs when compared to selective drugs.  Additionally, 
the actions of agonists and antagonists elicited distinct responses in locomotor 
activity.   
Some of the drugs given in the acute studies also blunted larval responses to 
changes in lighting conditions (i.e. transitions from light to dark, in most cases).  This 
was initially noted after ethanol administration.  Consistent with this finding, studies 
in rodents (Molina et al., 1987) and reports in humans (Johnston and Timney, 2008) 
have noted visual impairment as a consequence of ethanol use.  Additionally, the 
loss of impulsivity to a stimulus in a stop task has been reported (de Wit et al., 2000, 
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Feola et al., 2000).The acute exposures to SCH-23390 and haloperidol also affected 
the responses of larvae to lighting changes in the current work.  Previous studies 
have established that these drugs affect the response of rodents to external stimuli.  
When SCH-23390 was given in combination with a D2-selective antagonist to 
achieve type 1 and 2 receptor blockade in rats, decreased locomotor responses 
occurred following the application of several arousing stimuli (e.g. tail pinch, social 
interaction; Kiyatkin, 2008). Haloperidol caused a loss of stimulus control in rats 
trained to discriminate between two levers in an operant responding study based on 
visual and tactile environmental cues (Koek and Slangen, 1984).  An antipsychotic 
prescribed for patients with schizophrenia, haloperidol has been reported to have 
side effects that include vision impairment (Lynch et al., 1997).   
Interestingly, the present studies provide some insight into the 
pharmacodynamics of these drugs when considering effects on locomotor activity 
versus effects on vision.  Acute ethanol altered the response to the changes in 
lighting conditions at a lower dose than what was necessary to decrease locomotor 
activity, as was also the case with the haloperidol exposure.  The SCH-23390 
exposure, however, decreased larval locomotion prior to blunting the response to the 
lighting transition.  These data may be evidence of the dissociation of the drug 
effects on different neural substrates. 
The findings from the acute studies in this work are important because they 
support the conclusion that behavioral responses to neuroactive (and specifically, 
dopaminergic) drugs may be conserved across vertebrate species.  These drugs 
elicited similar responses in larval zebrafish to those in mammals, suggesting that 
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neural processing of these exposures may be the same in these vertebrate species, 
despite the differences in brain structure (i.e. the location of dopaminergic cell 
groups in the brain differ among species; Wullimann and Mueller, 2004).  In order to 
confirm the dopaminergic specificity of the effects of the selective drugs in zebrafish 
larvae, further studies could determine whether the effects of the agonists can be 
blocked by the antagonists.  Mammalian studies have established that D2 
stimulation is dependent on stimulation of D1 (Braun and Chase, 1986, Murray and 
Waddington, 1989); therefore, if zebrafish larvae are first administered SCH-23390, 
the effects of either SKF-38393 or quinpirole should be blocked.  Prior administration 
of haloperidol, however, should only block the effects of quinpirole.  Inability to block 
the effects of the agonists could suggest that other signaling pathways are involved.  
Indeed, while these drugs have high affinities for dopaminergic receptors in 
mammals, they also act on other targets including serotonergic, histaminergic, and 
cholinergic receptors (Bymaster et al., 1996, Hyttel, 1983, Millan et al., 2002).  The 
relative affinities of these alternative drug targets in zebrafish larvae should be 
assessed to address this uncertainty. 
The finding that dopaminergic drugs cause similar effects in larval zebrafish 
and mammals could lead to future studies of critical windows of development and 
the onset of dopaminergic movement disorders.  Dopaminergic insults with various 
toxicants during development have already been associated with the occurrence of 
both neurodevelopmental and neurodegenerative diseases (Braun et al., 2006, 
Miller and O'Callaghan, 2008).  Using the larval zebrafish model, the consequences 
of dopaminergic receptor blockade during different windows of development could 
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be easily assessed.  It is possible that aside from mechanisms like the destruction of 
dopaminergic neurons or the upregulation of dopamine transporters, exposure to 
toxicants that block receptor-mediated signaling at a critical time in development 
may have long-lasting effects on motor behavior.  For instance, increased dopamine 
levels induced by L-DOPA administration in pregnant rats disrupted dopaminergic 
neurogenesis in fetuses (McCarthy et al., 2007), and this change in brain structure 
may have had behavioral consequences (behavioral parameters were not included 
in this study).   
 
Specific Aim 3: Assess the perturbation of dopaminergic nervous system structure 
and function following developmental toxicant exposure. 
Animal models of human conditions like Parkinson’s disease and ADHD 
employ chemical lesioning of certain regions of mammalian brain to elicit the 
destruction of dopaminergic pathways.  Toxicants most often used to produce these 
lesions are MPTP and 6-OHDA.  In this aim, it was established that these lesions 
can also be created in the developing zebrafish. 
• How does MPTP exposure affect behavior and dopaminergic pathways in 
zebrafish larvae? 
Although developmental MPTP exposure did not alter larval zebrafish 
locomotion when tested on day 6, the highest dose did, however, affect the structure 
of dopaminergic regions in the brain.  These data are consistent with findings in 
mammals, where extensive damage must occur in the nigrostriatal pathway before 
behavioral manifestations occur (dopamine depletion > 80% in rats; Fornaguera and 
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Schwarting, 1999).  On the other hand, acute MPTP exposure on day 6, caused 
extensive behavioral changes.  The biphasic effects that occurred with acute MPTP 
exposure in zebrafish larvae are a novel finding, and have important implications in 
the context of the previous developmental studies with this lesioning model.  
Because acute MPTP had marked effects in the present work, and because the 
compound has a long half-life in biological tissues, discerning between the 
behavioral manifestations due to long-lasting developmental perturbations and the 
acute effects of the compound following developmental exposure in previous studies 
in zebrafish larvae is difficult (Bretaud et al., 2004, Lam et al., 2005, Sallinen et al., 
2009, Thirumalai and Cline, 2008).  In these studies, it is possible that MPTP was 
still present in zebrafish larvae when testing occurred, and thus, may have 
accounted for the changes in behavior that were observed.  In order to determine if 
MPTP is still present in larvae at the time of testing following developmental 
exposures, larvae could be anesthetized immediately after the behavioral test for 
HPLC analysis to detect the presence of the chemical.  
Previous reports of MPTP toxicity suggest that in some cases behavioral and 
histological consequences of MPTP may be transient (Anichtchik et al., 2004, 
Sallinen et al., 2009).  In order to determine if recovery is possible from the effects of 
the developmental exposure reported here, zebrafish larvae could be maintained 
and processed for representative histology studies investigating tyrosine 
hydroxylase immunoreactivity regularly over the following weeks.  In this way, 
dopaminergic pathway structure can be compared over time.  These larvae could 
also be tested for alterations in behavior prior to preparation for histology.  This 
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study would be important, because in addition to the possibility that the effects are 
transient, one must also consider that exposure to this toxicant during critical 
windows of development may have detrimental effects that do not become apparent 
until later in life. This type of consequence has been established with many chemical 
exposures, including cocaine (Messiah et al., 2011), which may disrupt vascular and 
metabolic programming that occurs prenatally, possibly resulting in cardiovascular 
disease and other complications later in life. 
• How does 6-OHDA exposure affect behavior and dopaminergic pathways in 
zebrafish larvae? 
Developmental 6-OHDA exposure produced both behavioral and 
morphological effects in 6-dpf larvae.  These data are consistent with mammalian 
findings, considering 6-OHDA has been used to model ADHD (with hyperactive 
locomotion; Luthman et al., 1997, Zhang et al., 2002). Because the exposure in the 
present work was started before the zebrafish blood-brain barrier was functional (at 
3 dpf; Jeong et al., 2008, Xie et al., 2010), the entire embryonic zebrafish brain, and 
thus, multiple dopaminergic/noradrenergic pathways involved in motor function, may 
be vulnerable to the toxicity of 6-OHDA.  Because 6-OHDA can also be given to 
model Parkinson’s disease (characterized by hypoactivity; Deumens et al., 2002) in 
rodents, it may be possible that developmental exposure to higher doses of the 
compound than given here could decrease locomotor activity in zebrafish larvae.   
Unlike MPTP, 6-OHDA had no effect on locomotor activity when given 
acutely.  Since the compound does not readily cross the blood-brain barrier, 6-
OHDA is routinely injected directly into the brain in acute mammalian studies to elicit 
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brain-related behavioral effects (Kostrzewa and Jacobowitz, 1974).  Because the 
blood-brain barrier is intact in 6-dpf zebrafish larvae, this finding was expected. 
  Due to the early exposure times in the developmental experiments, the 
structure and function of the nervous system may be perturbed by either 
dopaminergic toxicant.  If this is the case, the behavioral effects (or lack thereof) 
may be cumulative manifestations of altered signaling in multiple pathways.  
Following dopamine depletion in mammalian models of MPTP and 6-OHDA, several 
mechanisms of compensation can occur that involve other pathways.  Studies in 
rodents have shown hyperinnervation of serotonergic fibers in the striatum following 
neonatal 6-OHDA lesions (el Mansari et al., 1994).  Additionally, both MPTP and 6-
OHDA lesions in the brain are reported to produce dopaminergic (D1/D2/D4; Araki et 
al., 2000, Kostrzewa et al., 2008, Zhang et al., 2002), serotonergic (Kostrzewa et al., 
1993), muscarinic (Kostrzewa and Neely, 1993), and histaminergic (Nowak et al., 
2006) receptor supersensitivity.   
To analyze the ability of the dopaminergic nervous system to function 
normally following these developmental insults, selective dopamine receptor agents 
can be given acutely.  For example, dopamine receptor agonists (including the 
nonselective agonist apomorphine and the D2-like selective agonist quinpirole) had 
anti-parkinsonian effects in MPTP-lesioned monkeys (Akai et al., 1995).  
Additionally, in 6-OHDA hemi-lesioned rats, a D3 receptor antagonist had anti-
parkinsonian effects, relieving bradykinesia (Melo et al., 2010).  These results are 
consistent with what has been determined regarding receptor-mediated effects on 
activity: activation of D1 and D2 receptors stimulates activity (Beninger et al., 1991, 
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Missale et al., 1998), while activation of D3 suppresses activity (Kolasiewicz et al., 
2008, Missale et al., 1998).  If the behavioral changes in the developmental studies 
are mainly due to dopaminergic toxicity (or damage to dopamine neurons), larvae 
that are hyperactive due to 6-OHDA exposure should display decreased activity 
following acute antagonist administration.  Also, it has been reported that striatal 
lesions that are not severe enough to affect basal behavior may cause behavioral 
deficits in response to drug challenges (Fornaguera and Schwarting, 1999).  
Because of this, it may be possible to characterize the functional changes of the 
dopaminergic nervous system following developmental MPTP exposure in zebrafish 
larvae as well.  If the development of the neuronal network in the brain has been 
perturbed due to the dopaminergic insult, different behavioral responses to drug 
challenge may occur.  In this case, the function of other signaling pathways can also 
be assessed following the acute administration of drugs that selectively target those 
systems (e.g. serotonergic receptor agonists/antagonists).   
To support the functional drug challenge studies, gene expression studies 
can also be conducted to survey compensatory mechanisms and changes in the 
balance of neurotransmitter signalling in the nervous system that may affect 
locomotor activity.  Studies from our laboratory have characterized the expression 
pattern of several marker genes in larval nervous system development from 1-6 dpf 
(Fan et al., 2010).  Preliminary studies have also confirmed the expression of genes 
for proteins that are major targets of drug/toxicant action in the dopaminergic 
nervous system (e.g. dopamine receptors, dopamine transporter, etc.) at these 
same ages.  Additionally, genes representing targets in the cholinergic and 
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serotonergic signaling pathways (which can modulate dopaminergic signaling; 
Azmitia and Segal, 1978, Blaha and Winn, 1993, Frantz et al., 2002, Mena-Segovia 
et al., 2008) can be examined during the first 6 days of development, and this entire 
panel of expression patterns can be used to determine 1) if developmental 
exposures to MPTP or 6-OHDA perturb the development and balance of these 
systems, and 2) if gene expression changes correlate with the behavioral data in 
both acute and developmental exposure studies.  These studies would, however, 
only be initial steps towards elucidating the signaling mechanisms involved in 
altering locomotor activity (i.e. causing hyper- or hypoactivity); subsequent studies 
would be required to characterize expression and function at the protein level.  Both 
the drug challenge studies and the gene expression profiling may be important for 
thorough characterization of dopaminergic toxicity so that potential hazardous 
agents may be identified that may not alter basal activity in zebrafish larvae.  
The challenge studies may also be useful in the discovery of new therapeutic 
options for Parkinson’s disease and ADHD.  Screens can be conducted following 
developmental 6-OHDA or MPTP exposure to identify new molecules that may 
alleviate some of the behavioral/gene expression changes of the models.  Additional 
endpoints could be developed in these models that resemble signs in the target 
diseases.  For example, as mentioned previously, children with ADHD exhibit deficits 
in learning and memory.  This may be studied in zebrafish larvae using a place 
preference paradigm where larvae are trained to associate responses in distinctive 
environments with rewards (Steenbergen et al., 2011).  Testing with the larval 
zebrafish model would be an important, higher-throughput prioritization step to 
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precede studies in rodent models, and could prove beneficial in the costly drug 
development industry.   
Despite the numerous advantages highlighted here, there are also limitations 
to using this model.  First, there are undoubtedly differences in the pharmacokinetics 
of chemicals in zebrafish and mammals, making dose-response extrapolation 
between species difficult.  This is further complicated by the differences in the rates 
of development, since responses to chemicals may differ with age.  Finally, the 
neuroanatomy of the zebrafish nervous system is simpler than mammalian nervous 
systems (reviewed in Miklos, 1993), and this may cause differing levels of sensitivity 
to chemical exposures.     
Overall, this work noted several key findings that are an addition to the fields 
of zebrafish and dopaminergic nervous system research.  First, it was determined 
that larval zebrafish locomotion can be manipulated using visual stimuli.  Also, the 
responsiveness of the model to drugs that target the dopaminergic nervous system 
even at the young age of 6 dpf was established.  Moreover, zebrafish larvae were 
found to be able to discern between drug actions by responding with different 
locomotor patterns.  Finally, it was confirmed that zebrafish larvae are sensitive to 
chemical lesioning with dopaminergic toxicants, and the differential acute effects of 
these toxicants were established.  
The goal of this work was to model dopaminergic dysfunction in larval 
zebrafish.  This was accomplished by determining the behavioral impact of acute 
drug exposures, as well as developmental toxicant exposures.  Overall, larval 
zebrafish appear to be good predictors of dopaminergic action in mammals. 
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